"DRAVP_ID"	"Sequence"	"Sequence_Length"	"Name"	"Source"	"Target_Organism"	"Patent_Type"	"Patent_No"	"Publication_Date"	"Family_Info"	"Patent_Title"	"Comment"	"Abstract"	"Other_link"	"Connectives"
"DRAVPa1672"	"EAQSQEVKNW MTETLLVQNA N"	"21"	"Sequence 2 from Patent US 20090281041"	"Homo sapiens"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"No cooments found in patent"	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1673"	"AQEVKNWMTETLLVA"	"15"	"Sequence 3 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"No cooments found in patent"	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1671"	"KRKKRRHR"	"8"	"Sequence 94 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1670"	"KKEKKKSKK"	"9"	"Sequence 93 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1669"	"PQSRKKLR"	"8"	"Sequence 92 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1668"	"KHRKHPG"	"7"	"Sequence 91 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1667"	"KTRKHRG"	"7"	"Sequence 90 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1666"	"IKYFKKFPKD"	"10"	"Sequence 89 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1665"	"SKRVAKRKL"	"9"	"Sequence 88 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1664"	"PQPKKKP"	"7"	"Sequence 87 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1663"	"PPQKKIKS"	"8"	"Sequence 86 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1662"	"PLLKKIKQ"	"8"	"Sequence 85 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1661"	"EEDGPQKKKRRL"	"12"	"Sequence 84 from Patent US 20090258815"	"Polyomavirus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1660"	"PNKKKRK"	"7"	"Sequence 83 from Patent US 20090258815"	"Simian virus 40"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1659"	"APTKRKGS"	"8"	"Sequence 82 from Patent US 20090258815"	"Simian virus 40"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1658"	"VSRKRPR"	"7"	"Sequence 81 from Patent US 20090258815"	"Polyomavirus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1657"	"PKKARED"	"7"	"Sequence 80 from Patent US 20090258815"	"Polyomavirus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1656"	"MNKIPIKDLLNPG"	"13"	"Sequence 79 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1655"	"KRPAEDMEEEQAFKRSR"	"17"	"Sequence 78 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1654"	"PAAKRVKLD"	"9"	"Sequence 77 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1653"	"YNNQSSNFGPMKGGN"	"15"	"Sequence 76 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1652"	"KRKKEMANKSAPEAKKKK"	"18"	"Sequence 75 from Patent US 20090258815"	"Gallus gallus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1651"	"KRPAATKKAGQAKKKK"	"16"	"Sequence 74 from Patent US 20090258815"	"Xenopus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1649"	"EYLSRKGKLEL"	"11"	"Sequence 72 from Patent US 20090258815"	"Agrobacterium tumefaciens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1650"	"PKRPRDRHDGELGGRKRARG"	"20"	"Sequence 73 from Patent US 20090258815"	"Agrobacterium tumefaciens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1647"	"PRGRRQPIPKARQP"	"14"	"Sequence 70 from Patent US 20090258815"	"Hepatitis C virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1648"	"KRSAEGGNPPKPLKKLR"	"17"	"Sequence 71 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1645"	"KVNSRKRRKEVPGPNGATEED"	"21"	"Sequence 68 from Patent US 20090258815"	"Rattus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1646"	"PRRGPR"	"6"	"Sequence 69 from Patent US 20090258815"	"Hepatitis C virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1643"	"VNEAFETLKRC"	"11"	"Sequence 66 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1644"	"MPTEERVRKRKESNRESARRSRYRKAAHLK"	"30"	"Sequence 67 from Patent US 20090258815"	"Zea mays"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1642"	"CKRKTTNADRRKA"	"13"	"Sequence 65 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1640"	"LKRKLQR"	"7"	"Sequence 63 from Patent US 20090258815"	"avian neuroretina"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1641"	"RRKGKEK"	"7"	"Sequence 64 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1638"	"RKRRTKK"	"7"	"Sequence 61 from Patent US 20090258815"	"Arabidopsis sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1639"	"SDKKVRSRLIECA"	"13"	"Sequence 62 from Patent US 20090258815"	"Thermoplasma acidophilum"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1636"	"REKKEKEQKEKCA"	"13"	"Sequence 59 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1637"	"LEKKVKKKFDWCA"	"13"	"Sequence 60 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1635"	"GRKRKKRT"	"8"	"Sequence 58 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1633"	"RIRKKLR"	"7"	"Sequence 56 from Patent US 20090258815"	"Mus musculus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1634"	"KRAAEDDEDDDVDTKKQK"	"18"	"Sequence 57 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1631"	"RKRKKMPASQRSKRRKT"	"17"	"Sequence 54 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1632"	"RAIKRRPGLDFDDDGEGNSKFLR"	"23"	"Sequence 55 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1630"	"KKQTTLAFKPIKKGKKR"	"17"	"Sequence 53 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1629"	"RKEWLTNFMEDRRQRKL"	"17"	"Sequence 52 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1628"	"KKSKKGRQEALERLKKA"	"17"	"Sequence 51 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1627"	"KRMRNRIAASKCRKRKL"	"17"	"Sequence 50 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1626"	"RRERNKMAAAKCRNRRR"	"17"	"Sequence 49 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1625"	"RKCLQAGMNLEARKTKK"	"17"	"Sequence 48 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1624"	"PAKRARRGYK"	"10"	"Sequence 47 from Patent US 20090258815"	"canine parvovirus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1623"	"RRSMKRK"	"7"	"Sequence 46 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1622"	"RKRKK"	"5"	"Sequence 45 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1621"	"KRPRP"	"5"	"Sequence 44 from Patent US 20090258815"	"adenovirus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1620"	"LKDVRKRKLGPGH"	"13"	"Sequence 43 from Patent US 20090258815"	"epstein-barr virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1619"	"YKRPCKRSFIRFI"	"13"	"Sequence 42 from Patent US 20090258815"	"epstein-barr virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1618"	"PPRKKRTVV"	"9"	"Sequence 41 from Patent US 20090258815"	"Hepatitis C virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1617"	"RKRR"	"4"	"Sequence 40 from Patent US 20090258815"	"Arabidopsis sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1616"	"PRRRK"	"5"	"Sequence 39 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1615"	"KRPMNAFIVWAQAARRK"	"17"	"Sequence 38 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1614"	"RPRRK"	"5"	"Sequence 37 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1613"	"KRPMNAFIVWSRDQRRK"	"17"	"Sequence 36 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1612"	"MPKTRRRPRRSQRKRPPT"	"18"	"Sequence 35 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1611"	"RQARRNRRRRWR"	"12"	"Sequence 34 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1610"	"RKKRRQRRR"	"9"	"Sequence 33 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1609"	"APKRKSGVSKC"	"11"	"Sequence 32 from Patent US 20090258815"	"Polyomavirus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1608"	"KDCVINKHHRNRCQYCRLQR"	"20"	"Sequence 31 from Patent US 20090258815"	"Mus musculus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1607"	"PPRIYPQLPSAPT"	"13"	"Sequence 30 from Patent US 20090258815"	"Borna disease virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1606"	"PRPRKIPR"	"8"	"Sequence 29 from Patent US 20090258815"	"Borna disease virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1605"	"KKKKKEEEGEGKKK"	"14"	"Sequence 28 from Patent US 20090258815"	"Rattus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1604"	"KVTKRKHDNEGSGSKRPK"	"18"	"Sequence 27 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1603"	"KKKRRSREK"	"9"	"Sequence 26 from Patent US 20090258815"	"Drosophila sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1602"	"KKKKRKREK"	"9"	"Sequence 25 from Patent US 20090258815"	"Drosophila sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1601"	"CYGSKNTGAKKRKIDDA"	"17"	"Sequence 24 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1600"	"PYLNKRKGKP"	"10"	"Sequence 23 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1599"	"PPVKRERTS"	"9"	"Sequence 22 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1598"	"RKRRR"	"5"	"Sequence 21 from Patent US 20090258815"	"Rattus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1597"	"RGRRRRQR"	"8"	"Sequence 20 from Patent US 20090258815"	"Rattus sp."	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1596"	"KAKRQR"	"6"	"Sequence 19 from Patent US 20090258815"	"avian reticuloendothelios"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1595"	"GKKRSKA"	"7"	"Sequence 18 from Patent US 20090258815"	"Saccharomyces cerevisiae"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1594"	"PKKKRKV"	"7"	"Sequence 17 from Patent US 20090258815"	"Simian virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1593"	"KRPACTLKPECVQQLLVCSQEAKK"	"24"	"Sequence 16 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1592"	"RVHPYQR"	"7"	"Sequence 15 from Patent US 20090258815"	"Mus musculus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1591"	"RRMKWKK"	"7"	"Sequence 14 from Patent US 20090258815"	"Homo sapiens"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1590"	"RKKKRKVLALKAGLDI"	"16"	"Sequence 13 from Patent US 20090258815"	"Synthetic construct"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1589"	"YGRKKRRQRRRLPPLERLTLD"	"21"	"Sequence 12 from Patent US 20090258815"	"Synthetic construct"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1588"	"LPPLERLTLDRQARRNRRRRWR"	"22"	"Sequence 11 from Patent US 20090258815"	"Synthetic construct"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1587"	"RQARRNRRRRWRLPPLERLTLD"	"22"	"Sequence 10 from Patent US 20090258815"	"Synthetic construct"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1586"	"LSAQLYSSLSLD"	"12"	"Sequence 9 from Patent US 20090258815"	"Human T-cell lymphotropic"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1585"	"LPPDLRLTLD"	"10"	"Sequence 8 from Patent US 20090258815"	"Human immunodeficiency virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1584"	"LALKLAGLDI"	"10"	"Sequence 7 from Patent US 20090258815"	"Mus musculus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1583"	"LPPLERLTLD"	"10"	"Sequence 6 from Patent US 20090258815"	"Human immunodeficiency virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1582"	"YGRKKRRQRRR"	"11"	"Sequence 5 from Patent US 20090258815"	"Human immunodeficiency virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1581"	"RKKKRKV"	"7"	"Sequence 4 from Patent US 20090258815"	"Synthetic construct"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1580"	"PKKKRKV"	"7"	"Sequence 3 from Patent US 20090258815"	"Simian virus 40"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1579"	"RKKRRQRRR"	"9"	"Sequence 2 from Patent US 20090258815"	"Human immunodeficiency virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1578"	"RQARRNRRRRWR"	"12"	"Sequence 1 from Patent US 20090258815"	"Human immunodeficiency virus"	"Herpes viruse"	"Patent Application"	"US 2009/0258815 A1"	"2009-10-15"	"WO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2"	"Antiviral Peptide and Antiviral Agent"	"No cooments found in patent"	"Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES."		"Anti-Herpes viruse"
"DRAVPa1577"	"RLLLRLLYGY"	"10"	"Sequence 27 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1575"	"RLLLRYLLGY"	"10"	"Sequence 25 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1576"	"RLLLRLYLGY"	"10"	"Sequence 26 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1574"	"RLLYRLLLGY"	"10"	"Sequence 24 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1572"	"RYLLRLLLGY"	"10"	"Sequence 22 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1573"	"RLYLRLLLGY"	"10"	"Sequence 23 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1571"	"RLLLRLLWGY"	"10"	"Sequence 21 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1568"	"RLLWRLLLGY"	"10"	"Sequence 18 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1569"	"RLLLRWLLGY"	"10"	"Sequence 19 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1570"	"RLLLRLWLGY"	"10"	"Sequence 20 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1565"	"RLLLRLLIGY"	"10"	"Sequence 15 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1566"	"RWLLRLLLGY"	"10"	"Sequence 16 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1567"	"RLWLRLLLGY"	"10"	"Sequence 17 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1562"	"RLLLRLVLGY"	"10"	"Sequence 12 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1563"	"RLLLRLILGY"	"10"	"Sequence 13 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1564"	"RLLLRLLVGY"	"10"	"Sequence 14 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1559"	"RLLIRLLLGY"	"10"	"Sequence 9 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1560"	"RLLLRVLLGY"	"10"	"Sequence 10 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1561"	"RLLLRILLGY"	"10"	"Sequence 11 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1557"	"RLILRLLLGY"	"10"	"Sequence 7 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1558"	"RLLVRLLLGY"	"10"	"Sequence 8 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1554"	"RVLLRLLLGY"	"10"	"Sequence 4 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1555"	"RILLRLLLGY"	"10"	"Sequence 5 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1556"	"RLVLRLLLGY"	"10"	"Sequence 6 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1553"	"RLLLRLLLGY"	"10"	"Sequence 3 from Patent US 20090215699"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0215699 A1"	"2009-08-27"	"CA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/0215699 A1"	"Pharmaceutically Active Antiviral Peptides"	"No cooments found in patent"	"The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects."		"Anti-HIV"
"DRAVPa1552"	"SGSWLRDDWDWECTVLTDDKTWLQSKL"	"27"	"Sequence 91 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV89), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1551"	"SGSWLRDDWDWECTVLTDDKTWLQSKLDYKD"	"31"	"Sequence 90 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV88), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1550"	"SGSWLRDVWDWICTVLTDFKTWLQSKLDYKD"	"31"	"Sequence 89 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV87), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1549"	"ELGFQPGLKVAQHLAYPVPDVP"	"22"	"Sequence 88 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV86), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1548"	"LCLAGRGLQEAEGLLLELLSEHHPLLDV"	"28"	"Sequence 87 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV85), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1547"	"SWLRDVWDWIC"	"11"	"Sequence 86 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV84), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1546"	"DVWDWICTVLTD"	"12"	"Sequence 85 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV83), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1545"	"LRDVWDWICT"	"10"	"Sequence 84 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV82), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1544"	"LRDVWDWICTVLTDFKT"	"17"	"Sequence 83 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV81), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1543"	"IEQGMMLAEQFKQKALGLLQTASRHAEV"	"28"	"Sequence 81 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV80), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1542"	"DVRCHARKAVAHINSVWKD"	"19"	"Sequence 80 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV79), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1541"	"QDVLKEVKAAASKVKANLLSVEE"	"23"	"Sequence 79 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV78), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1540"	"SGSWLRDVWDWICTVLTDFKTWLQSKLDYK"	"30"	"Sequence 77 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV77), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1539"	"SWLRDIWDWVCTVLSDF"	"17"	"Sequence 76 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV76), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1538"	"SWLYDIVNWVCTVLADF"	"17"	"Sequence 75 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV75), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1537"	"SWLWDVWDWVLHVLSDF"	"17"	"Sequence 74 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV74), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1536"	"SWLHDIWDWVCIVLSDF"	"17"	"Sequence 73 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV73), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1535"	"SWLRTIWDWVCSVLADF"	"17"	"Sequence 72 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV72), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1534"	"SWLRIIWDWVCSWSDFK"	"17"	"Sequence 71 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV71), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1533"	"SWLRDIWEWVLSILTDF"	"17"	"Sequence 70 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV70), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1532"	"SWLRDVWDWVCTILTDF"	"17"	"Sequence 69 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV69), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1531"	"SWLRDVWDWICTVLTDF"	"17"	"Sequence 68 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV68), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1530"	"SWLRDIWDWVCTVLSD"	"16"	"Sequence 67 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV67), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1529"	"SWLYDIVNWVCTVLAD"	"16"	"Sequence 66 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV66), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1528"	"SWLWDVWDWVLHVLSD"	"16"	"Sequence 65 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV65), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1527"	"SWLHDIWDWVCIVLSD"	"16"	"Sequence 64 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV64), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1526"	"SWLRTIWDWVCSVLAD"	"16"	"Sequence 63 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV63), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1525"	"SWLRIIWDWVCSWSDF"	"16"	"Sequence 62 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV62), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1524"	"SWLRDIWEWVLSILTD"	"16"	"Sequence 61 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV61), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1523"	"SWLRDVWDWVCTILTD"	"16"	"Sequence 60 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV60), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1522"	"SWLRDVWDWICTVLTD"	"16"	"Sequence 59 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV59), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1521"	"SWLRDIWDWVCTVLS"	"15"	"Sequence 58 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV58), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1520"	"SWLYDIVNWVCTVLA"	"15"	"Sequence 57 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV57), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1519"	"SWLWDVWDWVLHVLS"	"15"	"Sequence 56 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV56), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1518"	"SWLHDIWDWVCIVLS"	"15"	"Sequence 55 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV55), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1517"	"SWLRTIWDWVCSVLA"	"15"	"Sequence 54 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV54), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1516"	"SWLRIIWDWVCSWSD"	"15"	"Sequence 53 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV53), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1515"	"SWLRDIWEWVLSILT"	"15"	"Sequence 52 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV52), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1514"	"SWLRDVWDWVCTILT"	"15"	"Sequence 51 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV51), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1513"	"SWLRDVWDWICTVLT"	"15"	"Sequence 50 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV50), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1512"	"GSWLRDIWDWVCTVLSDFRVWLKSKL"	"26"	"Sequence 49 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV49), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1511"	"GSWLYDIVNWVCTVLADFKLWLGAKI"	"26"	"Sequence 48 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV48), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1510"	"GSWLWDVWDWVLHVLSDFKTCLKAKF"	"26"	"Sequence 47 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV47), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1509"	"GSWLHDIWDWVCIVLSDFKTWLSAKI"	"26"	"Sequence 46 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV46), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1508"	"GSWLRTIWDWVCSVLADFKAWLSAKI"	"26"	"Sequence 45 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV45), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1507"	"GSWLRIIWDWVCSWSDFKTWLSAKI"	"25"	"Sequence 44 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV44), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1506"	"GSWLRDIWEWVLSILTDFKNWLSAKL"	"26"	"Sequence 43 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV43), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1505"	"GSWLRDVWDWVCTILTDFKNWLTSKL"	"26"	"Sequence 42 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV42), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1504"	"GSWLRDVWDWICTVLTDFKTWLQSKL"	"26"	"Sequence 41 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV41), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1503"	"SGSWLRDIWDWVCTVLSDFRVWLKSKL"	"27"	"Sequence 40 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV40), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1502"	"SGSWLYDIVNWVCTVLADFKLWLGAKI"	"27"	"Sequence 39 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV39), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1501"	"SGSWLWDVWDWVLHVLSDFKTCLKAKF"	"27"	"Sequence 38 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV38), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1500"	"SGSWLHDIWDWVCIVLSDFKTWLSAKI"	"27"	"Sequence 37 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV37), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1499"	"SGSWLRTIWDWVCSVLADFKAWLSAKI"	"27"	"Sequence 36 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV36), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1498"	"SGSWLRIIWDWVCSWSDFKTWLSAKI"	"26"	"Sequence 35 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV35), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1497"	"SGSWLRDIWEWVLSILTDFKNWLSAKL"	"27"	"Sequence 34 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV34), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1496"	"SGSWLRDVWDWVCTILTDFKNWLTSKL"	"27"	"Sequence 33 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV33), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1495"	"SGSWLRDVWDWICTVLTDFKTWLQSKL"	"27"	"Sequence 32 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV32), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1494"	"SGSLRDIWDWICEVLSDFKTWLKA"	"24"	"Sequence 31 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV31), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1493"	"SWLRDIWDWVCTVLSDFRVWLKSKL"	"25"	"Sequence 30 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV30), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1492"	"SWLYDIVNWVCTVLADFKLWLGAKI"	"25"	"Sequence 29 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV29), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1491"	"SWLWDVWDWVLHVLSDFKTCLKAKF"	"25"	"Sequence 28 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV28), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1490"	"SWLHDIWDWVCIVLSDFKTWLSAKI"	"25"	"Sequence 27 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV27), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1489"	"SWLRTIWDWVCSVLADFKAWLSAKI"	"25"	"Sequence 26 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV26), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1488"	"SWLRIIWDWVCSWSDFKTWLSAKI"	"24"	"Sequence 25 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV25), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1487"	"SWLRDIWEWVLSILTDFKNWLSAKL"	"25"	"Sequence 24 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV24), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1486"	"SWLRDVWDWVCTILTDFKNWLTSKL"	"25"	"Sequence 23 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV23), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1485"	"SWLRDVWDWICTVLTDFKTWLQSKL"	"25"	"Sequence 22 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV22), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1484"	"WLRDIWDWVCTVLSDFRVWLKSKL"	"24"	"Sequence 21 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV21), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1483"	"WLYDIVNWVCTVLADFKLWLGAKI"	"24"	"Sequence 20 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV20), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1482"	"WLWDVWDWVLHVLSDFKTCLKAKF"	"24"	"Sequence 19 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV19), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1481"	"WLHDIWDWVCIVLSDFKTWLSAKI"	"24"	"Sequence 18 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV18), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1480"	"WLRTIWDWVCSVLADFKAWLSAKI"	"24"	"Sequence 17 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV17), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1479"	"WLRIIWDWVCSVVSDFKTWLSAKI"	"24"	"Sequence 16 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV16), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1478"	"WLRDIWEWVLSILTDFKNWLSAKL"	"24"	"Sequence 15 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV15), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1477"	"WLRDVWDWVCTILTDFKNWLTSKL"	"24"	"Sequence 14 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV14), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1476"	"WLRDVWDWICTVLTDFKTWLQSKL"	"24"	"Sequence 13 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV13), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1475"	"LRDIWDWICEVLSDFKTWLKA"	"21"	"Sequence 12 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV12), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1474"	"SWLRDIWDWICEVL"	"14"	"Sequence 11 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV11), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."	"DRAVPe01079"	"Anti-HCV"
"DRAVPa1472"	"SWLYDIVNWVCTVC"	"14"	"Sequence 9 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV9), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1473"	"SWLRDIWDWVCTVC"	"14"	"Sequence 10 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV10), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1470"	"SWLHDIWDWVCIVC"	"14"	"Sequence 7 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV7), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1471"	"SWLWDVWDWVLHVL"	"14"	"Sequence 8 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV8), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1468"	"SWLRIIWDWVCSWC"	"14"	"Sequence 5 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV5), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1469"	"SWLRTIWDWVCSVC"	"14"	"Sequence 6 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV6), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1466"	"SWLRDVWDWVCTIL"	"14"	"Sequence 3 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV3), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1467"	"SWLRDIWEWVLSIL"	"14"	"Sequence 4 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV4), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses."	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1465"	"SWLRDVWDWICTVL"	"14"	"Sequence 2 from Patent US 20090105151"	"Hepatitis C virus"	"HCV"	"Patent Application"	"US 2009/0105151 A1"	"2009-04-23"	"WO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2"	"Amphipathic Alpha-Helical Peptide Compositions as Antiviral Agents"	"The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV2), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. "	"The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner."		"Anti-HCV"
"DRAVPa1464"	"PGDVYANGLVA"	"11"	"Sequence 32 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1462"	"RRKKAAVA"	"8"	"Sequence 30 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1463"	"PGYAGAVVNDL"	"11"	"Sequence 31 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1461"	"RRKKAAVAVVP"	"11"	"Sequence 29 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1460"	"RRKKAAVAVVPAVL"	"14"	"Sequence 28 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1458"	"RRKKLLAP"	"8"	"Sequence 26 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1459"	"RRKKAAVALLPAVLLAL"	"17"	"Sequence 27 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01188"	"Anti-HSV"
"DRAVPa1457"	"RRKKLLALLAP"	"11"	"Sequence 25 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1456"	"RRKKPAVLLALLAP"	"14"	"Sequence 24 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01196"	"Anti-HSV"
"DRAVPa1455"	"RRKKALLPAVLLALLAP"	"17"	"Sequence 23 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01193"	"Anti-HSV"
"DRAVPa1453"	"RRKKPAVLLA"	"10"	"Sequence 20 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1454"	"RRKKPAVLLALLALLA"	"16"	"Sequence 22 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1452"	"RRKKAVAVAVPAVLLALLAP"	"20"	"Sequence 19 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1451"	"RRKKAAVALLP"	"11"	"Sequence 18 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01190"	"Anti-HSV"
"DRAVPa1449"	"RRKK"	"4"	"Sequence 16 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1450"	"RRKKLAALPLVLAAPLAVLA"	"20"	"Sequence 17 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1448"	"DPKGDPKGVTVTVTVTVTGKGDPKPD"	"26"	"Sequence 13 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1447"	"GWTLNSAGYLLGKINLKALAALAKKIL"	"27"	"Sequence 12 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1446"	"YGRKKRRQRRRPGDVYANGLVA"	"22"	"Sequence 11 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=67 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1445"	"YGRKKRRQRRRPGYAGAVVNDL"	"22"	"Sequence 10 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=26 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1443"	"RQIKIWFPNRRMKWKK"	"16"	"Sequence 8 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=7 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1444"	"RQIKIFFPNRRMKFKK"	"16"	"Sequence 9 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=40 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1442"	"RQIKIWFPNRRMKWKKPGYAGAVVNDL"	"27"	"Sequence 7 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=9-12 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1441"	"KLALKLALKALKAALKLA"	"18"	"Sequence 5 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=11 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1440"	"RRKKPAVLLALLA"	"13"	"Sequence 4 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1439"	"RRKKAAVALLAVLLALLAPP"	"20"	"Sequence 3 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV"
"DRAVPa1437"	"QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 48 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.89 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1438"	"RRKKAAVALLPAVLLALLAP"	"20"	"Sequence 1 from Patent US 20050130884"	"Synthetic construct"	"HSV"	"Patent Application"	"US 2005/0130884 A1"	"2005-06-16"	"WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7"	"Pharmacologically active antiviral peptides and methods of their use"	"The peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=15-26 μM)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01185"	"Anti-HSV"
"DRAVPa1436"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ"	"51"	"Sequence 47 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.61 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1434"	"QQQNNLLRAIEAQQHLLQLTVWGIKQLAARILAVERYLKDQ"	"41"	"Sequence 45 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1435"	"QQQNNLLRAIEAQQHALQLTVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 46 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1433"	"QQQNNLLRAIEAQQHLLQLTVWGIAQLQARILAVERYLKDQ"	"41"	"Sequence 44 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1432"	"QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ"	"41"	"Sequence 43 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=1.34 μg/ml, IC90=3.81 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1430"	"QARQLVSGLVQQQNNILRALEATQHLVQLLVWGVKQLQARVLALERYIK"	"49"	"Sequence 41 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=3.892 μg/ml, IC90=14.53 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1431"	"QIRQLLSGIVQQQNNLLRAIEAIQHLLQLIVWGIKQLQARILAVERYLK"	"49"	"Sequence 42 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=13.605 μg/ml, IC90=33.56 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1429"	"QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ"	"51"	"Sequence 40 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.41 μg/ml, IC90=1.84 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1427"	"QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ"	"51"	"Sequence 38 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.18 μg/ml, IC90=0.88 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1428"	"QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ"	"51"	"Sequence 39 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.26 μg/ml, IC90=1.20 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1426"	"QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK"	"49"	"Sequence 37 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50<0.78 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1425"	"QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK"	"49"	"Sequence 36 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.73 μg/ml, IC90=3.03 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1423"	"QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ"	"51"	"Sequence 34 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.19 μg/ml, IC90=0.62 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1424"	"QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK"	"49"	"Sequence 35 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.14 μg/ml, IC90=0.69 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1422"	"WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL"	"36"	"Sequence 33 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."	"DRAVPe01974"	"Anti-HIV"
"DRAVPa1420"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK"	"49"	"Sequence 31 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.93 μg/ml, IC90=3.06 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1421"	"QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK"	"49"	"Sequence 32 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.59 μg/ml, IC90=1.90 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1419"	"QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ"	"41"	"Sequence 30 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=0.37 μg/ml, IC90=1.00 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1418"	"QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 29 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=2.81 μg/ml, IC90=5.86 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1416"	"QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 27 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=4.69 μg/ml, IC90=23.24 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1417"	"RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"34"	"Sequence 28 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1415"	"SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"45"	"Sequence 26 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1413"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"51"	"Sequence 24 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=3.73 μg/ml, IC90=12.301 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1414"	"SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"36"	"Sequence 25 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1412"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK"	"49"	"Sequence 23 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"The peptide shows antiviral activity against HIV IIIB.(IC50=4.69 μg/ml, IC90=23.24 μg/ml)"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1410"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"42"	"Sequence 21 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1411"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY"	"47"	"Sequence 22 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1409"	"LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG"	"36"	"Sequence 20 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1407"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI"	"38"	"Sequence 18 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1408"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR"	"44"	"Sequence 19 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1406"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG"	"37"	"Sequence 17 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1404"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV"	"35"	"Sequence 15 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1405"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW"	"36"	"Sequence 16 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1403"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"34"	"Sequence 14 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1401"	"MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"35"	"Sequence 12 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1402"	"MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV"	"36"	"Sequence 13 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1400"	"SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"36"	"Sequence 11 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1399"	"RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL"	"36"	"Sequence 10 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1397"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI"	"50"	"Sequence 8 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1398"	"ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ"	"36"	"Sequence 9 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1396"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV"	"40"	"Sequence 7 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1394"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL"	"36"	"Sequence 5 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1395"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL"	"38"	"Sequence 6 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1393"	"GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI"	"54"	"Sequence 4 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1391"	"NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"38"	"Sequence 2 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1392"	"GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"43"	"Sequence 3 from Patent US 20040091855"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1389"	"YQEWERKVDFLEENITALLEEAQIQQEKNMYELQKL"	"36"	"Sequence 80 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1390"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQLLGI"	"59"	"Sequence 1 from Patent US 20040091855"	"Human immunodeficiency virus"	"HIV"	"Patent Application"	"US 2004/0091855 A1"	"2004-05-13"	"US 2004/0091855 A1"	"Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom"	"No comments found in patent"	"Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers."		"Anti-HIV"
"DRAVPa1386"	"EALLRALQE"	"9"	"Sequence 77 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1387"	"WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF"	"39"	"Sequence 78 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe00254"	"Anti-HIV"
"DRAVPa1388"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT"	"39"	"Sequence 79 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1383"	"AARIEALLRALQE"	"13"	"Sequence 74 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1384"	"ARIEALLRALQE"	"12"	"Sequence 75 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1385"	"RIEALLRALQE"	"11"	"Sequence 76 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1380"	"TTWEAWDRAIAEYA"	"14"	"Sequence 71 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1381"	"TYWEAWDRAIAEY"	"13"	"Sequence 72 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1382"	"EL"	"2"	"Sequence 73 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1377"	"TTWEAWDRAIAEYAARI"	"17"	"Sequence 68 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1378"	"TTWEAWDRAIAEYAAR"	"16"	"Sequence 69 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1379"	"TTWEAWDRAIAEYAA"	"15"	"Sequence 70 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1374"	"TTWEAWDRAIAEYAARIEALLR"	"22"	"Sequence 65 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1375"	"TTWEAWDRAIAEYAARIEALL"	"21"	"Sequence 66 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1376"	"TTWEAWDRAIAEYAARIEA"	"19"	"Sequence 67 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1371"	"EQQEKNEAALREL"	"13"	"Sequence 62 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1372"	"TTWEAWDRAIAEYAARIEALLRALQ"	"25"	"Sequence 63 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1373"	"TTWEAWDRAIAEYAARIEALLRAL"	"24"	"Sequence 64 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1368"	"RIEALLRALQEQQEKNEAALRE"	"22"	"Sequence 59 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1369"	"QEQQEKNEAALREL"	"14"	"Sequence 60 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1370"	"LQEQQEKNEAALREL"	"15"	"Sequence 61 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1365"	"AIAEYAARIEALLRAAQEQQEKLEAALREL"	"30"	"Sequence 56 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1366"	"TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRE"	"37"	"Sequence 57 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1367"	"AARIEALLRALQEQQEKNEAALRE"	"24"	"Sequence 58 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1362"	"EYAARIEALLRAAQEQQEKLEAALREL"	"27"	"Sequence 53 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1363"	"AEYAARIEALLRAAQEQQEKLEAALREL"	"28"	"Sequence 54 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1364"	"IAEYAARIEALLRAAQEQQEKLEAALREL"	"29"	"Sequence 55 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1359"	"ALLRAAQEQQEKLEAALRE"	"19"	"Sequence 50 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1360"	"ALLRAAQEQQEKLEAALREL"	"20"	"Sequence 51 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with amide C-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1361"	"YAARIEALLRAAQEQQEKLEAALREL"	"26"	"Sequence 52 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1357"	"LRAAQEQQEKLEAALRE"	"17"	"Sequence 48 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1358"	"LRAALQEQQEKLEAALREL"	"19"	"Sequence 49 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with amide C-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1354"	"AEYAARIEALLRAAQE"	"16"	"Sequence 45 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1355"	"IAEYAARIEALLRAAQE"	"17"	"Sequence 46 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1356"	"AIAEYAARIEALLRAAQE"	"18"	"Sequence 47 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1351"	"QQEKLEAALRE"	"11"	"Sequence 42 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1352"	"QQEKLEAALREL"	"12"	"Sequence 43 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with amide C-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1353"	"EYAARIEALLRAAQE"	"15"	"Sequence 44 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1348"	"AIAEYAARIEALLRALQEQQEKNEAALREL"	"30"	"Sequence 39 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1349"	"TTWEAWDRAIAEYAARIEALLRALQE"	"26"	"Sequence 40 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1350"	"YAARIEALLRAAQE"	"14"	"Sequence 41 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1345"	"EYAARIEALLRALQEQQEKNEAALREL"	"27"	"Sequence 36 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1346"	"AEYAARIEALLRALQEQQEKNEAALREL"	"28"	"Sequence 37 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1347"	"IAEYAARIEALLRALQEQQEKNEAALREL"	"29"	"Sequence 38 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1342"	"ALLRALQEQQEKNEAALRE"	"19"	"Sequence 33 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1343"	"ALLRALQEQQEKNEAALREL"	"20"	"Sequence 34 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with amide C-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1344"	"YAARIEALLRALQEQQEKNEAALREL"	"26"	"Sequence 35 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1339"	"LRALQEQQEKNEAALRE"	"17"	"Sequence 30 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1340"	"LRALQEQQEKNEAALREL"	"18"	"Sequence 31 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with amide C-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1341"	"TTWEAWDRAIAEYAARIE"	"18"	"Sequence 32 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1336"	"TTWEAWDR"	"8"	"Sequence 27 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1337"	"AIAEYAARIEALLRALQE"	"18"	"Sequence 28 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1338"	"TTWEAWDRAIAEYAARIEAL"	"20"	"Sequence 29 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1333"	"AEYAARIEALLRALQE"	"16"	"Sequence 24 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1334"	"TTWEAWDRA"	"9"	"Sequence 25 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1335"	"IAEYAARIEALLRALQE"	"17"	"Sequence 26 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1330"	"TTWEAWDRAIA"	"11"	"Sequence 21 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1331"	"EYAARIEALLRALQE"	"15"	"Sequence 22 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1332"	"TTWEAWDRAI"	"10"	"Sequence 23 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1327"	"YAARIEALLRALQE"	"14"	"Sequence 18 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1328"	"QQEKNEAALRE"	"11"	"Sequence 19 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1329"	"QQEKNEAALREL"	"12"	"Sequence 20 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with amide C-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1325"	"TTWEAWDRAIAEYAARIEALLRAAQEQQEKIEAALREL"	"38"	"Sequence 15 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1326"	"TTWEAWDRAIAE"	"12"	"Sequence 17 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide was modified with acetyl N-terminus."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1322"	"TTWEAWDRAIAEYAARIEALIRAIQEQQEKLEAALREL"	"38"	"Sequence 12 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1323"	"TTWEAWDRAIAEYAARIEALIRALQEQQEKIEAALREL"	"38"	"Sequence 13 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1324"	"TTWEAWDRAIAEYAARIEALLRAIQEQQEKNEAALREL"	"38"	"Sequence 14 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1319"	"TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL"	"38"	"Sequence 9 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 μg/ml) and HIV-Res(IC50<0.10 μg/ml)."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1320"	"TTWEAWDRAIAEYAARIEALLRAAQEQQEKLEAALREL"	"38"	"Sequence 10 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 μg/ml) and HIV-Res(IC50<0.10 μg/ml)."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1321"	"TTWEAWDRAIAEYAARIEALIRALQEQQEKLEAALREL"	"38"	"Sequence 11 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1316"	"TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL"	"38"	"Sequence 6 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 μg/ml) and HIV-Res(IC50>0.10 μg/ml)."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe00262"	"Anti-HIV"
"DRAVPa1317"	"TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL"	"38"	"Sequence 7 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 μg/ml) and HIV-Res(IC50>0.10 μg/ml)."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe00265"	"Anti-HIV"
"DRAVPa1318"	"TTWEAWDRAIAEYAARIEALLRAAQEQQEKNEAALREL"	"38"	"Sequence 8 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 μg/ml)."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1314"	"WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL"	"36"	"Sequence 4 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe01974"	"Anti-HIV"
"DRAVPa1315"	"TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL"	"38"	"Sequence 5 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"The peptide shows antiviral activity against HIV-IIIB(IC50<0.10 μg/ml) and HIV-Res(IC50<0.10 μg/ml)."	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe00792"	"Anti-HIV"
"DRAVPa1311"	"WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"64"	"Sequence 1 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."		"Anti-HIV"
"DRAVPa1312"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 2 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe00520"	"Anti-HIV"
"DRAVPa1313"	"MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL"	"36"	"Sequence 3 from Patent US 20100261876 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2010/0261876 A1"	"2010-10-14"	"CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2"	"Novel Methods of Synthesis for Therapeutic Antiviral Peptides"	"No comments found in patent"	"Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides."	"DRAVPe00255"	"Anti-HIV"
"DRAVPa1309"	"TYICEVEDQKEE"	"12"	"Sequence 10 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1310"	"XPXLX"	"5"	"Sequence 11 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"X residues at position 1 and 5 are any amino acid, and can vary from 0 residues to about 100 residues at reach position."	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1308"	"LKIEDSDTYICEVEDQKEE"	"19"	"Sequence 9 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1306"	"KWLDAFYKDVAKELEKAF"	"18"	"Sequence 7 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1307"	"IKILGNQGSTLTKGPYSK"	"18"	"Sequence 8 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1304"	"ACYCRIPACIAGERRYGTCIYQGRLWAFCC"	"30"	"Sequence 5 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."	"DRAVPe00299"	"Anti-HIV"
"DRAVPa1305"	"DWLKAFYDKVAEKLKEAF"	"18"	"Sequence 6 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."	"DRAVPe01095"	"Anti-HIV"
"DRAVPa1303"	"ASTTTNYT"	"8"	"Sequence 4 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1301"	"TKPKTKPR"	"8"	"Sequence 2 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1302"	"AKTKPRQQ"	"8"	"Sequence 3 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1299"	"GTHPSSSAGLKNDLLEN"	"17"	"Sequence 58 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1300"	"TKPKTKPK"	"8"	"Sequence 1 from Patent US 5447915 A"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 5447915 A"	"1995-09-05"	"CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A"	"Terminally blocked antiviral peptides"	"No comments found in patent"	"This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds."		"Anti-HIV"
"DRAVPa1297"	"KREITFHGAKEISLS"	"15"	"Sequence 56 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1298"	"EQIADSQHRSHRQMV"	"15"	"Sequence 57 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1295"	"LTVPSERGLQRRR"	"13"	"Sequence 54 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1296"	"ALNGNGDPNNMDKAVKLY"	"18"	"Sequence 55 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1293"	"CXTCEQIADSQHXSHRQMV"	"19"	"Sequence 52 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 2 and 13 represent NMe-Ala and NMe-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1294"	"CXTCEQIADSQHXSHXQMV"	"19"	"Sequence 53 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 2 represents NMe-Ala and 'X' at position 13 and 16 indicates NMe-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1291"	"CATCEQIADSQHXSHRQMV"	"19"	"Sequence 50 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 13 represents Nme-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1292"	"CATCEQIADSQHRSHXQMV"	"19"	"Sequence 51 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 16 represents NMe-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1289"	"CXTCEQIADSQHXSHXQMV"	"19"	"Sequence 48 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 2 represents D-Ala and 'X' at position 13 and 16 indicates D-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1290"	"CXTCEQIADSQHRSHRQMV"	"19"	"Sequence 49 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 2 represents NMe-Ala."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1288"	"CXTCEQIADSQHXSHRQMV"	"19"	"Sequence 47 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 2 and 13 represent D-Ala and D-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1286"	"CATCEQIADSQHXSHRQMV"	"19"	"Sequence 45 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 13 represents D-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1287"	"CATCEQIADSQHRSHXQMV"	"19"	"Sequence 46 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 16 represents D-Arg."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1284"	"CATCEQIADSQHRSHRQMI"	"19"	"Sequence 43 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1285"	"CXTCEQIADSQHRSHRQMV"	"19"	"Sequence 44 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The 'X' at position 2 represents D-Ala."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1282"	"CATCEQIADSQHRSHRNMV"	"19"	"Sequence 41 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1283"	"CATCEQIADSQHRSHRQML"	"19"	"Sequence 42 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1280"	"CATCEQIADSNHRSHRQMV"	"19"	"Sequence 39 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1281"	"CATCEQIADSQHRTHRQMV"	"19"	"Sequence 40 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1278"	"CATCEQIAESQHRSHRQMV"	"19"	"Sequence 37 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1279"	"CATCEQIADTQHRSHRQMV"	"19"	"Sequence 38 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1276"	"CATCEQLADSQHRSHRQMV"	"19"	"Sequence 35 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1277"	"CATCEQVADSQHRSHRQMV"	"19"	"Sequence 36 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1274"	"CATCDQIADSQHRSHRQMV"	"19"	"Sequence 33 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1275"	"CATCENIADSQHRSHRQMV"	"19"	"Sequence 34 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1272"	"CATCEQIADSQHKSHKQMV"	"19"	"Sequence 31 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1273"	"CASCEQIADSQHRSHRQMV"	"19"	"Sequence 32 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1270"	"CATCEQIADSQHKSHRQMV"	"19"	"Sequence 29 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1271"	"CATCEQIADSQHRSHKQMV"	"19"	"Sequence 30 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1268"	"CATCEQIADSQHRSHRQAV"	"19"	"Sequence 27 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1269"	"CATCEQIADSQHRSHRQMA"	"19"	"Sequence 28 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1267"	"CATCEQIADSQHRSHRAMV"	"19"	"Sequence 26 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1265"	"CATCEQIADSQHRAHRQMV"	"19"	"Sequence 24 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1266"	"CATCEQIADSQHRSHAQMV"	"19"	"Sequence 25 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1263"	"CATCEQIADSAHRSHRQMV"	"19"	"Sequence 22 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1264"	"CATCEQIADSQHASHRQMV"	"19"	"Sequence 23 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1261"	"CATCEQIAASQHRSHRQMV"	"19"	"Sequence 20 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1262"	"CATCEQIADAQHRSHRQMV"	"19"	"Sequence 21 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1259"	"CATCEAIADSQHRSHRQMV"	"19"	"Sequence 18 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1260"	"CATCEQAADSQHRSHRQMV"	"19"	"Sequence 19 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1257"	"CAACEQIADSQHRSHRQMV"	"19"	"Sequence 16 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1258"	"CATCAQIADSQHRSHRQMV"	"19"	"Sequence 17 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1256"	"CATCEQIADSQHRSHRQMV"	"19"	"Sequence 15 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1255"	"CATCEQIADSQHRSHRQMV"	"19"	"Sequence 14 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1254"	"CATCEQIADSQHRHRQMV"	"18"	"Sequence 13 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"The peptide was modified with acetyl N-terminus."	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1253"	"CATCEQIADSQHRHRQMV"	"18"	"Sequence 12 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1252"	"CACEQIADSQHRSHRQMV"	"18"	"Sequence 11 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1251"	"CTCEQIADSQHRSHRQMV"	"18"	"Sequence 10 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1250"	"CATCADSQHRSHRQMV"	"16"	"Sequence 9 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1249"	"CATCIADSQHRSHRQMV"	"17"	"Sequence 8 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1248"	"CATCQIADSQHRSHRQMV"	"18"	"Sequence 7 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1247"	"CATCEQIADSQHRSH"	"15"	"Sequence 6 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1246"	"CATCEQIADSQHRSHR"	"16"	"Sequence 5 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1245"	"CATCEQIADSQHRSHRQ"	"17"	"Sequence 4 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1244"	"CATCEQIADSQHRSHRQM"	"18"	"Sequence 3 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1243"	"CATCEQIADSQHRSHRQMV"	"19"	"Sequence 2 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1242"	"CATCEQIADSQHRSHRQMV"	"19"	"Sequence 1 from Patent US 5616327"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US 5616327 A"	"1997-04-01"	"CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T2"	"M-protein peptides of influenza virus as antiviral agents"	"No comments found in patent"	"Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations."		"Anti-influenza virus"
"DRAVPa1241"	"APGDEPAPP"	"9"	"Sequence 12 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=115 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1240"	"EETRRMLHRAFDTLA"	"15"	"Sequence 11 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=32.5 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1239"	"AGATAEETA"	"9"	"Sequence 10 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=88.5 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1238"	"GATAEETA"	"8"	"Sequence 9 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=240 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1237"	"AGATAEETAA"	"10"	"Sequence 8 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=56.6 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1236"	"AGATAEETAY"	"10"	"Sequence 7 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=37.5 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1235"	"AAAPGDEPAPP"	"11"	"Sequence 6 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=90 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1234"	"AAPGDEPAPP"	"10"	"Sequence 5 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=152 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1233"	"APGDEPAPP"	"9"	"Sequence 4 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=188 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1232"	"APGDEPAPPY"	"10"	"Sequence 3 from Patent US 5859187 A"	"Synthetic construct"	"HSV"	"Granted Patent"	"US 5859187 A"	"1999-01-12"	"IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 A"	"Antiviral peptides"	"The peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=161 μM)."	"Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents."		"Anti-HSV"
"DRAVPa1231"	"QVNEKINQSLAFIRKSDELLHNVNAGKST"	"29"	"Sequence 232 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1230"	"ISQVNEKINQSLAFIRKSDELLHNVNAGKST"	"31"	"Sequence 231 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1229"	"FDASISQVNEKINQSLAFIRKSDEL"	"25"	"Sequence 230 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1228"	"FDASISQVNEKINQSLAFIRKSDELLH"	"27"	"Sequence 229 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1227"	"FDASISQVNEKINQSLAFIRKSDELLHNV"	"29"	"Sequence 228 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1226"	"FDASISQVNEKINQSLAFIRKSDELLHNVNA"	"31"	"Sequence 227 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1225"	"DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT"	"35"	"Sequence 226 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00912"	"Anti-HIV"
"DRAVPa1224"	"FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST"	"35"	"Sequence 225 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00911"	"Anti-HIV"
"DRAVPa1223"	"EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS"	"35"	"Sequence 224 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00910"	"Anti-HIV"
"DRAVPa1222"	"DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK"	"35"	"Sequence 223 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00909"	"Anti-HIV"
"DRAVPa1221"	"SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG"	"35"	"Sequence 222 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00908"	"Anti-HIV"
"DRAVPa1220"	"PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA"	"35"	"Sequence 221 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00907"	"Anti-HIV"
"DRAVPa1219"	"FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN"	"35"	"Sequence 220 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00906"	"Anti-HIV"
"DRAVPa1218"	"VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV"	"35"	"Sequence 219 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00905"	"Anti-HIV"
"DRAVPa1217"	"LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN"	"35"	"Sequence 218 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00904"	"Anti-HIV"
"DRAVPa1216"	"PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH"	"35"	"Sequence 217 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00903"	"Anti-HIV"
"DRAVPa1215"	"DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"35"	"Sequence 216 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00902"	"Anti-HIV"
"DRAVPa1214"	"YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL"	"35"	"Sequence 215 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00901"	"Anti-HIV"
"DRAVPa1213"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE"	"35"	"Sequence 214 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00900"	"Anti-HIV"
"DRAVPa1212"	"INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS"	"35"	"Sequence 213 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00898"	"Anti-HIV"
"DRAVPa1211"	"IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK"	"35"	"Sequence 212 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00897"	"Anti-HIV"
"DRAVPa1210"	"DEFDASISQVNEKINQSLAFIRKSDELL"	"28"	"Sequence 211 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1209"	"VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV"	"35"	"Sequence 210 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1208"	"PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTSTGPCRTCMTT"	"57"	"Sequence 209 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1207"	"PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSP"	"46"	"Sequence 208 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1206"	"SENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF"	"37"	"Sequence 207 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1205"	"SSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDL"	"35"	"Sequence 206 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1204"	"LQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHED"	"45"	"Sequence 205 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1203"	"LLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSI"	"35"	"Sequence 204 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1202"	"ASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDS"	"45"	"Sequence 203 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1201"	"SELEIKRYKNRVASRKCRAKFQLLQHYREVAAAKSSENDRLRLLL"	"45"	"Sequence 202 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1200"	"MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWG"	"63"	"Sequence 201 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1199"	"LSNLLQISNNSDEWLEALEIEHEKWKLTQWQSYEQF"	"36"	"Sequence 200 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1198"	"LLDNFESTWEQSKELWEQQEISIQNLHKSALQEYWN"	"36"	"Sequence 199 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1197"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNSF"	"36"	"Sequence 198 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1196"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASPWNWF"	"36"	"Sequence 197 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1195"	"YTSLIHSLIEESQNQQEKNEQELLELDKPASLWNWF"	"36"	"Sequence 196 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1194"	"YTSLIHSLIEESQNQQEKNEQELLEFDKWASLWNWF"	"36"	"Sequence 195 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1193"	"YTSLIHSLIEESQNQQEKLEQELLELDKWASLWNWF"	"36"	"Sequence 194 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1192"	"YTSLIHSLIEESQNLQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 193 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1191"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF"	"36"	"Sequence 192 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1190"	"YTSLIQSLIEESQNQQEKNEQQLLELDKWASLWNWF"	"36"	"Sequence 191 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1189"	"YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF"	"36"	"Sequence 190 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1188"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA"	"36"	"Sequence 189 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1187"	"YTSLIHSLIQQSQNQQQKNQQQLLQLDKWASLWNWF"	"36"	"Sequence 188 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1186"	"YTSLIHSLIQESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 187 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1185"	"YTSLIHSLIEQSQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 186 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1184"	"YTSLIHSLIEESQNQQEKNEQELLELNKWASLWNWF"	"36"	"Sequence 185 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1183"	"YTSLIHSLIEESQQQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 184 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1182"	"YTSLIQSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 183 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1181"	"YTSLIHSLIEESQNQQEKNQQELLQLDKWASLWNWF"	"36"	"Sequence 182 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1180"	"YTSLIHSLIEESQNQQEKNEQELLQLDKWASLWNWF"	"36"	"Sequence 181 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1179"	"YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF"	"36"	"Sequence 180 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1178"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLANWF"	"36"	"Sequence 179 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1177"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNAF"	"36"	"Sequence 178 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1176"	"CGGYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"39"	"Sequence 177 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1175"	"LELKKWASLWNWF"	"13"	"Sequence 176 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1174"	"LKLDKWASLWNWF"	"13"	"Sequence 175 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1173"	"LELDKAASLWNWF"	"13"	"Sequence 174 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1172"	"LELDKWASAWNWF"	"13"	"Sequence 173 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1171"	"LELDKWASLWNWA"	"13"	"Sequence 172 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1170"	"LELDKWASLWNAF"	"13"	"Sequence 171 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1169"	"LELDKWASLFNFF"	"13"	"Sequence 170 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1168"	"LELDKWASLANAF"	"13"	"Sequence 169 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1167"	"CLELDKWASLWNFFC"	"15"	"Sequence 168 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1166"	"CLELDKWASLANWFC"	"15"	"Sequence 167 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1165"	"CLELDKWASLWNWFC"	"15"	"Sequence 166 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1164"	"FWNWLSAWKDLELYPGSLELDKWASLWNWF"	"30"	"Sequence 165 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1163"	"RMKQLEDKVEELLSKNYHLENELELDKWASLWNWF"	"35"	"Sequence 164 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1162"	"FWNWLSAWKDLELKSLLEEVKDELQKMR"	"28"	"Sequence 163 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1161"	"RMKQLEDKVEELLSKLELDKWASLWNWF"	"28"	"Sequence 162 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1160"	"EAAAREAAAREAAARLELDKWASLWNWF"	"28"	"Sequence 161 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1159"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWLIKIFI"	"49"	"Sequence 160 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1158"	"WMEWDREINNYTSLIGSLIEESQNQQEKNEQELLE"	"35"	"Sequence 159 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1157"	"NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEEQNQQEKNEQELLELDKWASLWNWF"	"57"	"Sequence 158 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1156"	"TSITLQVRLPLLTRLLNTQIYRVDSISYNIQNREWY"	"36"	"Sequence 157 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1155"	"YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEI"	"36"	"Sequence 156 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1154"	"DQQIKQYKRLLDRLIIPLYDGLRQKDVIVSNQESN"	"35"	"Sequence 155 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1153"	"RMKQLEDKVEELLSKLEWIRRSNQKLDSI"	"29"	"Sequence 154 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1152"	"IDISIELNKAKSDLEESKEWIKKSNQKLDSIGNWH"	"35"	"Sequence 153 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1151"	"EWIRRSNQKLDSI"	"13"	"Sequence 152 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1150"	"LKEAIRDTNKAVQSVQSSIGNLIVAIKS"	"28"	"Sequence 151 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1149"	"AVQSVQSSIGNLIVAIKSVQDYVNKEIV"	"28"	"Sequence 150 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1148"	"IRDTNKAVQSVQSSIGNLIVAIKSVQDY"	"28"	"Sequence 149 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1147"	"AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA"	"35"	"Sequence 148 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1146"	"AAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSS"	"35"	"Sequence 147 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1145"	"ATSAQITAAVALVEAKQARSDIEKLKEA"	"28"	"Sequence 146 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1144"	"FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST"	"35"	"Sequence 145 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00911"	"Anti-HIV"
"DRAVPa1143"	"ASISQVNEKINQSLAFIRKSDELLHNVNAGKST"	"33"	"Sequence 144 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1142"	"FDASISQVNEKINQSLAFIRKSDELLHNVNAGK"	"33"	"Sequence 143 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1141"	"SLAFIRKSDELLHNVNAGKST"	"21"	"Sequence 142 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1140"	"FDASISQVNEKINQSLAFI"	"19"	"Sequence 141 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1139"	"AFIRKSDELLHNVNAGKST"	"19"	"Sequence 140 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1138"	"RMKQLEDKVEELLSKLAFIRKSDELLHNV"	"29"	"Sequence 139 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1137"	"PIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR"	"35"	"Sequence 138 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1136"	"SISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVS"	"36"	"Sequence 137 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1135"	"NDQKKLMSNNVQIVRQQSYSIMSIIKEE"	"28"	"Sequence 136 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1134"	"VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSK"	"35"	"Sequence 135 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50=328 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1133"	"ASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGV"	"37"	"Sequence 134 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1132"	"LLSTNKAVVSLSNGVSVLTSKVLDLKNY"	"28"	"Sequence 133 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1131"	"VLHLEGEVNKIKSALLSTNKAVVSLSNG"	"28"	"Sequence 132 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1130"	"LLSTNKAVVSLSNGVSVLTSKVLDLKNY"	"28"	"Sequence 131 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1129"	"VVSLSNGVSVLTSKVLDLKNYIDKQLL"	"27"	"Sequence 130 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1128"	"AVSKGYLSALRTGWYTSVITIELSNIKENKXNGTDA"	"36"	"Sequence 129 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1127"	"KENKXNGTDAKVKLIKQELDKYKNAVTELQLLMQS"	"35"	"Sequence 128 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1126"	"SNIKENKXNGTDAKVKLIKQELDKYKNAVTELQLL"	"35"	"Sequence 127 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1125"	"SVITIELSNIKENKXNGTDAKVKLIKQELDKYKNA"	"35"	"Sequence 126 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1124"	"TSVITIELSNIKENKXNGTDAKVKLIKQELDKYKN"	"35"	"Sequence 125 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1123"	"YTSVITIELSNIKENKXNGTDAKVKLIKQELDKYK"	"35"	"Sequence 124 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1122"	"AFIRKSDELLHNV"	"13"	"Sequence 123 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50=26 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1121"	"VSKGYSALRTGWYTSVITIELSNIKEN"	"27"	"Sequence 122 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group. The antiviral activity of peptide on RSV(IC50=165 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1120"	"IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"42"	"Sequence 121 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group. The antiviral activity of peptide on RSV(IC50>500 μg/ml)."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1119"	"TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF"	"47"	"Sequence 120 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1118"	"LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK"	"34"	"Sequence 119 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1117"	"PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED"	"35"	"Sequence 118 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00936"	"Anti-HIV"
"DRAVPa1116"	"YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT"	"56"	"Sequence 101 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1115"	"GTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP"	"70"	"Sequence 100 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1114"	"GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT"	"53"	"Sequence 99 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1113"	"ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL"	"54"	"Sequence 98 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1112"	"YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST"	"46"	"Sequence 97 from Patent US 6228983 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-RSV"
"DRAVPa1111"	"NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"38"	"Sequence 89 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1110"	"IEKTNEKFHQIEKEFSEVEGRIQDLEKY"	"28"	"Sequence 88 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1109"	"EQKLISEEDLLEKRREQLKHKLEQLRNS"	"28"	"Sequence 87 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1108"	"IARLEEKVKTLKAQNSELASTANMLREQ"	"28"	"Sequence 86 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1107"	"TDTLQAETDQLEDEKSALQTEIANLLKE"	"28"	"Sequence 85 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1106"	"MKQLEDKVEELLSKNYHLENEVARLKKL"	"28"	"Sequence 84 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1105"	"LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK"	"34"	"Sequence 83 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1104"	"SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM"	"34"	"Sequence 82 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1103"	"PISLERLDVGTNLGNAIAKLEAKELLESSDQILR"	"34"	"Sequence 81 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1102"	"PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL"	"34"	"Sequence 80 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1101"	"GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI"	"34"	"Sequence 79 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1100"	"LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ"	"34"	"Sequence 78 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1099"	"DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD"	"34"	"Sequence 77 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1098"	"IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS"	"34"	"Sequence 76 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1097"	"RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES"	"34"	"Sequence 75 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1096"	"HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE"	"34"	"Sequence 74 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1095"	"LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL"	"34"	"Sequence 73 from Patent US 6228983 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-MeV"
"DRAVPa1094"	"FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN"	"35"	"Sequence 72 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1093"	"DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG"	"35"	"Sequence 71 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1092"	"VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF"	"35"	"Sequence 70 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1091"	"KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV"	"35"	"Sequence 69 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1090"	"RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD"	"35"	"Sequence 68 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1089"	"ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW"	"35"	"Sequence 67 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1088"	"WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS"	"35"	"Sequence 66 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1087"	"EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN"	"35"	"Sequence 65 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1086"	"QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL"	"35"	"Sequence 64 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1085"	"WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK"	"35"	"Sequence 63 from Patent US 6228983 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-SIV"
"DRAVPa1084"	"AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV"	"35"	"Sequence 62 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1083"	"LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK"	"35"	"Sequence 61 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1082"	"KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN"	"35"	"Sequence 60 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1081"	"SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ"	"35"	"Sequence 59 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1080"	"RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV"	"35"	"Sequence 58 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1079"	"ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS"	"35"	"Sequence 57 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1078"	"QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK"	"35"	"Sequence 56 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1077"	"KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI"	"35"	"Sequence 55 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1076"	"AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA"	"35"	"Sequence 54 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1075"	"EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV"	"35"	"Sequence 53 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1074"	"VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI"	"35"	"Sequence 52 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1073"	"LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL"	"35"	"Sequence 51 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1072"	"AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI"	"35"	"Sequence 50 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1071"	"TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS"	"35"	"Sequence 49 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HPIV3"
"DRAVPa1070"	"ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT"	"35"	"Sequence 48 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00935"	"Anti-HPIV3"
"DRAVPa1069"	"IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST"	"35"	"Sequence 47 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00934"	"Anti-HPIV3"
"DRAVPa1068"	"SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS"	"35"	"Sequence 46 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00933"	"Anti-HPIV3"
"DRAVPa1067"	"ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS"	"35"	"Sequence 45 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00932"	"Anti-HPIV3"
"DRAVPa1066"	"DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ"	"35"	"Sequence 44 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00931"	"Anti-HPIV3"
"DRAVPa1065"	"IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH"	"35"	"Sequence 43 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00929"	"Anti-HPIV3"
"DRAVPa1064"	"PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW"	"35"	"Sequence 42 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00928"	"Anti-HPIV3"
"DRAVPa1063"	"DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN"	"35"	"Sequence 41 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00927"	"Anti-HPIV3"
"DRAVPa1062"	"LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG"	"35"	"Sequence 40 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00926"	"Anti-HPIV3"
"DRAVPa1061"	"ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI"	"35"	"Sequence 39 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00925"	"Anti-HPIV3"
"DRAVPa1060"	"VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS"	"35"	"Sequence 38 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00924"	"Anti-HPIV3"
"DRAVPa1059"	"SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD"	"35"	"Sequence 37 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00923"	"Anti-HPIV3"
"DRAVPa1058"	"NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL"	"35"	"Sequence 36 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00922"	"Anti-HPIV3"
"DRAVPa1057"	"NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK"	"35"	"Sequence 35 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00921"	"Anti-HPIV3"
"DRAVPa1056"	"LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ"	"35"	"Sequence 34 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00920"	"Anti-HPIV3"
"DRAVPa1055"	"TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN"	"35"	"Sequence 33 from Patent US 6228983 B1"	"Synthetic construct"	"HPIV3"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00919"	"Anti-HPIV3"
"DRAVPa1054"	"ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ"	"33"	"Sequence 32 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1053"	"IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK"	"33"	"Sequence 31 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1052"	"KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID"	"33"	"Sequence 30 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1051"	"NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI"	"33"	"Sequence 29 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1050"	"VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY"	"33"	"Sequence 28 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1049"	"EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN"	"33"	"Sequence 27 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1048"	"GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK"	"33"	"Sequence 26 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1047"	"LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD"	"33"	"Sequence 25 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1046"	"KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS"	"33"	"Sequence 24 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1045"	"SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT"	"33"	"Sequence 23 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1044"	"VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL"	"33"	"Sequence 22 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1043"	"AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV"	"33"	"Sequence 21 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1042"	"VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS"	"33"	"Sequence 20 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1041"	"ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR"	"34"	"Sequence 19 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1040"	"ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS"	"35"	"Sequence 18 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00918"	"Anti-HIV"
"DRAVPa1039"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"37"	"Sequence 17 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1038"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"48"	"Sequence 16 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group."	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1037"	"QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ"	"38"	"Sequence 10 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1036"	"LQARILAVERYLKDQQQ"	"17"	"Sequence 9 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1035"	"CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 8 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1034"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"36"	"Sequence 7 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1033"	"LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF"	"36"	"Sequence 6 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1032"	"YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 5 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1031"	"YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF"	"36"	"Sequence 4 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1030"	"YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 3 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1029"	"SSESFTLLEQWNNWKLQLAEQWLEQINEKHYLEDIS"	"36"	"Sequence 2 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."		"Anti-HIV"
"DRAVPa1028"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 1 from Patent US 6228983 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 6228983 B1"	"2001-05-08"	"WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62"	"Human respiratory syncytial virus peptides with antifusogenic and antiviral activities"	"No comments found in patent"	"The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides."	"DRAVPe00520"	"Anti-HIV"
"DRAVPa1027"	"PGDVYANGLVA"	"11"	"Sequence 44 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1026"	"PGYAGAVVNDL"	"11"	"Sequence 43 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1025"	"GRKKRRQXXRC"	"11"	"Sequence 42 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The 'X' at position 8 and 9 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1024"	"GRKKRRQXXRC"	"11"	"Sequence 41 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The 'X' at position 8 and 9 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1023"	"GRXXRRQRRRC"	"11"	"Sequence 40 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The 'X' at position 3 and 4 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1022"	"GRKKRRQRRRC"	"11"	"Sequence 39 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01935"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1021"	"GRKKRRQRRRC"	"11"	"Sequence 38 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01935"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1020"	"GRKKRRQRRR"	"10"	"Sequence 37 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01573"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1019"	"GRKKRRQRRR"	"10"	"Sequence 36 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01573"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1018"	"GRKKRRQRRRC"	"11"	"Sequence 35 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01935"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1017"	"LAVLAPGRKKRRQRRRC"	"17"	"Sequence 34 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1016"	"LVLAAPLAVLAPGRKKRRQRRRC"	"23"	"Sequence 33 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1015"	"LAALPLVLAAPLAVLAPGRKKRRQRRRC"	"28"	"Sequence 32 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1014"	"YGRKKRRQRRRPLAALPLVLAAPLAVLA"	"28"	"Sequence 31 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1013"	"GRKKRRQRRRPLAALPLVLAAPLAVLA"	"27"	"Sequence 30 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1012"	"RRKKAAVA"	"8"	"Sequence 29 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1011"	"RRKKAAVAVVP"	"11"	"Sequence 28 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1010"	"RRKKAAVAVVPAVL"	"14"	"Sequence 27 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1009"	"RRKKAAVALLPAVLLAL"	"17"	"Sequence 26 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01188"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1008"	"RRKKLLAP"	"8"	"Sequence 25 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1007"	"RRKKLLALLAP"	"11"	"Sequence 24 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1006"	"RRKKPAVLLALLAP"	"14"	"Sequence 23 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01196"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1005"	"RRKKALLPAVLLALLAP"	"17"	"Sequence 22 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01193"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1004"	"RRKKPAVLLALLALLA"	"16"	"Sequence 21 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1003"	"RRKKPAVLLA"	"10"	"Sequence 20 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1002"	"RRKKAVAVAVPAVLLALLAP"	"20"	"Sequence 19 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1001"	"RRKKAAVALLP"	"11"	"Sequence 18 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01190"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa1000"	"RRKKLAALPLVLAAPLAVLA"	"20"	"Sequence 17 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0999"	"RRKK"	"4"	"Sequence 16 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0998"	"DPKGDPKGVTVTVTVTVTGKGDPKPD"	"26"	"Sequence 13 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0997"	"GWTLNSAGYLLGKINLKALAALAKKIL"	"27"	"Sequence 12 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0996"	"YGRKKRRQRRRPGDVYANGLVA"	"22"	"Sequence 11 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=67 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0995"	"YGRKKRRQRRRPGYAGAVVNDL"	"22"	"Sequence 10 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=26 μm) and antifree virus activity(IC50=8 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0994"	"RQIKIFFPNRRMKFKK"	"16"	"Sequence 9 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=40 μm) and antifree virus activity(IC50=34 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0993"	"RQIKIWFPNRRMKWKK"	"16"	"Sequence 8 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=7 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0992"	"RQIKIWFPNRRMKWKKPGYAGAVVNDL"	"27"	"Sequence 7 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=9-12 μm) and antifree virus activity(IC50=6 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0991"	"KLALKLALKALKAALKLA"	"18"	"Sequence 6 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=23 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0990"	"KLALKLALKALKAALKLA"	"18"	"Sequence 5 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=11 μm) and antifree virus activity(IC50=4.5 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0989"	"RRKKPAVLLALLA"	"13"	"Sequence 4 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0988"	"RRKKAAVALLAVLLALLAPP"	"20"	"Sequence 3 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."		"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0987"	"RRKKAAVALLPAVLLALLAP"	"20"	"Sequence 2 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=15 μm) and antifree virus activity(IC50=21 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01185"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0986"	"RRKKAAVALLPAVLLALLAP"	"20"	"Sequence 1 from Patent US 7432045 B2"	"Synthetic construct"	"HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus"	"Granted Patent"	"US 7432045 B2"	"2008-10-07"	"WO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2"	"Method of inhibiting influenza infection with antiviral peptides"	"The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=15-26 μm)."	"This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections."	"DRAVPe01185"	"Anti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus"
"DRAVPa0985"	"LTWQEWDREINNYTSLIYSLIEESQNQQEENEQELL"	"36"	"Sequence 114 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0984"	"SLEQIWNNMTWMEWEREIDNYTSLIYSLI"	"29"	"Sequence 99 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0983"	"EWEREIDNYTSLIYSLIEESQNQQEKNEQE"	"30"	"Sequence 98 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0982"	"NNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE"	"36"	"Sequence 97 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0981"	"KSLEQIWNNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE"	"43"	"Sequence 96 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0980"	"LIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT"	"36"	"Sequence 95 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0979"	"SLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI"	"36"	"Sequence 94 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0978"	"TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN"	"36"	"Sequence 93 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0977"	"NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW"	"36"	"Sequence 92 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0976"	"WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW"	"36"	"Sequence 91 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0975"	"EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK"	"36"	"Sequence 90 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0974"	"MEWDREINNYTSLIHSLIEESQNQQEKNEQELLED"	"35"	"Sequence 89 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0973"	"WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL"	"36"	"Sequence 88 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."	"DRAVPe01974"	"Anti-HIV"
"DRAVPa0972"	"TWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE"	"36"	"Sequence 87 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0971"	"MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL"	"36"	"Sequence 86 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."	"DRAVPe00255"	"Anti-HIV"
"DRAVPa0970"	"NMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL"	"36"	"Sequence 85 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0969"	"NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQE"	"36"	"Sequence 84 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0968"	"WNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ"	"36"	"Sequence 83 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0967"	"IWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNE"	"36"	"Sequence 82 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0966"	"QIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKN"	"36"	"Sequence 81 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0965"	"EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEK"	"36"	"Sequence 80 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0964"	"LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQE"	"36"	"Sequence 79 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0963"	"SLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQ"	"36"	"Sequence 78 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0962"	"KSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQ"	"36"	"Sequence 77 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0961"	"NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQN"	"36"	"Sequence 76 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0960"	"NASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLI"	"36"	"Sequence 75 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0959"	"QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 74 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0958"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ"	"51"	"Sequence 73 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0957"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK"	"49"	"Sequence 72 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0956"	"QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ"	"41"	"Sequence 71 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0955"	"QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ"	"51"	"Sequence 70 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0954"	"QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ"	"51"	"Sequence 69 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0953"	"QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ"	"51"	"Sequence 68 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0952"	"QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK"	"49"	"Sequence 67 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0951"	"QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK"	"49"	"Sequence 66 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0950"	"QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK"	"49"	"Sequence 65 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0949"	"QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ"	"51"	"Sequence 64 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0948"	"QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK"	"49"	"Sequence 63 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0947"	"QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ"	"41"	"Sequence 62 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0946"	"QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 61 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0945"	"WQEWEQKITALLEQAQIQQEKIEYELQKLIEWEWF"	"35"	"Sequence 60 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0944"	"WQEWEQKITALLEQAQIQQEKNEYELQKLAEWAGLWAWF"	"39"	"Sequence 59 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0943"	"WQEWEQKITALLEQAQIQQEKNEYELQKLDKWAGLWEWF"	"39"	"Sequence 58 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0942"	"WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWNWF"	"39"	"Sequence 57 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0941"	"WQEWEREITALLEQAQIQQEKIEYELQKLDEWEWF"	"35"	"Sequence 56 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0940"	"WQEWEREITALLEQAQIQQEKNEYELQKLIEWEWF"	"35"	"Sequence 55 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0939"	"WQEWEREITALLEQAQIQQEKIEYELQKLIEWEWF"	"35"	"Sequence 54 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0938"	"WQEWDREITALLEQAQIQQEKNEYELQKLDEWEWF"	"35"	"Sequence 53 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0937"	"WQEWDREITALLEQAQIQQEKNEYELQKLDEWASLWEWF"	"39"	"Sequence 52 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0936"	"WQEWDREITALLEQAQIQQEKNEYELQKLDKWASLWNWF"	"39"	"Sequence 51 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0935"	"WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLEWEW"	"40"	"Sequence 50 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0934"	"WQEWDREISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWF"	"46"	"Sequence 49 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0933"	"WNWFITALLEQAQIQQEKNEYELQKLDKWASLWNWF"	"36"	"Sequence 48 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0932"	"NNMTWQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF"	"50"	"Sequence 47 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0931"	"WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF"	"46"	"Sequence 46 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0930"	"NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK"	"42"	"Sequence 45 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0929"	"MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"48"	"Sequence 44 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0928"	"DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"42"	"Sequence 43 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0927"	"WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKL"	"36"	"Sequence 42 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0926"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF"	"36"	"Sequence 41 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0925"	"YTSLIYSLLEKSQIQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 40 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0924"	"YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF"	"36"	"Sequence 39 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0923"	"YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 38 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0922"	"LSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAV"	"39"	"Sequence 37 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0921"	"CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC"	"44"	"Sequence 36 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0920"	"NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC"	"41"	"Sequence 35 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0919"	"NNLLRAIEAQQHLLQLTVWGIKQLQARILAV"	"31"	"Sequence 34 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0918"	"CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 33 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0917"	"WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL"	"36"	"Sequence 32 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."	"DRAVPe01974"	"Anti-HIV"
"DRAVPa0916"	"RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"34"	"Sequence 31 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0915"	"QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 30 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0914"	"SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"45"	"Sequence 29 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0913"	"SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"36"	"Sequence 28 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0912"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"51"	"Sequence 27 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0911"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK"	"49"	"Sequence 26 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0910"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY"	"47"	"Sequence 25 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0909"	"QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"42"	"Sequence 24 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0908"	"LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG"	"36"	"Sequence 23 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0907"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR"	"44"	"Sequence 22 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0906"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI"	"38"	"Sequence 21 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0905"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG"	"37"	"Sequence 20 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0904"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW"	"36"	"Sequence 19 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0903"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV"	"35"	"Sequence 18 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0902"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"34"	"Sequence 17 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0901"	"MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV"	"36"	"Sequence 16 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0900"	"MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"35"	"Sequence 15 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0899"	"SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"36"	"Sequence 14 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0898"	"RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL"	"36"	"Sequence 13 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0897"	"ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ"	"36"	"Sequence 12 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0896"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI"	"50"	"Sequence 11 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0895"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV"	"40"	"Sequence 10 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0894"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL"	"38"	"Sequence 9 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0893"	"GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL"	"36"	"Sequence 8 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0892"	"GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI"	"54"	"Sequence 7 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0891"	"GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT"	"43"	"Sequence 6 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0890"	"WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF"	"39"	"Sequence 5 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."	"DRAVPe00254"	"Anti-HIV"
"DRAVPa0889"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 4 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."	"DRAVPe00520"	"Anti-HIV"
"DRAVPa0888"	"NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"38"	"Sequence 3 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0887"	"WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"64"	"Sequence 2 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0886"	"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGI"	"60"	"Sequence 1 from Patent US 7556813 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7556813 B2"	"2009-07-07"	"CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2"	"Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides"	"No comments found in patent"	"Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer."		"Anti-HIV"
"DRAVPa0885"	"WEEWDREINNYTKLIHELIEESQNQQEENEQELLX"	"35"	"Sequence 15 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 35 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0884"	"WEEWDREINNYTXLIHELIEESQNQQEENEQELL"	"34"	"Sequence 14 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0883"	"WQEWEQKITALIEQAQIQQEKNEYELQKLDKWASLWEWFX"	"40"	"Sequence 13 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 40 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=15.7 nM against HIV-1 and TC50>25000 nM against PBMC)"	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0882"	"WQEWEQKITALLXQAQIQQEKNEYELQKLDKWASLWEWF"	"39"	"Sequence 12 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=7.78 nM against HIV-1 and TC50>25000 nM against PBMC)"	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0881"	"WEEWDREINNYTELIHELIEESQNQQEKNEQELLX"	"35"	"Sequence 11 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 35 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=9.09 nM against HIV-1 and TC50>25000 nM against PBMC)"	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0880"	"WEEWDREINNYTXLIHELIEESQNQQEKNEWELL"	"34"	"Sequence 10 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=3.94 nM against HIV-1 and TC50>25000 nM against PBMC)"	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0879"	"SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELLX"	"45"	"Sequence 9 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 45 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0878"	"SLEQIWNNMTWEEWDREINNYTXLIHELIEESQNQQEKNEQELL"	"44"	"Sequence 8 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The 'X' at position 23 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0877"	"WEEWDREINNYTKLIHELIEESQNQQEENEQELL"	"34"	"Sequence 7 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0876"	"WQEWERKVDFLEENITALLEEAQIQQEKNMYELQ"	"34"	"Sequence 6 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0875"	"WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL"	"34"	"Sequence 5 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."	"DRAVPe00519"	"Anti-HIV, Anti-SIV"
"DRAVPa0874"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 4 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."	"DRAVPe00520"	"Anti-HIV, Anti-SIV"
"DRAVPa0873"	"WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF"	"39"	"Sequence 3 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection."	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."	"DRAVPe00254"	"Anti-HIV, Anti-SIV"
"DRAVPa0872"	"WEEWDREINNYTKLIHELIEESQNQQEKNEQELL"	"34"	"Sequence 2 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=1.41 nM against HIV-1 and TC50=15900 nM against PBMC)"	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0871"	"SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELL"	"44"	"Sequence 1 from Patent US 7575750 B2"	"Synthetic construct"	"HIV, SIV"	"Granted Patent"	"US 7575750 B2"	"2009-08-18"	"WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118"	"Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=0.93 nM against HIV-1 and TC50=14300 nM against PBMC)"	"This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections."		"Anti-HIV, Anti-SIV"
"DRAVPa0870"	"NNLLRAIEAQQHMLQLTVWQIKQLQARILAVERYLKDQ"	"38"	"Sequence 545 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0869"	"NNLLRAIQAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"38"	"Sequence 544 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0868"	"NNLLRAIDAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"38"	"Sequence 543 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0867"	"SNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"38"	"Sequence 542 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0866"	"YTSLIHSLLEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 541 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0865"	"YTSLIHTLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 540 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0864"	"YTSLIHNLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 539 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0863"	"YTSLIHRLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 538 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0862"	"YTSLIYSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 537 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0861"	"YTSIIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 536 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0860"	"YTNLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 535 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0859"	"YTGLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 534 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0858"	"KEAIRD"	"6"	"Sequence 533 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0857"	"LKEAIRD"	"7"	"Sequence 532 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0856"	"KLKEAIRD"	"8"	"Sequence 531 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0855"	"EKLKEAIRD"	"9"	"Sequence 530 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0854"	"IEKLKEAIRD"	"10"	"Sequence 529 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0853"	"DIEKLKEAIRD"	"11"	"Sequence 528 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0852"	"SDIEKLKEAIRD"	"12"	"Sequence 527 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0851"	"RSDIEKLKEAIRD"	"13"	"Sequence 526 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0850"	"ARSDIEKLKEAIRD"	"14"	"Sequence 525 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0849"	"QARSDIEKLKEAIRD"	"15"	"Sequence 524 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0848"	"KQARSDIEKLKEAIRD"	"16"	"Sequence 523 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0847"	"AKQARSDIEKLKEAIRD"	"17"	"Sequence 522 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0846"	"EAKQARSDIEKLKEAIRD"	"18"	"Sequence 521 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0845"	"VEAKQARSDIEKLKEAIRD"	"19"	"Sequence 520 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0844"	"LVEAKQARSDIEKLKEAIRD"	"20"	"Sequence 519 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0843"	"ALVEAKQARSDIEKLKEAIRD"	"21"	"Sequence 518 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0842"	"VALVEAKQARSDIEKLKEAIRD"	"22"	"Sequence 517 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0841"	"AVALVEAKQARSDIEKLKEAIRD"	"23"	"Sequence 516 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0840"	"AAVALVEAKQARSDIEKLKEAIRD"	"24"	"Sequence 515 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0839"	"TAAVALVEAKQARSDIEKLKEAIRD"	"25"	"Sequence 514 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0838"	"ITAAVALVEAKQARSDIEKLKEAIRD"	"26"	"Sequence 513 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0837"	"QITAAVALVEAKQARSDIEKLKEAIRD"	"27"	"Sequence 512 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0836"	"AQITAAVALVEAKQARSDIEKLKEAIRD"	"28"	"Sequence 511 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0835"	"SAQITAAVALVEAKQARSDIEKLKEAIRD"	"29"	"Sequence 510 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0834"	"TSAQITAAVALVEAKQARSDIEKLKEAIRD"	"30"	"Sequence 509 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0833"	"ATSAQITAAVALVEAKQARSDIEKLKEAIRD"	"31"	"Sequence 508 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0832"	"VATSAQITAAVALVEAKQARSDIEKLKEAIRD"	"32"	"Sequence 507 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0831"	"GVATSAQITAAVALVEAKQARSDIEKLKEAIRD"	"33"	"Sequence 506 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0830"	"LGVATSAQITAAVALVEAKQARSDIEKLKEAIRD"	"34"	"Sequence 505 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0829"	"ALGVAT"	"6"	"Sequence 504 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0828"	"ALGVATS"	"7"	"Sequence 503 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0827"	"ALGVATSA"	"8"	"Sequence 502 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0826"	"ALGVATSAQ"	"9"	"Sequence 501 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0825"	"ALGVATSAQI"	"10"	"Sequence 500 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0824"	"ALGVATSAQIT"	"11"	"Sequence 499 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0823"	"ALGVATSAQITA"	"12"	"Sequence 498 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0822"	"ALGVATSAQITAA"	"13"	"Sequence 497 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0821"	"ALGVATSAQITAAV"	"14"	"Sequence 496 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0820"	"ALGVATSAQITAAVA"	"15"	"Sequence 495 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0819"	"ALGVATSAQITAAVAL"	"16"	"Sequence 494 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0818"	"ALGVATSAQITAAVALV"	"17"	"Sequence 493 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0817"	"ALGVATSAQITAAVALVE"	"18"	"Sequence 492 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0816"	"ALGVATSAQITAAVALVEA"	"19"	"Sequence 491 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0815"	"ALGVATSAQITAAVALVEAK"	"20"	"Sequence 490 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0814"	"ALGVATSAQITAAVALVEAKQ"	"21"	"Sequence 489 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0813"	"ALGVATSAQITAAVALVEAKQA"	"22"	"Sequence 488 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0812"	"ALGVATSAQITAAVALVEAKQAR"	"23"	"Sequence 487 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0811"	"ALGVATSAQITAAVALVEAKQARS"	"24"	"Sequence 486 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0810"	"ALGVATSAQITAAVALVEAKQARSD"	"25"	"Sequence 485 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0809"	"ALGVATSAQITAAVALVEAKQARSDI"	"26"	"Sequence 484 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0808"	"ALGVATSAQITAAVALVEAKQARSDIE"	"27"	"Sequence 483 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0807"	"ALGVATSAQITAAVALVEAKQARSDIEK"	"28"	"Sequence 482 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0806"	"ALGVATSAQITAAVALVEAKQARSDIEKL"	"29"	"Sequence 481 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0805"	"ALGVATSAQITAAVALVEAKQARSDIEKLK"	"30"	"Sequence 480 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0804"	"ALGVATSAQITAAVALVEAKQARSDIEKLKE"	"31"	"Sequence 479 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0803"	"ALGVATSAQITAAVALVEAKQARSDIEKLKEA"	"32"	"Sequence 478 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0802"	"ALGVATSAQITAAVALVEAKQARSDIEKLKEAI"	"33"	"Sequence 477 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0801"	"ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR"	"34"	"Sequence 476 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0799"	"KEWIRRS"	"7"	"Sequence 474 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0800"	"EWIRRS"	"6"	"Sequence 475 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0798"	"SKEWIRRS"	"8"	"Sequence 473 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0797"	"ESKEWIRRS"	"9"	"Sequence 472 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0796"	"EESKEWIRRS"	"10"	"Sequence 471 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0795"	"LEESKEWIRRS"	"11"	"Sequence 470 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0793"	"SDLEESKEWIRRS"	"13"	"Sequence 468 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0794"	"DLEESKEWIRRS"	"12"	"Sequence 469 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0792"	"KSDLEESKEWIRRS"	"14"	"Sequence 467 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0790"	"KAKSDLEESKEWIRRS"	"16"	"Sequence 465 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0791"	"AKSDLEESKEWIRRS"	"15"	"Sequence 466 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0789"	"NKAKSDLEESKEWIRRS"	"17"	"Sequence 464 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0788"	"LNKAKSDLEESKEWIRRS"	"18"	"Sequence 463 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0786"	"IELNKAKSDLEESKEWIRRS"	"20"	"Sequence 461 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0787"	"ELNKAKSDLEESKEWIRRS"	"19"	"Sequence 462 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0785"	"SIELNKAKSDLEESKEWIRRS"	"21"	"Sequence 460 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0784"	"ISIELNKAKSDLEESKEWIRRS"	"22"	"Sequence 459 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0783"	"DISIELNKAKSDLEESKEWIRRS"	"23"	"Sequence 458 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0782"	"IDISIELNKAKSDLEESKEWIRRS"	"24"	"Sequence 457 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0781"	"PIDISIELNKAKSDLEESKEWIRRS"	"25"	"Sequence 456 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0780"	"DPIDISIELNKAKSDLEESKEWIRRS"	"26"	"Sequence 455 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0779"	"LDPIDISIELNKAKSDLEESKEWIRRS"	"27"	"Sequence 454 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0778"	"ALDPIDISIELNKAKSDLEESKEWIRRS"	"28"	"Sequence 453 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0776"	"SVALDPIDISIELNKAKSDLEESKEWIRRS"	"30"	"Sequence 451 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0777"	"VALDPIDISIELNKAKSDLEESKEWIRRS"	"29"	"Sequence 452 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0775"	"NSVALDPIDISIELNKAKSDLEESKEWIRRS"	"31"	"Sequence 450 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0774"	"NNSVALDPIDISIELNKAKSDLEESKEWIRRS"	"32"	"Sequence 449 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0773"	"LNNSVALDPIDISIELNKAKSDLEESKEWIRRS"	"33"	"Sequence 448 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0772"	"TLNNSVALDPIDISIELNKAKSDLEESKEWIRRS"	"34"	"Sequence 447 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0771"	"ITLNNS"	"6"	"Sequence 446 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0770"	"ITLNNSV"	"7"	"Sequence 445 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0769"	"ITLNNSVA"	"8"	"Sequence 444 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0768"	"ITLNNSVAL"	"9"	"Sequence 443 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0767"	"ITLNNSVALD"	"10"	"Sequence 442 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0766"	"ITLNNSVALDP"	"11"	"Sequence 441 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0764"	"ITLNNSVALDPID"	"13"	"Sequence 439 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0765"	"ITLNNSVALDPI"	"12"	"Sequence 440 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0763"	"ITLNNSVALDPIDI"	"14"	"Sequence 438 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0762"	"ITLNNSVALDPIDIS"	"15"	"Sequence 437 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0761"	"ITLNNSVALDPIDISI"	"16"	"Sequence 436 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0760"	"ITLNNSVALDPIDISIE"	"17"	"Sequence 435 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0759"	"ITLNNSVALDPIDISIEL"	"18"	"Sequence 434 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0758"	"ITLNNSVALDPIDISIELN"	"19"	"Sequence 433 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0757"	"ITLNNSVALDPIDISIELNK"	"20"	"Sequence 432 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0756"	"ITLNNSVALDPIDISIELNKA"	"21"	"Sequence 431 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0755"	"ITLNNSVALDPIDISIELNKAK"	"22"	"Sequence 430 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0754"	"ITLNNSVALDPIDISIELNKAKS"	"23"	"Sequence 429 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0752"	"ITLNNSVALDPIDISIELNKAKSDL"	"25"	"Sequence 427 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0753"	"ITLNNSVALDPIDISIELNKAKSD"	"24"	"Sequence 428 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0751"	"ITLNNSVALDPIDISIELNKAKSDLE"	"26"	"Sequence 426 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0750"	"ITLNNSVALDPIDISIELNKAKSDLEE"	"27"	"Sequence 425 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0749"	"ITLNNSVALDPIDISIELNKAKSDLEES"	"28"	"Sequence 424 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0748"	"ITLNNSVALDPIDISIELNKAKSDLEESK"	"29"	"Sequence 423 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0747"	"ITLNNSVALDPIDISIELNKAKSDLEESKE"	"30"	"Sequence 422 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0746"	"ITLNNSVALDPIDISIELNKAKSDLEESKEW"	"31"	"Sequence 421 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0745"	"ITLNNSVALDPIDISIELNKAKSDLEESKEWI"	"32"	"Sequence 420 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0744"	"ITLNNSVALDPIDISIELNKAKSDLEESKEWIR"	"33"	"Sequence 419 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0743"	"ITLNNSVALDPIDISIELNKAKSDLEESKEWIRR"	"34"	"Sequence 418 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0742"	"ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS"	"35"	"Sequence 417 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00918"	"Anti-HPV 3"
"DRAVPa0741"	"KSDELL"	"6"	"Sequence 416 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0740"	"RKSDELL"	"7"	"Sequence 415 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0738"	"FIRKSDELL"	"9"	"Sequence 413 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0739"	"IRKSDELL"	"8"	"Sequence 414 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0737"	"AFIRKSDELL"	"10"	"Sequence 412 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0736"	"LAFIRKSDELL"	"11"	"Sequence 411 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0735"	"SLAFIRKSDELL"	"12"	"Sequence 410 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0734"	"QSLAFIRKSDELL"	"13"	"Sequence 409 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0733"	"NQSLAFIRKSDELL"	"14"	"Sequence 408 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0732"	"INQSLAFIRKSDELL"	"15"	"Sequence 407 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0731"	"KINQSLAFIRKSDELL"	"16"	"Sequence 406 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0730"	"EKINQSLAFIRKSDELL"	"17"	"Sequence 405 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0729"	"NEKINQSLAFIRKSDELL"	"18"	"Sequence 404 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0727"	"QVNEKINQSLAFIRKSDELL"	"20"	"Sequence 402 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0728"	"VNEKINQSLAFIRKSDELL"	"19"	"Sequence 403 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0726"	"SQVNEKINQSLAFIRKSDELL"	"21"	"Sequence 401 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0725"	"ISQVNEKINQSLAFIRKSDELL"	"22"	"Sequence 400 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0724"	"SISQVNEKINQSLAFIRKSDELL"	"23"	"Sequence 399 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0723"	"ASISQVNEKINQSLAFIRKSDELL"	"24"	"Sequence 398 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0722"	"DASISQVNEKINQSLAFIRKSDELL"	"25"	"Sequence 397 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0721"	"FDASISQVNEKINQSLAFIRKSDELL"	"26"	"Sequence 396 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0720"	"EFDASISQVNEKINQSLAFIRKSDELL"	"27"	"Sequence 395 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0719"	"DEFDASISQVNEKINQSLAFIRKSDELL"	"28"	"Sequence 394 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0718"	"SDEFDASISQVNEKINQSLAFIRKSDELL"	"29"	"Sequence 393 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0717"	"PSDEFDASISQVNEKINQSLAFIRKSDELL"	"30"	"Sequence 392 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0716"	"FPSDEFDASISQVNEKINQSLAFIRKSDELL"	"31"	"Sequence 391 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0714"	"LVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"33"	"Sequence 389 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0715"	"VFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"32"	"Sequence 390 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0713"	"PLVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"34"	"Sequence 388 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0712"	"DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"35"	"Sequence 387 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00902"	"Anti-RSV"
"DRAVPa0711"	"YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"36"	"Sequence 386 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0710"	"FYDPLV"	"6"	"Sequence 385 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0709"	"FYDPLVF"	"7"	"Sequence 384 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0708"	"FYDPLVFP"	"8"	"Sequence 383 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0707"	"FYDPLVFPS"	"9"	"Sequence 382 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0706"	"FYDPLVFPSD"	"10"	"Sequence 381 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0705"	"FYDPLVFPSDE"	"11"	"Sequence 380 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0703"	"FYDPLVFPSDEFD"	"13"	"Sequence 378 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0704"	"FYDPLVFPSDEF"	"12"	"Sequence 379 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0702"	"FYDPLVFPSDEFDA"	"14"	"Sequence 377 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0701"	"FYDPLVFPSDEFDAS"	"15"	"Sequence 376 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0700"	"FYDPLVFPSDEFDASI"	"16"	"Sequence 375 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0699"	"FYDPLVFPSDEFDASIS"	"17"	"Sequence 374 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0698"	"FYDPLVFPSDEFDASISQ"	"18"	"Sequence 373 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0697"	"FYDPLVFPSDEFDASISQV"	"19"	"Sequence 372 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0696"	"FYDPLVFPSDEFDASISQVN"	"20"	"Sequence 371 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0695"	"FYDPLVFPSDEFDASISQVNE"	"21"	"Sequence 370 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0694"	"FYDPLVFPSDEFDASISQVNEK"	"22"	"Sequence 369 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0693"	"FYDPLVFPSDEFDASISQVNEKI"	"23"	"Sequence 368 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0691"	"FYDPLVFPSDEFDASISQVNEKINQ"	"25"	"Sequence 366 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0692"	"FYDPLVFPSDEFDASISQVNEKIN"	"24"	"Sequence 367 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0690"	"FYDPLVFPSDEFDASISQVNEKINQS"	"26"	"Sequence 365 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0689"	"FYDPLVFPSDEFDASISQVNEKINQSL"	"27"	"Sequence 364 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0688"	"FYDPLVFPSDEFDASISQVNEKINQSLA"	"28"	"Sequence 363 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0687"	"FYDPLVFPSDEFDASISQVNEKINQSLAF"	"29"	"Sequence 362 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0686"	"FYDPLVFPSDEFDASISQVNEKINQSLAFI"	"30"	"Sequence 361 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0685"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIR"	"31"	"Sequence 360 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0684"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRK"	"32"	"Sequence 359 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0683"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKS"	"33"	"Sequence 358 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0682"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD"	"34"	"Sequence 357 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0681"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE"	"35"	"Sequence 356 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00900"	"Anti-RSV"
"DRAVPa0680"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL"	"36"	"Sequence 355 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0679"	"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL"	"37"	"Sequence 354 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0678"	"LLMQST"	"6"	"Sequence 353 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0676"	"LQLLMQST"	"8"	"Sequence 351 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0677"	"QLLMQST"	"7"	"Sequence 352 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0675"	"ELQLLMQST"	"9"	"Sequence 350 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0673"	"VTELQLLMQST"	"11"	"Sequence 348 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0674"	"TELQLLMQST"	"10"	"Sequence 349 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0672"	"AVTELQLLMQST"	"12"	"Sequence 347 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0671"	"NAVTELQLLMQST"	"13"	"Sequence 346 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0669"	"YKNAVTELQLLMQST"	"15"	"Sequence 344 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0670"	"KNAVTELQLLMQST"	"14"	"Sequence 345 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0668"	"KYKNAVTELQLLMQST"	"16"	"Sequence 343 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0666"	"LDKYKNAVTELQLLMQST"	"18"	"Sequence 341 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0667"	"DKYKNAVTELQLLMQST"	"17"	"Sequence 342 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0665"	"ELDKYKNAVTELQLLMQST"	"19"	"Sequence 340 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0663"	"KQELDKYKNAVTELQLLMQST"	"21"	"Sequence 338 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0664"	"QELDKYKNAVTELQLLMQST"	"20"	"Sequence 339 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0661"	"LIKQELDKYKNAVTELQLLMQST"	"23"	"Sequence 336 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0662"	"IKQELDKYKNAVTELQLLMQST"	"22"	"Sequence 337 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0660"	"KLIKQELDKYKNAVTELQLLMQST"	"24"	"Sequence 335 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0659"	"VKLIKQELDKYKNAVTELQLLMQST"	"25"	"Sequence 334 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0657"	"AKVKLIKQELDKYKNAVTELQLLMQST"	"27"	"Sequence 332 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0658"	"KVKLIKQELDKYKNAVTELQLLMQST"	"26"	"Sequence 333 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0656"	"DAKVKLIKQELDKYKNAVTELQLLMQST"	"28"	"Sequence 331 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0654"	"GTDAKVKLIKQELDKYKNAVTELQLLMQST"	"30"	"Sequence 329 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0655"	"TDAKVKLIKQELDKYKNAVTELQLLMQST"	"29"	"Sequence 330 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0653"	"NGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"31"	"Sequence 328 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0652"	"CNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"32"	"Sequence 327 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0650"	"NKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"34"	"Sequence 325 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0651"	"KCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"33"	"Sequence 326 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0649"	"KENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"36"	"Sequence 324 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0647"	"NIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"38"	"Sequence 322 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0648"	"IKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"37"	"Sequence 323 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0646"	"SNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"39"	"Sequence 321 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0645"	"LSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"40"	"Sequence 320 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0643"	"IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"42"	"Sequence 318 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0644"	"ELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"41"	"Sequence 319 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0642"	"TIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"43"	"Sequence 317 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0641"	"ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"44"	"Sequence 316 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0639"	"SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"46"	"Sequence 314 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0640"	"VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"45"	"Sequence 315 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0638"	"TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"47"	"Sequence 313 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0636"	"YTSVITI"	"7"	"Sequence 311 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0637"	"YTSVIT"	"6"	"Sequence 312 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0635"	"YTSVITIE"	"8"	"Sequence 310 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0634"	"YTSVITIEL"	"9"	"Sequence 309 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0632"	"YTSVITIELSN"	"11"	"Sequence 307 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0633"	"YTSVITIELS"	"10"	"Sequence 308 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0631"	"YTSVITIELSNI"	"12"	"Sequence 306 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0629"	"YTSVITIELSNIKE"	"14"	"Sequence 304 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0630"	"YTSVITIELSNIK"	"13"	"Sequence 305 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0628"	"YTSVITIELSNIKEN"	"15"	"Sequence 303 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0626"	"YTSVITIELSNIKENKC"	"17"	"Sequence 301 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0627"	"YTSVITIELSNIKENK"	"16"	"Sequence 302 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0625"	"YTSVITIELSNIKENKCN"	"18"	"Sequence 300 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0624"	"YTSVITIELSNIKENKCNG"	"19"	"Sequence 299 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0622"	"YTSVITIELSNIKENKCNGTD"	"21"	"Sequence 297 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0623"	"YTSVITIELSNIKENKCNGT"	"20"	"Sequence 298 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0621"	"YTSVITIELSNIKENKCNGTDA"	"22"	"Sequence 296 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0619"	"YTSVITIELSNIKENKCNGTDAKV"	"24"	"Sequence 294 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0620"	"YTSVITIELSNIKENKCNGTDAK"	"23"	"Sequence 295 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0618"	"YTSVITIELSNIKENKCNGTDAKVK"	"25"	"Sequence 293 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0617"	"YTSVITIELSNIKENKCNGTDAKVKL"	"26"	"Sequence 292 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0615"	"YTSVITIELSNIKENKCNGTDAKVKLIK"	"28"	"Sequence 290 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0616"	"YTSVITIELSNIKENKCNGTDAKVKLI"	"27"	"Sequence 291 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0614"	"YTSVITIELSNIKENKCNGTDAKVKLIKQ"	"29"	"Sequence 289 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0613"	"YTSVITIELSNIKENKCNGTDAKVKLIKQE"	"30"	"Sequence 288 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0612"	"YTSVITIELSNIKENKCNGTDAKVKLIKQEL"	"31"	"Sequence 287 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0611"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELD"	"32"	"Sequence 286 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0610"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDK"	"33"	"Sequence 285 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0609"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKY"	"34"	"Sequence 284 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0608"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYK"	"35"	"Sequence 283 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0607"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN"	"36"	"Sequence 282 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0606"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA"	"37"	"Sequence 281 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0605"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV"	"38"	"Sequence 280 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0604"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVT"	"39"	"Sequence 279 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0602"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEL"	"41"	"Sequence 277 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0603"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE"	"40"	"Sequence 278 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0601"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQ"	"42"	"Sequence 276 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0600"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQL"	"43"	"Sequence 275 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0599"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLL"	"44"	"Sequence 274 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0597"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQ"	"46"	"Sequence 272 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0598"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLM"	"45"	"Sequence 273 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0596"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQS"	"47"	"Sequence 271 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0595"	"VFTNWL"	"6"	"Sequence 270 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0593"	"WDVFTNWL"	"8"	"Sequence 268 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0594"	"DVFTNWL"	"7"	"Sequence 269 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0592"	"SWDVFTNWL"	"9"	"Sequence 267 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0591"	"NSWDVFTNWL"	"10"	"Sequence 266 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0590"	"LNSWDVFTNWL"	"11"	"Sequence 265 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0589"	"KLNSWDVFTNWL"	"12"	"Sequence 264 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0587"	"LQKLNSWDVFTNWL"	"14"	"Sequence 262 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0588"	"QKLNSWDVFTNWL"	"13"	"Sequence 263 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0586"	"ELQKLNSWDVFTNWL"	"15"	"Sequence 261 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0585"	"YELQKLNSWDVFTNWL"	"16"	"Sequence 260 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0584"	"MYELQKLNSWDVFTNWL"	"17"	"Sequence 259 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0582"	"KNMYELQKLNSWDVFTNWL"	"19"	"Sequence 257 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0583"	"NMYELQKLNSWDVFTNWL"	"18"	"Sequence 258 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0581"	"EKNMYELQKLNSWDVFTNWL"	"20"	"Sequence 256 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0580"	"QEKNMYELQKLNSWDVFTNWL"	"21"	"Sequence 255 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0579"	"QQEKNMYELQKLNSWDVFTNWL"	"22"	"Sequence 254 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0578"	"IQQEKNMYELQKLNSWDVFTNWL"	"23"	"Sequence 253 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0576"	"AQIQQEKNMYELQKLNSWDVFTNWL"	"25"	"Sequence 251 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0577"	"QIQQEKNMYELQKLNSWDVFTNWL"	"24"	"Sequence 252 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0575"	"QAQIQQEKNMYELQKLNSWDVFTNWL"	"26"	"Sequence 250 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0574"	"EQAQIQQEKNMYELQKLNSWDVFTNWL"	"27"	"Sequence 249 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0573"	"LEQAQIQQEKNMYELQKLNSWDVFTNWL"	"28"	"Sequence 248 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0572"	"SLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"29"	"Sequence 247 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0570"	"SQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"31"	"Sequence 245 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0571"	"QSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"30"	"Sequence 246 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0569"	"ISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"32"	"Sequence 244 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0568"	"NISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"33"	"Sequence 243 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0567"	"ANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"34"	"Sequence 242 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0565"	"LEANIS"	"6"	"Sequence 240 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0566"	"EANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"35"	"Sequence 241 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0564"	"LEANISQ"	"7"	"Sequence 239 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0563"	"LEANISQS"	"8"	"Sequence 238 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0562"	"LEANISQSL"	"9"	"Sequence 237 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0561"	"LEANISQSLE"	"10"	"Sequence 236 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0559"	"LEANISQSLEQA"	"12"	"Sequence 234 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0560"	"LEANISQSLEQ"	"11"	"Sequence 235 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0558"	"LEANISQSLEQAQ"	"13"	"Sequence 233 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0557"	"LEANISQSLEQAQI"	"14"	"Sequence 232 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0556"	"LEANISQSLEQAQIQ"	"15"	"Sequence 231 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0554"	"LEANISQSLEQAQIQQE"	"17"	"Sequence 229 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0555"	"LEANISQSLEQAQIQQ"	"16"	"Sequence 230 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0553"	"LEANISQSLEQAQIQQEK"	"18"	"Sequence 228 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0552"	"LEANISQSLEQAQIQQEKN"	"19"	"Sequence 227 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0551"	"LEANISQSLEQAQIQQEKNM"	"20"	"Sequence 226 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0550"	"LEANISQSLEQAQIQQEKNMY"	"21"	"Sequence 225 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0548"	"LEANISQSLEQAQIQQEKNMYEL"	"23"	"Sequence 223 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0549"	"LEANISQSLEQAQIQQEKNMYE"	"22"	"Sequence 224 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0547"	"LEANISQSLEQAQIQQEKNMYELQ"	"24"	"Sequence 222 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0546"	"LEANISQSLEQAQIQQEKNMYELQK"	"25"	"Sequence 221 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0545"	"LEANISQSLEQAQIQQEKNMYELQKL"	"26"	"Sequence 220 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0544"	"LEANISQSLEQAQIQQEKNMYELQKLN"	"27"	"Sequence 219 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0542"	"LEANISQSLEQAQIQQEKNMYELQKLNSW"	"29"	"Sequence 217 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0543"	"LEANISQSLEQAQIQQEKNMYELQKLNS"	"28"	"Sequence 218 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0541"	"LEANISQSLEQAQIQQEKNMYELQKLNSWD"	"30"	"Sequence 216 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0540"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDV"	"31"	"Sequence 215 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0539"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDVF"	"32"	"Sequence 214 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0538"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDVFT"	"33"	"Sequence 213 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0536"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNW"	"35"	"Sequence 211 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0537"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTN"	"34"	"Sequence 212 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0535"	"RYLKDQ"	"6"	"Sequence 210 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0534"	"ERYLKDQ"	"7"	"Sequence 209 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0533"	"VERYLKDQ"	"8"	"Sequence 208 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0531"	"LAVERYLKDQ"	"10"	"Sequence 206 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0532"	"AVERYLKDQ"	"9"	"Sequence 207 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0530"	"ILAVERYLKDQ"	"11"	"Sequence 205 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0529"	"RILAVERYLKDQ"	"12"	"Sequence 204 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0528"	"ARILAVERYLKDQ"	"13"	"Sequence 203 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0526"	"LQARILAVERYLKDQ"	"15"	"Sequence 201 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0527"	"QARILAVERYLKDQ"	"14"	"Sequence 202 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0525"	"QLQARILAVERYLKDQ"	"16"	"Sequence 200 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0524"	"KQLQARILAVERYLKDQ"	"17"	"Sequence 199 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0523"	"IKQLQARILAVERYLKDQ"	"18"	"Sequence 198 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0522"	"QIKQLQARILAVERYLKDQ"	"19"	"Sequence 197 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0520"	"VWQIKQLQARILAVERYLKDQ"	"21"	"Sequence 195 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0521"	"WQIKQLQARILAVERYLKDQ"	"20"	"Sequence 196 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0519"	"TVWQIKQLQARILAVERYLKDQ"	"22"	"Sequence 194 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0518"	"LTVWQIKQLQARILAVERYLKDQ"	"23"	"Sequence 193 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0517"	"QLTVWQIKQLQARILAVERYLKDQ"	"24"	"Sequence 192 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0516"	"LQLTVWQIKQLQARILAVERYLKDQ"	"25"	"Sequence 191 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0514"	"HLLQLTVWQIKQLQARILAVERYLKDQ"	"27"	"Sequence 189 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0515"	"LLQLTVWQIKQLQARILAVERYLKDQ"	"26"	"Sequence 190 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0513"	"QHLLQLTVWQIKQLQARILAVERYLKDQ"	"28"	"Sequence 188 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0512"	"QQHLLQLTVWQIKQLQARILAVERYLKDQ"	"29"	"Sequence 187 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0511"	"AQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"30"	"Sequence 186 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0509"	"IEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"32"	"Sequence 184 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0510"	"EAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"31"	"Sequence 185 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0508"	"AIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"33"	"Sequence 183 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0507"	"RAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"34"	"Sequence 182 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0506"	"LRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"35"	"Sequence 181 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0505"	"LLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"36"	"Sequence 180 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0503"	"NNLLRA"	"6"	"Sequence 178 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0504"	"NLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"37"	"Sequence 179 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0502"	"NNLLRAI"	"7"	"Sequence 177 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0500"	"NNLLRAIEA"	"9"	"Sequence 175 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0501"	"NNLLRAIE"	"8"	"Sequence 176 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0499"	"NNLLRAIEAQ"	"10"	"Sequence 174 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0498"	"NNLLRAIEAQQ"	"11"	"Sequence 173 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0496"	"NNLLRAIEAQQHL"	"13"	"Sequence 171 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0497"	"NNLLRAIEAQQH"	"12"	"Sequence 172 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0495"	"NNLLRAIEAQQHLL"	"14"	"Sequence 170 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0493"	"NNLLRAIEAQQHLLQL"	"16"	"Sequence 168 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0494"	"NNLLRAIEAQQHLLQ"	"15"	"Sequence 169 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0492"	"NNLLRAIEAQQHLLQLT"	"17"	"Sequence 167 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0491"	"NNLLRAIEAQQHLLQLTV"	"18"	"Sequence 166 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0489"	"NNLLRAIEAQQHLLQLTVWQ"	"20"	"Sequence 164 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0490"	"NNLLRAIEAQQHLLQLTVW"	"19"	"Sequence 165 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0488"	"NNLLRAIEAQQHLLQLTVWQI"	"21"	"Sequence 163 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0486"	"NNLLRAIEAQQHLLQLTVWQIKQ"	"23"	"Sequence 161 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0487"	"NNLLRAIEAQQHLLQLTVWQIK"	"22"	"Sequence 162 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0485"	"NNLLRAIEAQQHLLQLTVWQIKQL"	"24"	"Sequence 160 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0484"	"NNLLRAIEAQQHLLQLTVWQIKQLQ"	"25"	"Sequence 159 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0482"	"NNLLRAIEAQQHLLQLTVWQIKQLQAR"	"27"	"Sequence 157 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0483"	"NNLLRAIEAQQHLLQLTVWQIKQLQA"	"26"	"Sequence 158 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0481"	"NNLLRAIEAQQHLLQLTVWQIKQLQARI"	"28"	"Sequence 156 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0480"	"NNLLRAIEAQQHLLQLTVWQIKQLQARIL"	"29"	"Sequence 155 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0478"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAV"	"31"	"Sequence 153 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0479"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILA"	"30"	"Sequence 154 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0477"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVE"	"32"	"Sequence 152 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0476"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVER"	"33"	"Sequence 151 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0474"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYL"	"35"	"Sequence 149 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0475"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERY"	"34"	"Sequence 150 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0473"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLK"	"36"	"Sequence 148 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0472"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKD"	"37"	"Sequence 147 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0470"	"ASLWNWF"	"7"	"Sequence 145 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0471"	"SLWNWF"	"6"	"Sequence 146 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0469"	"WASLWNWF"	"8"	"Sequence 144 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0468"	"KWASLWNWF"	"9"	"Sequence 143 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0466"	"LDKWASLWNWF"	"11"	"Sequence 141 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0467"	"DKWASLWNWF"	"10"	"Sequence 142 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0465"	"ELDKWASLWNWF"	"12"	"Sequence 140 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0464"	"LELDKWASLWNWF"	"13"	"Sequence 139 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0462"	"ELLELDKWASLWNWF"	"15"	"Sequence 137 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0463"	"LLELDKWASLWNWF"	"14"	"Sequence 138 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0461"	"QELLELDKWASLWNWF"	"16"	"Sequence 136 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0460"	"EQELLELDKWASLWNWF"	"17"	"Sequence 135 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0458"	"KNEQELLELDKWASLWNWF"	"19"	"Sequence 133 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0459"	"NEQELLELDKWASLWNWF"	"18"	"Sequence 134 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0457"	"EKNEQELLELDKWASLWNWF"	"20"	"Sequence 132 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0456"	"QEKNEQELLELDKWASLWNWF"	"21"	"Sequence 131 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0454"	"NQQEKNEQELLELDKWASLWNWF"	"23"	"Sequence 129 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0455"	"QQEKNEQELLELDKWASLWNWF"	"22"	"Sequence 130 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0453"	"QNQQEKNEQELLELDKWASLWNWF"	"24"	"Sequence 128 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0452"	"SQNQQEKNEQELLELDKWASLWNWF"	"25"	"Sequence 127 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0450"	"EESQNQQEKNEQELLELDKWASLWNWF"	"27"	"Sequence 125 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0451"	"ESQNQQEKNEQELLELDKWASLWNWF"	"26"	"Sequence 126 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0449"	"IEESQNQQEKNEQELLELDKWASLWNWF"	"28"	"Sequence 124 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0448"	"LIEESQNQQEKNEQELLELDKWASLWNWF"	"29"	"Sequence 123 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0446"	"HSLIEESQNQQEKNEQELLELDKWASLWNWF"	"31"	"Sequence 121 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0447"	"SLIEESQNQQEKNEQELLELDKWASLWNWF"	"30"	"Sequence 122 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0445"	"IHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"32"	"Sequence 120 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0444"	"LIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"33"	"Sequence 119 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0442"	"TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"35"	"Sequence 117 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0443"	"SLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"34"	"Sequence 118 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0441"	"YTSLIH"	"6"	"Sequence 116 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0440"	"YTSLIHS"	"7"	"Sequence 115 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0438"	"YTSLIHSLI"	"9"	"Sequence 113 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0439"	"YTSLIHSL"	"8"	"Sequence 114 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0437"	"YTSLIHSLIE"	"10"	"Sequence 112 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0436"	"YTSLIHSLIEE"	"11"	"Sequence 111 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0434"	"YTSLIHSLIEESQ"	"13"	"Sequence 109 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0435"	"YTSLIHSLIEES"	"12"	"Sequence 110 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0433"	"YTSLIHSLIEESQN"	"14"	"Sequence 108 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0432"	"YTSLIHSLIEESQNQ"	"15"	"Sequence 107 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0431"	"YTSLIHSLIEESQNQQ"	"16"	"Sequence 106 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0429"	"YTSLIHSLIEESQNQQEK"	"18"	"Sequence 104 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0430"	"YTSLIHSLIEESQNQQE"	"17"	"Sequence 105 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0428"	"YTSLIHSLIEESQNQQEKN"	"19"	"Sequence 103 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0427"	"YTSLIHSLIEESQNQQEKNE"	"20"	"Sequence 102 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0425"	"YTSLIHSLIEESQNQQEKNEQE"	"22"	"Sequence 100 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0426"	"YTSLIHSLIEESQNQQEKNEQ"	"21"	"Sequence 101 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0424"	"YTSLIHSLIEESQNQQEKNEQEL"	"23"	"Sequence 99 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0423"	"YTSLIHSLIEESQNQQEKNEQELL"	"24"	"Sequence 98 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0421"	"YTSLIHSLIEESQNQQEKNEQELLEL"	"26"	"Sequence 96 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0422"	"YTSLIHSLIEESQNQQEKNEQELLE"	"25"	"Sequence 97 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0420"	"YTSLIHSLIEESQNQQEKNEQELLELD"	"27"	"Sequence 95 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0419"	"YTSLIHSLIEESQNQQEKNEQELLELDK"	"28"	"Sequence 94 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00675"	"Anti-HIV"
"DRAVPa0417"	"YTSLIHSLIEESQNQQEKNEQELLELDKWA"	"30"	"Sequence 92 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0418"	"YTSLIHSLIEESQNQQEKNEQELLELDKW"	"29"	"Sequence 93 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0416"	"YTSLIHSLIEESQNQQEKNEQELLELDKWAS"	"31"	"Sequence 91 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0415"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASL"	"32"	"Sequence 90 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0413"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWN"	"34"	"Sequence 88 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0414"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLW"	"33"	"Sequence 89 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0412"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW"	"35"	"Sequence 87 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0411"	"LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK"	"34"	"Sequence 86 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0409"	"PISLERLDVGTNLGNAIAKLEAKELLESSDQILR"	"34"	"Sequence 84 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0410"	"SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM"	"34"	"Sequence 85 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0408"	"PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL"	"34"	"Sequence 83 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0407"	"GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI"	"34"	"Sequence 82 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0405"	"DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD"	"34"	"Sequence 80 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0406"	"LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ"	"34"	"Sequence 81 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0404"	"IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS"	"34"	"Sequence 79 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0403"	"RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES"	"34"	"Sequence 78 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0401"	"LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL"	"34"	"Sequence 76 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0402"	"HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE"	"34"	"Sequence 77 from Patent US 7582301 B1"	"Synthetic construct"	"MeV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-MeV"
"DRAVPa0400"	"LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK"	"34"	"Sequence 75 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0399"	"PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED"	"35"	"Sequence 74 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00936"	"Anti-HIV"
"DRAVPa0397"	"DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG"	"35"	"Sequence 72 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0398"	"FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN"	"35"	"Sequence 73 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0396"	"VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF"	"35"	"Sequence 71 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0395"	"KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV"	"35"	"Sequence 70 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0393"	"ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW"	"35"	"Sequence 68 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0394"	"RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD"	"35"	"Sequence 69 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0392"	"WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS"	"35"	"Sequence 67 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0391"	"EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN"	"35"	"Sequence 66 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0390"	"QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL"	"35"	"Sequence 65 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0388"	"TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF"	"47"	"Sequence 63 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0389"	"WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK"	"35"	"Sequence 64 from Patent US 7582301 B1"	"Synthetic construct"	"SIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-SIV"
"DRAVPa0387"	"AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV"	"35"	"Sequence 62 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0386"	"LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK"	"35"	"Sequence 61 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0384"	"SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ"	"35"	"Sequence 59 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0385"	"KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN"	"35"	"Sequence 60 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0383"	"RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV"	"35"	"Sequence 58 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0382"	"ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS"	"35"	"Sequence 57 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0380"	"KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI"	"35"	"Sequence 55 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0381"	"QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK"	"35"	"Sequence 56 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0379"	"AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA"	"35"	"Sequence 54 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0378"	"EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV"	"35"	"Sequence 53 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0376"	"LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL"	"35"	"Sequence 51 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0377"	"VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI"	"35"	"Sequence 52 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0375"	"AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI"	"35"	"Sequence 50 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0374"	"TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS"	"35"	"Sequence 49 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HPV 3"
"DRAVPa0372"	"IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST"	"35"	"Sequence 47 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00934"	"Anti-HPV 3"
"DRAVPa0373"	"ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT"	"35"	"Sequence 48 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00935"	"Anti-HPV 3"
"DRAVPa0371"	"SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS"	"35"	"Sequence 46 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00933"	"Anti-HPV 3"
"DRAVPa0370"	"ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS"	"35"	"Sequence 45 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00932"	"Anti-HPV 3"
"DRAVPa0368"	"IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH"	"35"	"Sequence 43 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00929"	"Anti-HPV 3"
"DRAVPa0369"	"DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ"	"35"	"Sequence 44 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00931"	"Anti-HPV 3"
"DRAVPa0367"	"PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW"	"35"	"Sequence 42 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00928"	"Anti-HPV 3"
"DRAVPa0366"	"DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN"	"35"	"Sequence 41 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00927"	"Anti-HPV 3"
"DRAVPa0365"	"LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG"	"35"	"Sequence 40 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00926"	"Anti-HPV 3"
"DRAVPa0363"	"VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS"	"35"	"Sequence 38 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00924"	"Anti-HPV 3"
"DRAVPa0364"	"ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI"	"35"	"Sequence 39 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00925"	"Anti-HPV 3"
"DRAVPa0362"	"SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD"	"35"	"Sequence 37 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00923"	"Anti-HPV 3"
"DRAVPa0361"	"NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL"	"35"	"Sequence 36 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00922"	"Anti-HPV 3"
"DRAVPa0359"	"LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ"	"35"	"Sequence 34 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00920"	"Anti-HPV 3"
"DRAVPa0360"	"NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK"	"35"	"Sequence 35 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00921"	"Anti-HPV 3"
"DRAVPa0358"	"TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN"	"35"	"Sequence 33 from Patent US 7582301 B1"	"Synthetic construct"	"HPV 3"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00919"	"Anti-HPV 3"
"DRAVPa0357"	"YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT"	"56"	"Sequence 32 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0356"	"GTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP"	"70"	"Sequence 31 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0355"	"ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ"	"33"	"Sequence 30 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0354"	"IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK"	"33"	"Sequence 29 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0353"	"KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID"	"33"	"Sequence 28 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0352"	"NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI"	"33"	"Sequence 27 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0351"	"VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY"	"33"	"Sequence 26 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0350"	"EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN"	"33"	"Sequence 25 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0349"	"GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK"	"33"	"Sequence 24 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0348"	"LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD"	"33"	"Sequence 23 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0347"	"KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS"	"33"	"Sequence 22 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0346"	"SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT"	"33"	"Sequence 21 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0345"	"VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL"	"33"	"Sequence 20 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0344"	"AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV"	"33"	"Sequence 19 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0343"	"VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS"	"33"	"Sequence 18 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0342"	"VITIELSNIKENKMNGDAKVKLIKQELDKYKNAV"	"34"	"Sequence 17 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0341"	"VITIELSNIKENKCNGDAKVKLIKQELDKYKNAV"	"34"	"Sequence 16 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0340"	"TSVITIELSNIKENKCNGDAKVKLIKQELDKYKN"	"34"	"Sequence 15 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0339"	"YTSVITIELSNIKENKCNGDAKVKLIKQELDKYK"	"34"	"Sequence 14 from Patent US 7582301 B1"	"Synthetic construct"	"RSV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-RSV"
"DRAVPa0338"	"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST"	"48"	"Sequence 13 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0337"	"GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT"	"53"	"Sequence 12 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0336"	"ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL"	"54"	"Sequence 11 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0335"	"YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST"	"46"	"Sequence 10 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0334"	"QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ"	"38"	"Sequence 9 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0333"	"CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ"	"41"	"Sequence 8 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0332"	"LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL"	"36"	"Sequence 7 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0331"	"LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF"	"36"	"Sequence 6 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0330"	"YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 5 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0329"	"YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF"	"36"	"Sequence 4 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0328"	"YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 3 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0327"	"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ"	"38"	"Sequence 2 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"The peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107."	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."		"Anti-HIV"
"DRAVPa0326"	"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF"	"36"	"Sequence 1 from Patent US 7582301 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7582301 B1"	"2009-09-01"	"CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##"	"Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides"	"No comments found in patent"	"Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component."	"DRAVPe00520"	"Anti-HIV"
"DRAVPa0325"	"RXXWEQWWDX"	"10"	"Sequence 20 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"The 'X' at position 3 indicates Thr,Val or Ile, the 'X' at position 2 indicates Glu or Asp,and the 'X' at position 10 indicates Asn or Asp."	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0324"	"RETWETWWAD"	"10"	"Sequence 19 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0323"	"KETWEVWWTE"	"10"	"Sequence 18 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0322"	"KETWDTWWTE"	"10"	"Sequence 17 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0321"	"KETWEXWWXX"	"10"	"Sequence 16 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"The 'X' at position 6 indicates Thr or Ala, the 'X' at position 10 indicates Glu or Asp,and the 'X' at position 9 indicates Thr,Ala,Val or Ile."	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0320"	"KETWEAWWTD"	"10"	"Sequence 15 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0319"	"KETWEXWWME"	"10"	"Sequence 14 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"The 'X' at position 6 indicates Thr or Ala."	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0318"	"KETWEXWWTX"	"10"	"Sequence 13 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"The 'X' at position 6 indicates Thr or Ala, and the 'X' at position 10 indicates Glu or Asp."	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0317"	"RETWDQWWTD"	"10"	"Sequence 12 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0316"	"REIWEQWWDN"	"10"	"Sequence 11 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0315"	"KETWETWWAE"	"10"	"Sequence 10 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0314"	"KETWETWWIE"	"10"	"Sequence 9 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0313"	"KETWEAWWME"	"10"	"Sequence 8 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0312"	"KETWEAWWTE"	"10"	"Sequence 7 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0311"	"GALFLGFLGAAKETWETWWTE"	"21"	"Sequence 6 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0310"	"RGTKALTEVIPLTED"	"15"	"Sequence 5 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0309"	"GFLGAAGSTMGAWSQKETWETWWTE"	"25"	"Sequence 4 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0308"	"GFLGAA"	"6"	"Sequence 3 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0307"	"GALFLGFLGAAGSTMGAWSQPKSKRKV"	"27"	"Sequence 2 from Patent US 7790171 B1"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0306"	"KETWETWWTE"	"10"	"Sequence 1 from Patent US 7790171 B1"	"Synthetic construct(residues 395-404 of HIV-1 BH10"	"HIV"	"Granted Patent"	"US 7790171 B1"	"2010-09-07"	"WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1"	"Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase"	"No comments found in patent"	"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa0305"	"CCCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"39"	"Sequence 126 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0304"	"GGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"37"	"Sequence 125 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0303"	"CCCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL"	"39"	"Sequence 124 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0302"	"GGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL"	"37"	"Sequence 123 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0301"	"CCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"46"	"Sequence 122 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0300"	"GGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"44"	"Sequence 121 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0299"	"CCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL"	"38"	"Sequence 120 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0298"	"IEKKIEEIEEKIEEIEK"	"17"	"Sequence 119 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0297"	"IEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL"	"34"	"Sequence 118 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0296"	"IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARILGGCC"	"38"	"Sequence 117 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0295"	"CCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"38"	"Sequence 116 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0294"	"IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"34"	"Sequence 115 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0293"	"IEKKIEEIEKKIEEIEK"	"17"	"Sequence 114 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0292"	"IEKKIEAIEK"	"10"	"Sequence 113 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0291"	"IEKKIEAIEKKIEAIEKKIEAIEK"	"24"	"Sequence 112 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0290"	"CCCGGIEEKIEEIEELLQLTVWGIKQLQARIL"	"32"	"Sequence 111 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0289"	"GGGIEEKIEEIEELLQLTVWGIKQLQARIL"	"30"	"Sequence 110 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0288"	"CCGGIEEKIEEIEELLQLTVWGIKQLQARIL"	"31"	"Sequence 109 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0287"	"IEEKIEEIEELLQLTVWGIKQLQARIL"	"27"	"Sequence 108 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0286"	"IEEKIEEIEE"	"10"	"Sequence 107 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0285"	"GGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL"	"37"	"Sequence 106 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0284"	"CCCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL"	"39"	"Sequence 105 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0283"	"GGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"44"	"Sequence 104 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0282"	"CCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"46"	"Sequence 103 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0281"	"CCGGIEKKIEAIEKLLQLTVWGIKQLQARIL"	"31"	"Sequence 102 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0280"	"IEKKIEAIEKLLQLTVWGIKQLQARIL"	"27"	"Sequence 101 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0279"	"CCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL"	"38"	"Sequence 100 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0278"	"IEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL"	"34"	"Sequence 99 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0277"	"CCGGIEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL"	"45"	"Sequence 98 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0276"	"IEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL"	"41"	"Sequence 97 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0275"	"CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQIKKEIEAI"	"47"	"Sequence 96 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0274"	"CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQ"	"41"	"Sequence 95 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0273"	"LLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI"	"40"	"Sequence 94 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0272"	"CCGGLLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI"	"44"	"Sequence 93 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0271"	"IKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK"	"34"	"Sequence 92 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0270"	"IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARILGGCC"	"38"	"Sequence 91 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0269"	"CCGGIKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL"	"38"	"Sequence 90 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0268"	"IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL"	"34"	"Sequence 89 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0267"	"IKKKIEAIEKLIQLIVWGIKQIQARILGGCC"	"31"	"Sequence 88 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0266"	"CCGGIKKKIEAIEKLIQLIVWGIKQIQARIL"	"31"	"Sequence 87 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0265"	"IKKKIEAIEKLIQLIVWGIKQIQARIL"	"27"	"Sequence 86 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0264"	"LIQLIVWGIKQIQARIL"	"17"	"Sequence 85 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0263"	"ASQLL"	"5"	"Sequence 84 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0262"	"IKKKIEAIEKLLQLTVWGIKQLQARILGGCC"	"31"	"Sequence 83 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0261"	"GGCC"	"4"	"Sequence 82 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0260"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIA"	"41"	"Sequence 81 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0259"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQAAIL"	"41"	"Sequence 80 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0258"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLAARIL"	"41"	"Sequence 79 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0257"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALQARIL"	"41"	"Sequence 78 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0256"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIAQLQARIL"	"41"	"Sequence 77 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0255"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVAGIKQLQARIL"	"41"	"Sequence 76 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0254"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTAWGIKQLQARIL"	"41"	"Sequence 75 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0253"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQATVWGIKQLQARIL"	"41"	"Sequence 74 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0252"	"IKKEIEAIKKEQEAIKKKIEAIEKLLALTVWGIKQLQARIL"	"41"	"Sequence 73 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0251"	"IKKEIEAIKKEQEAIKKKIEAIEKALQLTVWGIKQLQARIL"	"41"	"Sequence 72 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0250"	"GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA"	"46"	"Sequence 71 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0249"	"GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA"	"46"	"Sequence 70 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0248"	"GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"46"	"Sequence 69 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0247"	"GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"46"	"Sequence 68 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0246"	"ERVVQNVSYIAQTQDQFTHLFRNINNRLNVLHRRVS"	"36"	"Sequence 67 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0245"	"NHTFEVENSTLNGMDLIERQIKILYAMILQTHADVQ"	"36"	"Sequence 66 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0244"	"ATHQETIEKVTEALKINNLRLVTLEHQVLVIGLKVE"	"36"	"Sequence 65 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0243"	"QTLANATAAQQDALEATYAMVQHVAKGVRILEARVA"	"36"	"Sequence 64 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0242"	"QSLANATAAQQNVLEATYAMVQHVAKGVRILEARVA"	"36"	"Sequence 63 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0241"	"AGIVQQQQQLLDVVKRQQELLRLTVWGTKNLQTRVS"	"36"	"Sequence 62 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0240"	"CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKALAAAIA"	"38"	"Sequence 61 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0239"	"LLQLTVWGIKALAAAIA"	"17"	"Sequence 60 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0238"	"IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILAVERYLK"	"41"	"Sequence 59 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0237"	"IKKEIEAIKKEQEAIKKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"55"	"Sequence 58 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0236"	"IKKEIEAIKKEQEAIKKEIEAQQHLLQLTVWGIKQLQARIL"	"41"	"Sequence 57 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0235"	"RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARILAVERYLK"	"52"	"Sequence 56 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0234"	"IEKKIEEIEKKIEEIEKKIEEIEEKLLQLTVWGIKQLQARILAVERYLK"	"49"	"Sequence 55 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0233"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK"	"48"	"Sequence 54 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0232"	"ARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK"	"48"	"Sequence 53 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0231"	"SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK"	"43"	"Sequence 52 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0230"	"IEAQQHLLQLTVWGIKQLQARILAVERYLK"	"30"	"Sequence 51 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0229"	"LLQLTVWGIKQLQARILAVERYLK"	"24"	"Sequence 50 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0228"	"AVERYLK"	"7"	"Sequence 49 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0227"	"IEAQQHLLQLTVWGIKQLQARIL"	"23"	"Sequence 48 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0226"	"IKKKIEAIEK"	"10"	"Sequence 45 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0225"	"LLQLTVWGIKQLQARIL"	"17"	"Sequence 44 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0224"	"IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILGGCC"	"38"	"Sequence 43 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0223"	"CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL"	"38"	"Sequence 42 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0222"	"IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL"	"34"	"Sequence 41 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0221"	"IKKEIEAIKKEQEAIKK"	"17"	"Sequence 40 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0220"	"KIEEIESKIKKIENEIARIKK"	"21"	"Sequence 39 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0219"	"KIEEIESKQKKIENEIARIKKL"	"22"	"Sequence 38 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0218"	"KIKKIENEIARIKKL"	"15"	"Sequence 37 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0217"	"KQKKIENEIAAIKKL"	"15"	"Sequence 36 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0216"	"RMKQIEDKIEEIESKQKKIENEIARIKKL"	"29"	"Sequence 35 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0215"	"IEKKIEE"	"7"	"Sequence 34 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0214"	"IEKKIEA"	"7"	"Sequence 33 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0213"	"IEKKIEEIEKKIEEIEKKIEEIEK"	"24"	"Sequence 32 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0212"	"IKKEIEAIKKEQEAIKKKIEAIEK"	"24"	"Sequence 31 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0211"	"RMKQIEDKIEEILSKQYHIENEIARIKKLIGER"	"33"	"Sequence 30 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0210"	"YGGIEKKIEAIEKKIEAIEKKIEAIEKKIEA"	"31"	"Sequence 29 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0209"	"CCGG"	"4"	"Sequence 28 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0208"	"CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKALAAAIA"	"49"	"Sequence 27 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0207"	"CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL"	"49"	"Sequence 26 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0206"	"RMKQIEDKIEEIESKQKKIENEIARIKKLISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"66"	"Sequence 25 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."	"DRAVPe00815"	"Anti-HIV"
"DRAVPa0205"	"RMKQIEDKIEEIESKQKKIENEIARIKKLIEAQQHLLQLTVWGIKQLQARIL"	"52"	"Sequence 24 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."	"DRAVPe00814"	"Anti-HIV"
"DRAVPa0204"	"RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL"	"45"	"Sequence 23 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."	"DRAVPe00812"	"Anti-HIV"
"DRAVPa0203"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWDIKQLQARIL"	"41"	"Sequence 22 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0202"	"SGGCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"48"	"Sequence 21 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0201"	"CCGGIKKKIEAIEKLLQLTVWGIKQLQARIL"	"31"	"Sequence 20 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0200"	"IEKKIEEIEKKIEEIEKKIEEIEEKISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"62"	"Sequence 19 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0199"	"CCGGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"66"	"Sequence 18 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0198"	"GKGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"65"	"Sequence 17 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0197"	"IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL"	"62"	"Sequence 16 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."	"DRAVPe00818"	"Anti-HIV"
"DRAVPa0196"	"CCGGIEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL"	"52"	"Sequence 15 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0195"	"IEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL"	"48"	"Sequence 14 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0194"	"CCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL"	"52"	"Sequence 13 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0193"	"GCCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL"	"53"	"Sequence 12 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=0.316 nM)."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0192"	"GGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL"	"50"	"Sequence 11 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=2.173 nM)."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0191"	"IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL"	"48"	"Sequence 10 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."	"DRAVPe00817"	"Anti-HIV"
"DRAVPa0190"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"41"	"Sequence 1 from Patent US 7811577 B2 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=1.7 nM; HIV Bal:IC50=3.2 nM).The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."	"DRAVPe00816"	"Anti-HIV"
"DRAVPa0188"	"KNIYRPDKFLQCVKNPEDSSCTSEI"	"25"	"Sequence 22 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0189"	"GKGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"44"	"Sequence 3 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0187"	"SGPGTTKRFPETVLACVKYTEIH"	"23"	"Sequence 21 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0186"	"NTRKSIIGPGRAFYTTGQIIGDIRQAH"	"27"	"Sequence 20 from Patent US 8080633"	"Human immunodeficiency virus(HIV-1 subtype B gp120"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0185"	"RWRQQWSGPGTTKRFPETVLARCVKYTEIH"	"30"	"Sequence 19 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0184"	"GPGTTK"	"6"	"Sequence 18 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0182"	"RWRQQWSGPGTTKRFPETVLARCVKYTEIH"	"30"	"Sequence 16 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0183"	"RQQWSGPGTTKRFPETVLARCVKYTEIH"	"28"	"Sequence 17 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0181"	"SGPGTTKRFPETVLARCVKYTEIH"	"24"	"Sequence 15 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0180"	"RWRQTWSGPGTTK"	"13"	"Sequence 14 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0179"	"RQTWSGPGTTKRFPETVLARCVKYTEIH"	"28"	"Sequence 13 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0178"	"RWRQTWSGPGTTKRFPETVLARCVKYTEIH"	"30"	"Sequence 12 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0177"	"KRPGNKTVVPITLMSGLVFHSQPINRPRQAW"	"31"	"Sequence 11 from Patent US 8080633"	"Human immunodeficiency virus(HIV-2)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0175"	"RPGVQEIIGPMAWYSMGLNNSRAY"	"24"	"Sequence 9 from Patent US 8080633"	"Human immunodeficiency virus(HIV subgroup O)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0176"	"RPGNNTRGQIGPGMTFYNIENIVGDTRA"	"28"	"Sequence 10 from Patent US 8080633"	"Simian immunodeficiency virus(SIV cpz)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0174"	"TRPGNNTGGQVQIGPAMTFYNIEKIVGDRQAY"	"32"	"Sequence 8 from Patent US 8080633"	"Human immunodeficiency virus(HIV subgroup N)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0173"	"TRPSNNTRTSRIGPGRVFYKTGDIIGDIRKAY"	"32"	"Sequence 7 from Patent US 8080633"	"Human immunodeficiency virus(HIV sub E)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0172"	"TRPYNRQRTPIGLGQALYTTRYTTRIIGQAY"	"31"	"Sequence 6 from Patent US 8080633"	"Human immunodeficiency virus(HIV sub D)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0171"	"TRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAH"	"33"	"Sequence 5 from Patent US 8080633"	"Human immunodeficiency virus(HIV sub C)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0170"	"TRPNNNTRRSIRIGPGQAFYATGDIIGDIRQAH"	"33"	"Sequence 4 from Patent US 8080633"	"Human immunodeficiency virus(HIV sub A)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0169"	"TRPNNNTRKSIIGPGRAFYTTGQIIGDIRQAH"	"32"	"Sequence 3 from Patent US 8080633"	"Human immunodeficiency virus(HIV sub B)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0167"	"RWRQTWSGPGTTKRFPETVLARCVKYTEIH"	"30"	"Sequence 1 from Patent US 8080633"	"Homo sapiens"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0168"	"NTRKSHIGPGRAFYTTGIIGDIRQAH"	"26"	"Sequence 2 from Patent US 8080633"	"Human immunodeficiency virus(HIV gp120 299-324)"	"HIV"	"Granted Patent"	"US 8080633 B2"	"2011-12-20"	"WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1"	"Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides"		"Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus."		"Anti-HIV"
"DRAVPa0166"	"GICRCICGRRICRCICGR"	"18"	"Sequence 140 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."	"DRAVPe01560"	"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0165"	"RYICRCICGRGICRCICG"	"18"	"Sequence 139 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."	"DRAVPe01563"	"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0164"	"GICRCICGRYICRCICGR"	"18"	"Sequence 138 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."	"DRAVPe01562"	"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0163"	"GICYCICGKGICRCICGR"	"18"	"Sequence 137 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0162"	"RXICGXXIC"	"9"	"Sequence 136 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The 'X' at position 2 and 6 indicates Arg or Lys, and the 'X' at position 7 indicates Arg, Lys or Gly.The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0161"	"GVCRCICGRGVCRCICGR"	"18"	"Sequence 135 from Patent US 2009/0264344  A1"	"Orangutan"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0160"	"GVCRCICGRGVCRCICRR"	"18"	"Sequence 134 from Patent US 2009/0264344  A1"	"Orangutan"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0159"	"GICRCICGRRICRCICGK"	"18"	"Sequence 133 from Patent US 2009/0264344  A1(Retrocyclin 2F)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0158"	"GICKCICGRRICRCICGR"	"18"	"Sequence 132 from Patent US 2009/0264344  A1(Retrocyclin 2E)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0157"	"GICRCICGRRICKCICGR"	"18"	"Sequence 131 from Patent US 2009/0264344  A1(Retrocyclin 2D)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0156"	"GICRCICGRKICRCICGR"	"18"	"Sequence 130 from Patent US 2009/0264344  A1(Retrocyclin 2C)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0155"	"GICRCICGKKICRCICGR"	"18"	"Sequence 129 from Patent US 2009/0264344  A1(Retrocyclin 2B)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0154"	"GICRCICGKRICRCICGR"	"18"	"Sequence 128 from Patent US 2009/0264344  A1(Retrocyclin 2A)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0153"	"GICKCICGKGICKCICGR"	"18"	"Sequence 127 from Patent US 2009/0264344  A1(K Retrocyclin-1)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0152"	"GICRCICGKGICRCYCGR"	"18"	"Sequence 126 from Patent US 2009/0264344  A1(RC101/103 hybrid)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0151"	"CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL"	"45"	"Sequence 2 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=0.04 nM; HIV Bal:IC50=0.34 nM;HIV 89.6:IC50=8 nM;HIV SHIV89.6p:IC50=6.9 Nm;HIV MN-1:IC50=0.9 nM;HIV NL43:IC50=0.1 nM).The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0150"	"RCLCVLRIC"	"9"	"Sequence 119 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0149"	"RCLCVLRVC"	"9"	"Sequence 118 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0148"	"RCLCTLRIC"	"9"	"Sequence 117 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0147"	"RCLCTLRVC"	"9"	"Sequence 116 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0146"	"RCLCGLRIC"	"9"	"Sequence 115 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0145"	"RCLCGLRVC"	"9"	"Sequence 114 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0144"	"RCICVLRFC"	"9"	"Sequence 113 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0143"	"RCICVLRVC"	"9"	"Sequence 112 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0142"	"RCICTLRFC"	"9"	"Sequence 111 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0141"	"RCICTLRVC"	"9"	"Sequence 110 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0140"	"RCICRLRFC"	"9"	"Sequence 109 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0139"	"RCICRLRVC"	"9"	"Sequence 108 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0138"	"RCICGRRIC"	"9"	"Sequence 107 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0137"	"RCLCVRRVC"	"9"	"Sequence 106 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0136"	"RCLCVLRIC"	"9"	"Sequence 105 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0135"	"RCLCTRRFC"	"9"	"Sequence 104 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0134"	"RCLCGRRVC"	"9"	"Sequence 103 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0133"	"RCLCTLRIC"	"9"	"Sequence 102 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0132"	"RCLCRRRFC"	"9"	"Sequence 101 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0131"	"RCLCRRRVC"	"9"	"Sequence 100 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0130"	"RCLCRLRIC"	"9"	"Sequence 99 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0129"	"RCICGLRVC"	"9"	"Sequence 98 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0128"	"RCICGLRFC"	"9"	"Sequence 97 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0127"	"RCICGRRFC"	"9"	"Sequence 96 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0126"	"RCICVRRVC"	"9"	"Sequence 95 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0125"	"RCICRLRIC"	"9"	"Sequence 94 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0124"	"RCICVLRFC"	"9"	"Sequence 93 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0123"	"RCICTLRIC"	"9"	"Sequence 92 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0122"	"RCICTRRFC"	"9"	"Sequence 91 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0121"	"RCICTRRVC"	"9"	"Sequence 90 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0120"	"RCICRRRFC"	"9"	"Sequence 89 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0119"	"RCICRRRVC"	"9"	"Sequence 88 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0118"	"RCLCGRRFC"	"9"	"Sequence 87 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0117"	"RCLCGRRVC"	"9"	"Sequence 86 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0116"	"RCLCGLRVC"	"9"	"Sequence 85 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0115"	"RCLCVRRIC"	"9"	"Sequence 84 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0114"	"RCLCTRRIC"	"9"	"Sequence 83 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0113"	"RCLCRRRVC"	"9"	"Sequence 82 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0112"	"RCICGRRFC"	"9"	"Sequence 81 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0111"	"RCICGRRVC"	"9"	"Sequence 80 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0110"	"RCICGLRIC"	"9"	"Sequence 79 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0109"	"RCICVRRIC"	"9"	"Sequence 78 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0108"	"RCICTRRIC"	"9"	"Sequence 77 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0107"	"RCICRRRIC"	"9"	"Sequence 76 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0106"	"RCLCGRRIC"	"9"	"Sequence 75 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0105"	"RCICGRRIC"	"9"	"Sequence 74 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0104"	"IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA"	"41"	"Sequence 4 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"No comments found in patent"	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0103"	"CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA"	"45"	"Sequence 5 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0102"	"IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"41"	"Sequence 6 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0101"	"CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL"	"45"	"Sequence 7 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0100"	"IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA"	"41"	"Sequence 8 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0099"	"CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA"	"45"	"Sequence 9 from Patent US 7811577 B2"	"Synthetic construct"	"HIV"	"Granted Patent"	"US 7811577 B2"	"2010-12-12"	"WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2"	"Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity"	"The peptide was modified with acetyl N-terminus and amide C-terminus."	"Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process."		"Anti-HIV"
"DRAVPa0098"	"RCLCVLGIC"	"9"	"Sequence 64 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0097"	"RCLCVLGVC"	"9"	"Sequence 63 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0096"	"RCLCTLGIC"	"9"	"Sequence 62 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0095"	"RCLCTLGVC"	"9"	"Sequence 61 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0094"	"RCLCGLGIC"	"9"	"Sequence 60 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0093"	"RCLCGLGVC"	"9"	"Sequence 59 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0092"	"RCICVLGFC"	"9"	"Sequence 58 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0091"	"RCICVLGVC"	"9"	"Sequence 57 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0090"	"RCICTLGFC"	"9"	"Sequence 56 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0089"	"RCICTLGVC"	"9"	"Sequence 55 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0088"	"RCICRLGFC"	"9"	"Sequence 54 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0087"	"RCICRLGVC"	"9"	"Sequence 53 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0086"	"RCICGRGIC"	"9"	"Sequence 52 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0085"	"RCLCVRGVC"	"9"	"Sequence 51 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0084"	"RCLCVLGIC"	"9"	"Sequence 50 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0083"	"RCLCTRGFC"	"9"	"Sequence 49 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0082"	"RCLCTRGVC"	"9"	"Sequence 48 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0081"	"RCLCTLGIC"	"9"	"Sequence 47 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0080"	"RCLCRRGFC"	"9"	"Sequence 46 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0079"	"RCLCRRGVC"	"9"	"Sequence 45 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0078"	"RCLCRLGIC"	"9"	"Sequence 44 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0077"	"RCICGLGVC"	"9"	"Sequence 43 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0076"	"RCICGLGFC"	"9"	"Sequence 42 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0075"	"RCICGRGFC"	"9"	"Sequence 41 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0074"	"RCICVRGVC"	"9"	"Sequence 40 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0073"	"RCICRLGIC"	"9"	"Sequence 39 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0072"	"RCICVLGFC"	"9"	"Sequence 38 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0071"	"RCICTLGIC"	"9"	"Sequence 37 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0070"	"RCICTRGFC"	"9"	"Sequence 36 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0069"	"RCICTRGVC"	"9"	"Sequence 35 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0068"	"RCICRRGFC"	"9"	"Sequence 34 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0067"	"RCICRRGVC"	"9"	"Sequence 33 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0066"	"RCLCGRGFC"	"9"	"Sequence 32 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0065"	"RCLCGRGVC"	"9"	"Sequence 31 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0064"	"RCLCGLGVC"	"9"	"Sequence 30 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0063"	"RCLCVRGIC"	"9"	"Sequence 29 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0062"	"RCLCTRGIC"	"9"	"Sequence 28 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0061"	"RCLCRRGVC"	"9"	"Sequence 27 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0060"	"RCICGRGFC"	"9"	"Sequence 26 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0059"	"RCICGRGVC"	"9"	"Sequence 25 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0058"	"RCICGLGIC"	"9"	"Sequence 24 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0057"	"RCICVRGIC"	"9"	"Sequence 23 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0056"	"RCICTRGIC"	"9"	"Sequence 22 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0055"	"RCICRRGIC"	"9"	"Sequence 21 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0054"	"RCLCGRGIC"	"9"	"Sequence 20 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0053"	"RCICGRGIC"	"9"	"Sequence 19 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0052"	"MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL"	"76"	"Sequence 17 from Patent US 2009/0264344  A1"	"Macaca mulatta"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0051"	"MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL"	"76"	"Sequence 15 from Patent US 2009/0264344  A1"	"Macaca mulatta"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0050"	"MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD"	"97"	"Sequence 13 from Patent US 2009/0264344  A1(human defensin 4)"	"Homo sapiens"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0049"	"AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL"	"59"	"Sequence 12 from Patent US 2009/0264344  A1"	"Homo sapiens"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0048"	"RGCICRCIGRGCICRCIG"	"18"	"Sequence 10 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0047"	"GICICICGRGICYCICGR"	"18"	"Sequence 9 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0046"	"GICICICGYGICRCICGR"	"18"	"Sequence 8 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0045"	"GICYCICGRGICRCICGR"	"18"	"Sequence 7 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0044"	"GICRCICGRGYCRCICGR"	"18"	"Sequence 6 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0043"	"GYCRCICGRGICRCICGR"	"18"	"Sequence 5 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0042"	"GICRCICGRGICRCYCGR"	"18"	"Sequence 4 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0041"	"GICRCYCGRGICRCICGR"	"18"	"Sequence 3 from Patent US 2009/0264344  A1"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."		"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0040"	"GICRCICGKGICRCICGR"	"18"	"Sequence 2 from Patent US 2009/0264344  A1(RC-101)"	"Synthetic construct"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."	"DRAVPe01561"	"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0039"	"GICRCICGRGICRCICGR"	"18"	"Sequence 1 from Patent US 2009/0264344  A1"	"Homo sapiens"	"HIV-1,HSV-1,HSV-2"	"Patent Application"	"US 2009/0264344 A1"	"2009-10-22"	"US 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B2"	"Retrocyclins: Antiviral and Antimicrobial Peptides"	"The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. The mean IC50 value of RC-101 for the seven subtype B strains was <1.25 μg/ml (<660 nM)."	"Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens."	"DRAVPe01559"	"Anti-HIV-1,Anti-HSV-1,Anti-HSV-2"
"DRAVPa0038"	"MEHFRWG"	"7"	"Sequence 1 from Patent US 7244710(α-MSH [4-10])"	"Homo sapiens"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0037"	"HFRWGKPV"	"8"	"Sequence 2 from Patent US 7244710(α-MSH [6-13])"	"Homo sapiens"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0036"	"SYSMEHFRWGKPV"	"13"	"Sequence 3 from Patent US 7244710(α-MSH [1-13])"	"Homo sapiens"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0035"	"VPKCCKPV"	"8"	"Sequence 4 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0034"	"CKPV"	"4"	"Sequence 5 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0033"	"VPKXCKPV"	"8"	"Sequence 6 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), the 'X' at position 4 indicates Penicillamine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0032"	"VPKXXKPV"	"8"	"Sequence 7 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), the 'X' at position 4 and 5 indicates Penicillamine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0031"	"VPKCCKPV"	"8"	"Sequence 8 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), and the Cys at position 4 and 5 refers to Omocysteine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0030"	"VPKCCKPV"	"8"	"Sequence 9 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0029"	"VPKCXKPV"	"8"	"Sequence 10 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0028"	"VPKCCKPV"	"8"	"Sequence 11 from Patent US 7244710"	"Synthetic construct"	"Herpesvirus,HIV"	"Granted Patent"	"US 7244710 B2"	"2007-07-17"	"FR 1456903 A##ES 323291 A1##SU 622426 A3"	"Treatment Of Ophthalmic Infections Using Antimicrobial Peptides"	"The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription."	"The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (α-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (α-MSH) include α-MSH (1–13) which is SYSMEHFRWGKPV, α-MSH (4–10) which is MEHFRWG, α-MSH (6–13) which is HFRWGKPV, α-MSH (11–13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter."		"Herpesvirus,Anti-HIV"
"DRAVPa0027"	"IPLRGAFINGRWDSQCHRFSNGAIAAA"	"27"	"Sequence 27 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0026"	"IPLRGAFINGRWDSQCHRFSNGAAACA"	"27"	"Sequence 26 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0025"	"IPLRGAFINGRWDSQCHRFSNAAIACA"	"27"	"Sequence 25 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0024"	"IPLRGAFINGRWDSQCHRFSAGAIACA"	"27"	"Sequence 24 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0023"	"IPLRGAFINGRWDSQCHRFANGAIACA"	"27"	"Sequence 23 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0022"	"IPLRGAFINGRWDSQCHRASNGAIACA"	"27"	"Sequence 22 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0021"	"IPLRGAFINGRWDSQCHAFSNGAIACA"	"27"	"Sequence 21 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0020"	"IPLRGAFINGRWDSQCARFSNGAIACA"	"27"	"Sequence 20 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0019"	"IPLRGAFINGRWDSQAHRFSNGAIACA"	"27"	"Sequence 19 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0018"	"IPLRGAFINGRWDSACHRFSNGAIACA"	"27"	"Sequence 18 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0017"	"IPLRGAFINGRWDAQCHRFSNGAIACA"	"27"	"Sequence 17 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0016"	"IPLRGAFINGRWASQCHRFSNGAIACA"	"27"	"Sequence 16 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0015"	"IPLRGAFINGRADSQCHRFSNGAIACA"	"27"	"Sequence 15 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0014"	"IPLRGAFINGAWDSQCHRFSNGAIACA"	"27"	"Sequence 14 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0013"	"IPLRGAFINARWDSQCHRFSNGAIACA"	"27"	"Sequence 13 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0012"	"IPLRGAFIAGRWDSQCHRFSNGAIACA"	"27"	"Sequence 12 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0011"	"IPLRGAFANGRWDSQCHRFSNGAIACA"	"27"	"Sequence 11 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0010"	"IPLRGAAINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 10 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0009"	"IPLRAAFINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 9 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0008"	"IPLAGAFINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 8 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0007"	"IPARGAFINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 7 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0006"	"IALRGAFINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 6 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0005"	"APLRGAFINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 5 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0004"	"SFITKLKDVAIGVAKGAGLGILKTLTCKLDNSCA"	"34"	"Sequence 4 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0003"	"SFVTKLKDVAIGVAKGAGLGILKTLTCKLDNSCA"	"34"	"Sequence 3 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0002"	"SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC"	"37"	"Sequence 2 from Patent US 20190367567"	"Synthetic construct"	"H1N1"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1"
"DRAVPa0001"	"IPLRGAFINGRWDSQCHRFSNGAIACA"	"27"	"Sequence 1 from Patent US 20190367567(Urumin)"	"Synthetic construct"	"H1N1,H1N2"	"Patent Application"	"US 2019/0367567 A1"	"2019-12-05"	"WO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4"	"Peptides and Uses for Managing Viral Infections"	"The peptide exhibits no toxicity to human red blood cells.IC50=2.5-5 μM tested by graded concentrations of Urumin (0.6-320 μM) against PR8 virus by plaque assay."	"It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same."		"H1N1,H1N2"
"DRAVPa1674"	"AQEVKXWMTXTLLVA"	"15"	"Sequence 4 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=4.29 ± 0.62 μM) and exhibits cytotoxicity against MT-2 cells(CC50>116 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1675"	"AQAVKXWMTXTLLVA"	"15"	"Sequence 5 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=2.36 ± 0.33 μM) and exhibits cytotoxicity against MT-2 cells(CC50=30.2 ± 4.32 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1676"	"AQEVKXWMTXTLLVAKKK"	"18"	"Sequence 6 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=6.29 ± 0.54 μM) and exhibits cytotoxicity against MT-2 cells(CC50=13.24 ± 0.5 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1677"	"AQKVEXWMTXTLLVA"	"15"	"Sequence 7 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=5.15 ± 0.76 μM) and exhibits cytotoxicity against MT-2 cells(CC50>112 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1678"	"AQAVKXWMTXTLLVENA"	"17"	"Sequence 8 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=2.95 ± 0.33 μM) and exhibits cytotoxicity against MT-2 cells(CC50>102 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1679"	"AQAVKXWMTXTLLKANAE"	"18"	"Sequence 9 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=17.4 ± 0.90 μM) and exhibits cytotoxicity against MT-2 cells(CC50>48 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1680"	"EQLVWXKMTXALAVT"	"15"	"Sequence 10 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50>56 μM) and exhibits cytotoxicity against MT-2 cells(CC50>112 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1681"	"AQEVKNWMTE TLLVA"	"15"	"Sequence 11 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"No cooments found in patent"	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1682"	"AQAVKNWMTXTLLXA"	"15"	"Sequence 12 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=4.6 ± 0.40 μM) and exhibits cytotoxicity against MT-2 cells(CC50=67.3 ± 4.4 μM).The 'X' at position 10 and 14 indicates (S)-a-2-(2'-pentenyl)alanine, X(10) and X(14) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1683"	"AQAWKXWATXTLLVAE"	"16"	"Sequence 13 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=3.7 ± 0.06 μM) and exhibits cytotoxicity against MT-2 cells(CC50>106 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1684"	"AQAVKXWMEXTLKVAE"	"16"	"Sequence 14 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50>52.7 μM) and exhibits cytotoxicity against MT-2 cells(CC50>105.4 μM).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1685"	"AQAVKXWMTETLXVA"	"15"	"Sequence 15 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=7.97 ± 1.03 μM) and exhibits cytotoxicity against MT-2 cells(CC50>140.4 μM).The 'X' at position 6 and 13 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(13) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1686"	"AQAWKXWATETLXVAN"	"16"	"Sequence 16 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=9.3 ± 1.6 μM) and exhibits cytotoxicity against MT-2 cells(CC50>130 μM).The 'X' at position 6 and 13 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(13) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1687"	"IAQAKVEXWMTXTLLVAN"	"18"	"Sequence 17 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"The peptide shows antiviral activity against HIV-1 IIIB(IC50=7.2 ± 1.2 μM) and exhibits cytotoxicity against MT-2 cells(CC50>124.4 μM).The 'X' at position 8 and 12 indicates (S)-a-2-(2'-pentenyl)alanine, X(8) and X(12) are cross-linked by hydrocarbon stapling."	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1688"	"AQAVKNWMTETLLVA"	"15"	"Sequence 19 from Patent US 20090281041"	"Synthetic construct"	"HIV"	"Patent Application"	"US 2009/0281041 A1"	"2009-11-12"	"CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2"	"Antiviral Cell-Penetrating Peptides"	"No cooments found in patent"	"Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus."		"Anti-HIV"
"DRAVPa1689"	"RRKKAAVALLPAVLLALLAP"	"20"	"Sequence 1 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"95 ± 2% inhibition against influenza virus at 10 μM.(EC50= 2.6 ± 1.0 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01185"	"Anti-influenza virus"
"DRAVPa1690"	"RRKKAAVALLPAVLLALLA"	"19"	"Sequence 2 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 2% inhibition against influenza virus at 10 μM.(EC50=0.5 ± 0.3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01186"	"Anti-influenza virus"
"DRAVPa1691"	"RRKKAAVALLPAVLLALL"	"18"	"Sequence 3 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"95 ± 2% inhibition against influenza virus at 10 μM.(EC50= 0.6 ± 0.3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01187"	"Anti-influenza virus"
"DRAVPa1692"	"RRKKAAVALLPAVLLAL"	"17"	"Sequence 4 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"89 ± 3% inhibition against influenza virus at 10 μM.(EC50= 3.8 ± 1.9 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01188"	"Anti-influenza virus"
"DRAVPa1693"	"RRKKAAVALLPAVLLA"	"16"	"Sequence 5 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"96 ± 3% inhibition against influenza virus at 10 μM.(EC50= 2.8 ± 1.1 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01189"	"Anti-influenza virus"
"DRAVPa1694"	"RRKKAAVALLPAVLL"	"15"	"Sequence 6 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1695"	"RRKKAAVALLPAVL"	"14"	"Sequence 7 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1696"	"RRKKAAVALLPAV"	"13"	"Sequence 8 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1697"	"RRKKAAVALLPA"	"12"	"Sequence 9 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1698"	"RRKKAAVALLP"	"11"	"Sequence 10 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"4 ± 8% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01190"	"Anti-influenza virus"
"DRAVPa1699"	"RRKKAAVALL"	"10"	"Sequence 11 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1700"	"RRKKAAVAL"	"9"	"Sequence 12 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1701"	"RRKKAAVA"	"8"	"Sequence 13 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1702"	"RRKKAAV"	"7"	"Sequence 14 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1703"	"RRKKAA"	"6"	"Sequence 15 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1704"	"RRKKA"	"5"	"Sequence 16 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1705"	"RRKK"	"4"	"Sequence 17 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1706"	"RRKKAVALLPAVLLALLAP"	"19"	"Sequence 18 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 6% inhibition against influenza virus at 10 μM.(EC50= 0.8 ± 0.3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01191"	"Anti-influenza virus"
"DRAVPa1707"	"RRKKVALLPAVLLALLAP"	"18"	"Sequence 19 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 4% inhibition against influenza virus at 10 μM.(EC50= 0.5 ± 0.4 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01192"	"Anti-influenza virus"
"DRAVPa1708"	"RRKKALLPAVLLALLAP"	"17"	"Sequence 20 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 3% inhibition against influenza virus at 10 μM.(EC50= 0.7± 0.3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01193"	"Anti-influenza virus"
"DRAVPa1709"	"RRKKLLPAVLLALLAP"	"16"	"Sequence 21 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94± 4% inhibition against influenza virus at 10 μM.(EC50=0.8 ± 0.3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01194"	"Anti-influenza virus"
"DRAVPa1710"	"RRKKLPAVLLALLAP"	"15"	"Sequence 22 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 4% inhibition against influenza virus at 10 μM.(EC50= 0.9 ± 0.3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01195"	"Anti-influenza virus"
"DRAVPa1711"	"RRKKVLLALLAP"	"12"	"Sequence 23 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"90 ± 4% inhibition against influenza virus at 10 μM.(EC50=4.0 ± 0.8 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01198"	"Anti-influenza virus"
"DRAVPa1712"	"RRKKLLALLAP"	"11"	"Sequence 24 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1713"	"RRKKALLAP"	"9"	"Sequence 25 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1714"	"RRKKLLAP"	"8"	"Sequence 26 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1715"	"RRKKLAP"	"7"	"Sequence 27 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1716"	"RRKKAP"	"6"	"Sequence 28 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1717"	"RRKKP"	"5"	"Sequence 29 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1718"	"RRKKAALLVLAALAVLA"	"17"	"Sequence 30 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1719"	"RRKKLAALPLVLAAPLAVLA"	"20"	"Sequence 31 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1720"	"RRKKVALLAVLLALLA"	"16"	"Sequence 32 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 4% inhibition against influenza virus at 10 μM.(EC50= 0.5 ± 0.5 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01200"	"Anti-influenza virus"
"DRAVPa1721"	"RRKKAAVALLAVLLALLA"	"18"	"Sequence 43 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"95 ± 2% inhibition against influenza virus at 10 μM.(EC50=1.6 ± 1.2 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01199"	"Anti-influenza virus"
"DRAVPa1722"	"RRKKLLAVLLALLA"	"14"	"Sequence 44 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"95 ± 2% inhibition against influenza virus at 10 μM.(EC50= 3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01202"	"Anti-influenza virus"
"DRAVPa1723"	"RRKKLAVLLALLA"	"13"	"Sequence 45 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"94 ± 0% inhibition against influenza virus at 10 μM.(EC50= 3 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."	"DRAVPe01203"	"Anti-influenza virus"
"DRAVPa1724"	"RRKKAAAAAAAAA"	"13"	"Sequence 49 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"87.5% inhibition against influenza virus at 10 μM.(EC50~7 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1725"	"RKKLAVLLALLA"	"12"	"Sequence 50 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"75% inhibition against influenza virus at 10 μM.(EC50=8 μM)"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1726"	"RKAVLLALLA"	"10"	"Sequence 51 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"50% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1727"	"KLAVLLALLA"	"10"	"Sequence 52 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"25% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1728"	"KKLAVLLALLA"	"11"	"Sequence 53 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1729"	"EEDDLAVLLALLA"	"13"	"Sequence 54 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1730"	"RRKKLAVAAALLA"	"13"	"Sequence 55 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1731"	"RRKKLAVLLAAAA"	"13"	"Sequence 56 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"0% inhibition against influenza virus at 10 μM."	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1732"	"EEDD"	"4"	"Sequence 61 from Patent US 20100041604"	"Synthetic construct"	"Influenza Virus"	"Patent Application"	"US 2010/0041604 A1"	"2010-02-18"	"CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B2"	"Novel Antiviral Peptides Against Influenza Virus"	"No comments found in patent"	"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa1733"	"CVHAYRS"	"7"	"Sequence 1 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1734"	"CVHAYRA"	"7"	"Sequence 2 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1735"	"CVHAFRS"	"7"	"Sequence 3 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1736"	"CVHAFRA"	"7"	"Sequence 4 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1737"	"CVHSYRS"	"7"	"Sequence 5 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1738"	"CVHSYRA"	"7"	"Sequence 6 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1739"	"CVHSFRS"	"7"	"Sequence 7 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1740"	"CVHSFRA"	"7"	"Sequence 8 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1741"	"CVHTYRS"	"7"	"Sequence 9 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1742"	"CVHTYRA"	"7"	"Sequence 10 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1743"	"CVHTFRS"	"7"	"Sequence 11 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1744"	"CVHTFRA"	"7"	"Sequence 12 from Patent US 7476649 B2"	"Sos scrofus(pig)"	"Infuenza Virus,Vaccinia Virus,HIV"	"Granted Patent"	"US 7476649 B2"	"2009-01-13"	"WO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US20040043936"	"Antiproliferative and antiviral proteins and peptides"		"The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents."		"Anti-influenza virus,Anti-vaccinia virus,Anti-HIV"
"DRAVPa1745"	"NGAICWGPCPTAFRQIGNCGHFKVRCCKIR"	"30"	"P9"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"US20230165936 A1"	"2023-06-01"	"WO/2021/185071，CN115379849，EP4121087"	"Compositions of anti-viral peptides and methods of use thereof"		"Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus."	"DRAVPe01761"	"Anti-SARS-CoV-2"
"DRAVPa1746"	"NGAICWGPCPTAFRQIGNCGRFRVRCCRIR"	"30"	"P9R"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"US20230165936 A1"	"2023-06-01"	"WO/2021/185071，CN115379849，EP4121087"	"Compositions of anti-viral peptides and methods of use thereof"		"Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus."	"DRAVPe01763"	"Anti-SARS-CoV-2"
"DRAVPa1747"	"PAEPYTTVTTQNTASQTMS"	"19"	"PS19"	"Synthetic construct"	"ASFV"	"Granted Patent"	"US 8592552 B2"	"2013-11-26"	"WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE"	" Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8"		"New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8."		"Anti-ASFV"
"DRAVPa1748"	"RRRRRRRRPAEPYTTVTTQNTASQTMS"	"27"	"RS27"	"Synthetic construct"	"ASFV"	"Granted Patent"	"US 8592552 B2"	"2013-11-26"	"WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE"	" Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8"		"New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8."		"Anti-ASFV"
"DRAVPa1749"	"SLVSSDESSSGSSHSSGEHS"	"20"	"SS20"	"Synthetic construct"	"ASFV"	"Granted Patent"	"US 8592552 B2"	"2013-11-26"	"WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE"	" Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8"		"New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8."		"Anti-ASFV"
"DRAVPa1750"	"RRRRRRRRSLVSSDESSSGSSHSSGEHS"	"28"	"RS28"	"Synthetic construct"	"ASFV"	"Granted Patent"	"US 8592552 B2"	"2013-11-26"	"WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE"	" Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8"		"New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8."		"Anti-ASFV"
"DRAVPa1751"	"RRRRRRRRHPAEPGSTVTTQNTASQTMS"	"28"	"COVA1"	"Synthetic construct"	"ASFV"	"Granted Patent"	"US 8592552 B2"	"2013-11-26"	"WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE"	" Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8"		"New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8."		"Anti-ASFV"
"DRAVPa1752"	"RRRRRRRRHPTESGSTVTTQNSAAQTMS"	"28"	"PEP1"	"Synthetic construct"	"ASFV"	"Granted Patent"	"US 8592552 B2"	"2013-11-26"	"WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DE"	" Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8"		"New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC10."		"Anti-ASFV"
"DRAVPa1753"	"KYKETDLLILFKDDYFAKKNEERK"	"24"	"Sequence 1 from Patent US20090233868 A1"	"Human La protein"	" HCV"	"Patent Application"	"US20090233868 A1"	"2009-09-17"	"WO/2006/117805，IN520/CHE/2005，EP1877431，US20110091966，CA2606668"	"Small antiviral peptides against hepatitis C virus"		"Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication."		"Anti-HCV"
"DRAVPa1754"	"KYKETDL"	"7"	"Sequence 2 from Patent US20090233868 A1"	"Human La protein"	" HCV"	"Patent Application"	"US20090233868 A1"	"2009-09-17"	"WO/2006/117805，IN520/CHE/2005，EP1877431，US20110091966，CA2606668"	"Small antiviral peptides against hepatitis C virus"		"Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication."		"Anti-HCV"
"DRAVPa1755"	"KIKRWR"	"6"	"Sequence 10 from Patent CN104072579 B"	"Synthetic construct"	"HIV"	"Granted Patent"	"CN104072579 B"	"2017-01-25"	"CN104072579 B"	"Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide"		"The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses."		"Anti-HIV"
"DRAVPa1756"	"KIWWK"	"5"	"Sequence 2 from Patent CN104072579 B"	"Synthetic construct"	"HIV"	"Granted Patent"	"CN104072579 B"	"2017-01-25"	"CN104072579 B"	"Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide"		"The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses."		"Anti-HIV"
"DRAVPa1757"	"KKWK"	"4"	"Sequence 13 from Patent CN104072579 B"	"Synthetic construct"	"H5N1"	"Granted Patent"	"CN104072579 B"	"2017-01-25"	"CN104072579 B"	"Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide"		"The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses."		"Anti-H5N1"
"DRAVPa1758"	"KWK"	"3"	"Sequence 12 from Patent CN104072579 B"	"Synthetic construct"	"H5N1"	"Granted Patent"	"CN104072579 B"	"2017-01-25"	"CN104072579 B"	"Small molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptide"		"The invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses."		"Anti-H5N1"
"DRAVPa1759"	"CNDFRSKTC"	"9"	"Sequence 1 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N2"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1760"	"NDFRSKT"	"7"	"Sequence 2 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N3"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1761"	"QHSTKWF"	"7"	"Sequence 3 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N4"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1762"	"LPYAAKH"	"7"	"Sequence 4 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N5"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1763"	"ILGDKVG"	"7"	"Sequence 5 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N6"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1764"	"LPYGSKH"	"7"	"Sequence 6 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N7"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1765"	"ILGYKVG"	"7"	"Sequence 7 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N8"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1766"	"HPQFLSL"	"7"	"Sequence 8 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N9"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1767"	"GLYNHPQ"	"7"	"Sequence 9 from Patent US20110135676 B2"	"Synthetic construct"	"AIV"	"Granted Patent"	"US20110135676 B2"	"2014-11-11"	"WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 20082061"	"Antiviral peptide against avian influenza virus H9N10"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-AIV"
"DRAVPa1768"	"KETWETWWTE"	"10"	"Sequence 1 from Patent US20110064793 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"US20110064793 A1"	"2011-03-17"	"WO/2002/015661,US7790171,EP1311538,AU2001292153,AT420103"	"INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS"		"The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections."		"Anti-HIV"
"DRAVPa1769"	"SPMLVAYD"	"8"	"Sequence 2 from Patent US20110064793 A1"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US11304989 B2"	"2022-04-19"	"WO/2019/069307,EP3691672,CN111163792"	"Peptides for use in the treatment of viral infections"	"                                                                                                                                                                                                                                                                                      "	"Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent."		"Anti-influenza virus"
"DRAVPa1770"	"HVKGKHLCP"	"9"	"Sequence 3 from Patent US20110064793 A1"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US11304989 B3"	"2022-04-19"	"WO/2019/069307,EP3691672,CN111163792"	"Peptides for use in the treatment of viral infections"		"Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent."		"Anti-influenza virus"
"DRAVPa1771"	"HKGLDSAV"	"8"	"Sequence 4 from Patent US20110064793 A1"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US11304989 B4"	"2022-04-19"	"WO/2019/069307,EP3691672,CN111163792"	"Peptides for use in the treatment of viral infections"		"Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent."		"Anti-influenza virus"
"DRAVPa1772"	"YVNQTDIY"	"8"	"Sequence 5 from Patent US20110064793 A1"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US11304989 B5"	"2022-04-19"	"WO/2019/069307,EP3691672,CN111163792"	"Peptides for use in the treatment of viral infections"		"Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent."		"Anti-influenza virus"
"DRAVPa1773"	"SNGTIIHVK"	"9"	"Sequence 6 from Patent US20110064793 A1"	"Synthetic construct"	"influenza virus"	"Granted Patent"	"US11304989 B6"	"2022-04-19"	"WO/2019/069307,EP3691672,CN111163792"	"Peptides for use in the treatment of viral infections"		"Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent."		"Anti-influenza virus"
"DRAVPa1774"	"WNFFDWFSGLMSWFGGPLKLY"	"21"	"Sequence 5 from Patent US20150337015 B2"	"Synthetic construct"	"RVFV"	"Granted Patent"	"US20150337015 B2"	"2017-01-31"	"WO/2014/123614"	" Antiviral rift valley fever virus peptides and methods of use"		"The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus."		"Anti-RVFV"
"DRAVPa1775"	"WNFFDWFSGLMSWFGGPLK"	"19"	"Sequence 6 from Patent US20150337015 B2"	"Synthetic construct"	"RVFV"	"Granted Patent"	"US20150337015 B2"	"2017-01-31"	"WO/2014/123614"	" Antiviral rift valley fever virus peptides and methods of use"		"The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus."		"Anti-RVFV"
"DRAVPa1776"	"WNFFDWFSGLMSWFGGPLKTI"	"21"	"Sequence 7 from Patent US20150337015 B2"	"Synthetic construct"	"RVFV"	"Granted Patent"	"US20150337015 B2"	"2017-01-31"	"WO/2014/123614"	" Antiviral rift valley fever virus peptides and methods of use"		"The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus."		"Anti-RVFV"
"DRAVPa1777"	"SWNFFDWFSGLMSWFGGPLK"	"20"	"Sequence 8 from Patent US20150337015 B2"	"Synthetic construct"	"RVFV"	"Granted Patent"	"US20150337015 B2"	"2017-01-31"	"WO/2014/123614"	" Antiviral rift valley fever virus peptides and methods of use"		"The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus."		"Anti-RVFV"
"DRAVPa1778"	"SGSWNFFDWFSGLMSWFGG"	"19"	"Sequence 9 from Patent US20150337015 B2"	"Synthetic construct"	"RVFV"	"Granted Patent"	"US20150337015 B2"	"2017-01-31"	"WO/2014/123614"	" Antiviral rift valley fever virus peptides and methods of use"		"The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus."		"Anti-RVFV"
"DRAVPa1779"	"SGSWNFFDWFSGLMSWFGGPL"	"21"	"Sequence 10 from Patent US20150337015 B2"	"Synthetic construct"	"RVFV"	"Granted Patent"	"US20150337015 B2"	"2017-01-31"	"WO/2014/123614"	" Antiviral rift valley fever virus peptides and methods of use"		"The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus."		"Anti-RVFV"
"DRAVPa1780"	"YQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFESIENSQALVDQSNKILNSAEKGNTGF"	"67"	"Sequence 1 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1781"	"PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGF"	"78"	"Sequence 2 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1782"	"YQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNV"	"34"	"Sequence 3 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1783"	"PVSSSFDPIKFPEDQFNVALDQVFESIENSQAL"	"33"	"Sequence 4 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1784"	"ALDQVFESIENSQALVDQSNKILNSAEKGNTGF"	"33"	"Sequence 5 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1785"	"YQLSKVEGEQHVIKGRPVSSSFDPIKFP"	"28"	"Sequence 6 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1786"	"EDQFNVALDQVFESIEEDQFNVALDQVFESIEEKGNTGF"	"39"	"Sequence 7 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1787"	"KFPEDQFNVALDQVFESIENSQALVDQSNKILNSAEK"	"37"	"Sequence 8 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1788"	"EDQFNVALDQVFESIENSQALVDQSNKILNSAEK"	"34"	"Sequence 9 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1789"	"PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN"	"36"	"Sequence 10 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1790"	"DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID"	"37"	"Sequence 11 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1791"	"RLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGF"	"36"	"Sequence 12 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1792"	"NIQKEIDRLNEVAKNLNESLIDLQEL"	"26"	"Sequence 13 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1793"	"LNESLIDLQELGKYEQYIKWPWYVWLGF"	"28"	"Sequence 14 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1794"	"QELGKYEQYIKWPWYVWLGF"	"20"	"Sequence 15 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1795"	"YEQYIKWPWYVWLGF"	"15"	"Sequence 16 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1796"	"YEQYIKWPWYVWLG"	"14"	"Sequence 17 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1797"	"YIKWPWYVWL"	"10"	"Sequence 18 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1798"	"PELDSFKEELDKYFKNHTSP"	"20"	"Sequence 19 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1799"	"PNLPDFKEELDQWFKNQTSVAPDLSLDYINVTLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVW"	"73"	"Sequence 20 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1800"	"PNLPDFKEELDQWFKNQTSVAPDLSLD"	"27"	"Sequence 21 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1801"	"YINVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKW"	"42"	"Sequence 22 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1802"	"QVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKW"	"33"	"Sequence 23 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1803"	"QEAIKVLNQSYINLKDIGTYEYYVKWPW"	"28"	"Sequence 24 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1804"	"QSYINLKDIGTYEYYVKWPW"	"20"	"Sequence 25 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1805"	"YEYYVKWPWYVW"	"12"	"Sequence 26 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1806"	"QDAIKKLNESYINLKEVGTYEMYVKWPWYVW"	"31"	"Sequence 27 from Patent US20040229219 A1"	"Mouse hepatitis virus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1807"	"FLGFLG"	"6"	"Sequence 28 from Patent US20040229219 A1"	"Human immunodeficiency virus type 1"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1808"	"TTTS"	"4"	"Sequence 29 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1809"	"ELDKY"	"5"	"Sequence 30 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1810"	"ELDKW"	"5"	"Sequence 31 from Patent US20040229219 A1"	"Human immunodeficiency virus type 1"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1811"	"PEL"	"3"	"Sequence 32 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1812"	"PDFKE"	"5"	"Sequence 33 from Patent US20040229219 A1"	"Mouse hepatitis virus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1813"	"FKEELDK"	"7"	"Sequence 34 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1814"	"KWPWYVWL"	"8"	"Sequence 35 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1815"	"QALVDQ"	"6"	"Sequence 36 from Patent US20040229219 A1"	"Human metapneumovirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1816"	"GRKKRRQRRRP"	"11"	"Sequence 38 from Patent US20040229219 A1"	"Human immunodeficiency virus type 1"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1817"	"ELRVRLASHLRKLRKRLLRDADD"	"23"	"Sequence 39 from Patent US20040229219 A1"	"Homo sapiens"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1818"	"RIQDAIK"	"7"	"Sequence 40 from Patent US20040229219 A1"	"Mouse hepatitis virus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1819"	"RLNEVAK"	"7"	"Sequence 41 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1820"	"ENQKQIANQFNKAISQIQESL"	"21"	"Sequence 42 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1821"	"KVQDVVNQNAQALNTLVKQL"	"20"	"Sequence 43 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1822"	"KYEQYIKWPWYVW"	"13"	"Sequence 44 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1823"	"TYEMYVKWPWYVW"	"13"	"Sequence 45 from Patent US20040229219 A1"	"Mouse hepatitis virus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1824"	"TYEYYVKWPWYVW"	"13"	"Sequence 46 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1825"	"YEWKWIYWYPVKQ"	"13"	"Sequence 47 from Patent US20040229219 A1"	"Synthetic construct"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1826"	"PNLPDFKEELDQWFKNQTSVAPDLSLDYINVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVWLLICLAGVA"	"83"	"Sequence 48 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1827"	"PNPPDFKEELDKWFKNQTSIAPDLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLIGLAGVA"	"85"	"Sequence 49 from Patent US20040229219 A1"	"Mouse hepatitis virus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1828"	"PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIA"	"84"	"Sequence 50 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1829"	"WTFGAGAALQIPFAMQMAY"	"19"	"Sequence 51 from Patent US20040229219 A1"	"Human coronavirus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1830"	"RIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLI"	"36"	"Sequence 52 from Patent US20040229219 A1"	"Mouse hepatitis virus"	"SARS"	"Patent Application"	"US20040229219 A1"	"2004-11-18"	"WO/2005/007078"	"Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)"		"The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus."		"Anti-SARS"
"DRAVPa1831"	"HGVSGHGQHGVHG"	"13"	"Sequence 1 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 3 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1832"	"GVSGHGQHGVHG"	"12"	"Sequence 12 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 4 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1833"	"VSGHGQHGVH"	"10"	"Sequence 14 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 5 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1834"	"SGHGQHGV"	"8"	"Sequence 15 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 6 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1835"	"PSLTGHGFHGVYD"	"13"	"Sequence 16 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 7 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1836"	"FIVSAHGDHGV"	"11"	"Sequence 17 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 8 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1837"	"THGQHGV"	"7"	"Sequence 18 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 9 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1838"	"HGHGVHG"	"7"	"Sequence 19 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 10 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1839"	"LASLHGQHGV"	"10"	"Sequence 20 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 11 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1840"	"CVVTGHGSHGVFV"	"13"	"Sequence 2 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 12 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1841"	"ISGHGQHGVP"	"10"	"Sequence 3 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 13 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1842"	"CGHGNHGVH"	"9"	"Sequence 4 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 14 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1843"	"IVARIHGQNHGL"	"12"	"Sequence 5 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 15 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1844"	"HGSDGHGVQHG"	"11"	"Sequence 6 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 16 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1845"	"FGHGHGV"	"7"	"Sequence 7 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 17 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1846"	"HGNHGVLA"	"7"	"Sequence 8 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 18 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1847"	"HGDSGHGQHGVD"	"12"	"Sequence 9 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 19 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1848"	"HGHGVPL"	"7"	"Sequence 10 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 20 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1849"	"SGHGAVHGVM"	"10"	"Sequence 11 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 21 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1850"	"YAMSGHGHGVFI"	"12"	"Sequence 13 from Patent US20170058000 B2"	"Synthetic construct"	"H3N2"	"Granted Patent"	"US20170058000 B2"	"2018-11-13"	"WO/2013/176563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014"	"Bioactive peptide complexes"		"The proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 22 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target."		"Anti-H3N2"
"DRAVPa1851"	"GEKKRRETVEREGG"	"14"	"Sequence 1 from Patent US20160346383 B2"	"Synthetic construct"	"encephalomyocarditis virus"	"Granted Patent"	"US20160346383 B2"	"2017-06-20"	"WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089"	"Ezrin-derived peptides and pharmaceutical compositions thereof"		"The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1聽EKKRRETVERE X2X3, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof."		"Anti-encephalomyocarditis virus"
"DRAVPa1852"	"TEKKRRETVEREKE"	"14"	"Sequence 2 from Patent US20160346383 B2"	"human ezrin protein"	"encephalomyocarditis virus"	"Granted Patent"	"US20160346383 B2"	"2017-06-20"	"WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089"	"Ezrin-derived peptides and pharmaceutical compositions thereof"		"The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1聽EKKRRETVERE X2X4, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof."		"Anti-encephalomyocarditis virus"
"DRAVPa1853"	"TEKKR"	"5"	"Sequence 3 from Patent US20160346383 B2"	"human ezrin protein"	"encephalomyocarditis virus"	"Granted Patent"	"US20160346383 B2"	"2017-06-20"	"WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089"	"Ezrin-derived peptides and pharmaceutical compositions thereof"		"The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1聽EKKRRETVERE X2X5, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof."		"Anti-encephalomyocarditis virus"
"DRAVPa1854"	"RETVEREKE"	"9"	"Sequence 4 from Patent US20160346383 B2"	"human ezrin protein"	"encephalomyocarditis virus"	"Granted Patent"	"US20160346383 B2"	"2017-06-20"	"WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089"	"Ezrin-derived peptides and pharmaceutical compositions thereof"		"The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1聽EKKRRETVERE X2X6, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof."		"Anti-encephalomyocarditis virus"
"DRAVPa1855"	"DKEWILQKIYEIMRRLDEEG"	"20"	"Sequence 1 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-19."		"Anti-SARS-CoV-2"
"DRAVPa1856"	"DKEWILQKIYEIMRLLDELG"	"20"	"Sequence 4 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-20."		"Anti-SARS-CoV-2"
"DRAVPa1857"	"DKEWILQKIYEIMRKLDEDG"	"20"	"Sequence 6 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-21."		"Anti-SARS-CoV-2"
"DRAVPa1858"	"DKEWILQKIYEIMRRLDEEGHAEASMRVSDLIYEFMKKD"	"39"	"Sequence 53 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-22."		"Anti-SARS-CoV-2"
"DRAVPa1859"	"DKEWILQKIYEIMRRLDEEGHGEASLRVSDLIYEFMKKD"	"39"	"Sequence 54 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-23."		"Anti-SARS-CoV-2"
"DRAVPa1860"	"DKEWILQKIYEIMRKLDEDGHAEASMRVSDLIYEFMKKD"	"39"	"Sequence 52 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-24."		"Anti-SARS-CoV-2"
"DRAVPa1861"	"DKEWILQKIYEIMRRLDEEGHGEASLRVSDLIYEFMKRD"	"39"	"Sequence 55 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-25."		"Anti-SARS-CoV-2"
"DRAVPa1862"	"DKEWILQKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD"	"39"	"Sequence 58 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-26."		"Anti-SARS-CoV-2"
"DRAVPa1863"	"DKLWILQKIYEIMVRLDEEGHGEASLMVSDLIYEFMKRD"	"39"	"Sequence 60 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-27."		"Anti-SARS-CoV-2"
"DRAVPa1864"	"DKEWILYKIYEIMVRLDEEGHGEASLMVSDLIYEFMKRD"	"39"	"Sequence 62 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-28."		"Anti-SARS-CoV-2"
"DRAVPa1865"	"DKLWILQKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD"	"39"	"Sequence 64 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-29."		"Anti-SARS-CoV-2"
"DRAVPa1866"	"DKEWILYKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD"	"39"	"Sequence 66 from Patent US20240309059 A1"	"Synthetic construct"	"SARS-COV-2"	"Patent Application"	"US20240309059 A1"	"2024-09-19"	"WO/2023/282281,JPWO2023282281,EP4368631"	"PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENT"		"Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-30."		"Anti-SARS-CoV-2"
"DRAVPa1867"	"WEEWDKKIEEYTKKIEELIKKSONOOIDL"	"29"	"Sequence 66 from Patent US20240309059 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"CN106543273 A"	"2017-03-29"		"Polypeptide for inhibiting HIV infection and medicinal application thereof"		"The invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome."		"Anti-HIV"
"DRAVPa1868"	"MTWEEWDKKIEEYTKKIEELIKKSONOOIDL"	"31"	"Sequence 66 from Patent US20240309059 A1"	"Synthetic construct"	"HIV"	"Patent Application"	"CN106543273 A"	"2017-03-29"		"Polypeptide for inhibiting HIV infection and medicinal application thereof"		"The invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome."		"Anti-HIV"
"DRAVPa1869"	"RVTQMNLNDRLASLYDKV"	"18"	"Sequence 1 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N1"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 20 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N1"
"DRAVPa1870"	"RATQMNLNDRLASLYDKV"	"18"	"Sequence 6 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N2"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N2"
"DRAVPa1871"	"RVTAMNLNDRLASLYDKV"	"18"	"Sequence 7 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N3"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 22 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N3"
"DRAVPa1872"	"RVTQANLNDRLASLYDKV"	"18"	"Sequence 8 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N4"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 23 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N4"
"DRAVPa1873"	"RVTQMNANDRLASLYDKV"	"18"	"Sequence 9 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N5"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 24 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N5"
"DRAVPa1874"	"RVTQMNLNARLASLYDKV"	"18"	"Sequence 10 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N6"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 25 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N6"
"DRAVPa1875"	"RVTQMNLNDRLVSLYDKV"	"18"	"Sequence 11 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N7"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 26 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N7"
"DRAVPa1876"	"RVTQMNLNDRLASLYAKV"	"18"	"Sequence 12 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N8"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 27 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N8"
"DRAVPa1877"	"RVTQMNLNDRLASLYDAV"	"18"	"Sequence 13 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N9"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 28 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N9"
"DRAVPa1878"	"NDRLASLYDKV"	"11"	"Sequence 14 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N10"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 29 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N10"
"DRAVPa1879"	"NLNDRLASLYDKV"	"13"	"Sequence 15 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N11"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 30 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N11"
"DRAVPa1880"	"RVTQMNLADRLASLYDKV"	"18"	"Sequence 16 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N12"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 31 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N12"
"DRAVPa1881"	"RVTQMNLNDALASLYDKV"	"18"	"Sequence 17 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N13"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 32 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N13"
"DRAVPa1882"	"RVTQMNLNDRLAALYDKV"	"18"	"Sequence 18 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N14"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 33 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N14"
"DRAVPa1883"	"RVTQMNLNDRLASLYDKV"	"18"	"Sequence 19 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N15"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 34 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N15"
"DRAVPa1884"	"RVTQMNLNDRAASLYDKV"	"18"	"Sequence 21 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N16"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 35 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N16"
"DRAVPa1885"	"RVTQMNLNDRLASLADKV"	"18"	"Sequence 22 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N17"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 36 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N17"
"DRAVPa1886"	"GRKKRRQRRRPPQACWMSPRHLGTC"	"25"	"Sequence 23 from Patent CN116964073 A"	"Synthetic construct"	"SARS-CoV-2,MERS-CoV,BCoV,H1N18"	"Patent Application"	"CN116964073 A"	"2023-10-27"	"WO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603"	"Peptides for treating respiratory tract infections of viral origin"		"A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 37 and an antiviral drug."		"Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N18"
"DRAVPa1887"	"DIFCDWWRWVISVLDSVK"	"18"	"Sequence 1 from Patent WO2024054009A1  "	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1888"	"DVVSIWFKWIDCLWDSVR"	"18"	"Sequence 2 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1889"	"RLVKSIWDWFCIVVDSWD "	"18"	"Sequence 3 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1890"	"DVWCSWVSWVIKLFRDID"	"18"	"Sequence 4 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1891"	"DWVDCFWSWLIKVIDRVS"	"18"	"Sequence 5 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1892"	"SVVCDWWDVIIKWFDRLS"	"18"	"Sequence 6 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1893"	"DWVSKFWRILICVWDSVD"	"18"	"Sequence 7 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1894"	"DVVDDWWSVLCKWFRIIS"	"18"	"Sequence 8 from Patent WO2024054009A1 "	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1895"	"RVFCIVWDWVKSWIDDLS"	"18"	"Sequence 9 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1896"	"SWVDSFWDWLIRVIKCVD"	"18"	"Sequence 10 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1897"	"DVVDIVLRWICSWWSDFK"	"18"	"Sequence 11 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1898"	"RVIDCWVDWWSIVFKSLD"	"18"	"Sequence 12 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1899"	"SVFCSLWRWVIDWVDDIK"	"18"	"Sequence 13 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1900"	"KLVDSIWSWFICVVRDWD"	"18"	"Sequence 14 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1901"	"DVFCIWIDWVKSLWRDVS"	"18"	"Sequence 15 from Patent WO2024054009A1"	"Synthetic construct"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1902"	" DWLRIIWWWVCSVVSDFK"	"18"	"Sequence 16 from Patent WO2024054009A1"	"HCV"	"dengue virus"	"Patent Application"	"WO2024054009A1"	"2024-03-14"	"KR20220114326A,
KR2023013277W"	"NOVEL ANTIVIRAL PEPTIDE"		"The present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide."		"Anti-dengue virus"
"DRAVPa1903"	"NDFRSKT"	"7"	"Sequence 1 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088370A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1904"	"TKSRFDN"	"7"	"Sequence 2 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088371A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1905"	"CNDFRSKTC"	"9"	"Sequence 3 from Patent US10538554B2 "	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088372A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."	"DRAVPe00458"	"Anti-influenza virus"
"DRAVPa1906"	"CTKSRFDNC"	"9"	"Sequence 4 from Patent US10538554B2 "	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088373A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1907"	"RRKKCTWARFINC"	"13"	"Sequence 17 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088374A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1908"	"RRKKCTWCRFINC"	"13"	"Sequence 18 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088375A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1909"	"RRKKCTWDRFINC"	"13"	"Sequence 19 from Patent US10538554B2 "	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088376A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1910"	"RRKKCTWERFINC"	"13"	"Sequence 20 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088377A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1911"	"RRKKCTWFRFINC"	"13"	"Sequence 21 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088378A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1912"	"RRKKCTWGRFINC"	"13"	"Sequence 22 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088379A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1913"	"RRKKCTWHRFINC"	"13"	"Sequence 23 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088380A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1914"	"RRKKCTWIRFINC"	"13"	"Sequence 24 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088381A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1915"	"RRKKCTWKRFINC"	"13"	"Sequence 25 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088382A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1916"	"RRKKCTWLRFINC"	"13"	"Sequence 26 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088383A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1917"	"RRKKCTWMRFINC"	"13"	"Sequence 27 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088384A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1918"	"RRKKCTWNRFINC"	"13"	"Sequence 28 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088385A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1919"	"RRKKCTWPRFINC"	"13"	"Sequence 29 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088386A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1920"	"RRKKCTWQRFINC"	"13"	"Sequence 30 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088387A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1921"	"RRKKCTWRRFINC"	"13"	"Sequence 31 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088388A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1922"	"RRKKCTWSRFINC"	"13"	"Sequence 32 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088389A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1923"	"RRKKCTWTRFINC"	"13"	"Sequence 33 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088390A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1924"	"RRKKCTWVRFINC"	"13"	"Sequence 34 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088391A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1925"	"RRKKCTWWRFINC"	"13"	"Sequence 35 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088392A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1926"	"RRKKCTWYRFINC"	"13"	"Sequence 36 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088393A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1927"	"RRKKCTWFAFINC"	"13"	"Sequence 37 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088394A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1928"	"RRKKCTWFCFINC"	"13"	"Sequence 38 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088395A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1929"	"RRKKCTWFDFINC"	"13"	"Sequence 39 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088396A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1930"	"RRKKCTWFEFINC"	"13"	"Sequence 40 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088397A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1931"	"RRKKCTWFFFINC"	"13"	"Sequence 41 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088398A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1932"	"RRKKCTWFGFINC"	"13"	"Sequence 42 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088399A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1933"	"RRKKCTWFHFINC"	"13"	"Sequence 43 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088400A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1934"	"RRKKCTWFIFINC"	"13"	"Sequence 44 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088401A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1935"	"RRKKCTWFKFINC"	"13"	"Sequence 45 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088402A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1936"	"RRKKCTWFLFINC"	"13"	"Sequence 46 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088403A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1937"	"RRKKCTWFMFINC"	"13"	"Sequence 47 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088404A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1938"	"RRKKCTWFNFINC"	"13"	"Sequence 48 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088405A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1939"	"RRKKCTWFPFINC"	"13"	"Sequence 49 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088406A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1940"	"RRKKCTWFQFINC"	"13"	"Sequence 50 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088407A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1941"	"RRKKCWWFTWIAC"	"13"	"Sequence 51 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088408A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1942"	"RRKKCTWFSFINC"	"13"	"Sequence 52 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088409A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1943"	"RRKKCTWFTFINC"	"13"	"Sequence 53 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088410A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1944"	"RRKKCTWFVFINC"	"13"	"Sequence 54 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088411A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1945"	"RRKKCTWFWFINC"	"13"	"Sequence 55 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088412A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1946"	"RRKKCTWFYFINC"	"13"	"Sequence 56 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088413A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1947"	"RRKKCWWFTYIAC"	"13"	"Sequence 57 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088414A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1948"	"RRKKCAWFTFINC"	"13"	"Sequence 58 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088415A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1949"	"RRKKCCWFTFINC"	"13"	"Sequence 59 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088416A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1950"	"RRKKCDWFTFINC"	"13"	"Sequence 60 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088417A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1951"	"RRKKCEWFTFINC"	"13"	"Sequence 61 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088418A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1952"	"RRKKCFWFTFINC"	"13"	"Sequence 62 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088419A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1953"	"RRKKCGWFTFINC"	"13"	"Sequence 63 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088420A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1954"	"RRKKCHWFTFINC"	"13"	"Sequence 64 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088421A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1955"	"RRKKCIWFTFINC"	"13"	"Sequence 65 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088422A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1956"	"RRKKCKWFTFINC"	"13"	"Sequence 66 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088423A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1957"	"RRKKCLWFTFINC"	"13"	"Sequence 67 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088424A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1958"	"RRKKCMWFTFINC"	"13"	"Sequence 68 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088425A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1959"	"RRKKCNWFTFINC"	"13"	"Sequence 69 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088426A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1960"	"RRKKCPWFTFINC"	"13"	"Sequence 70 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088427A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1961"	"RRKKCQWFTFINC"	"13"	"Sequence 71 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088428A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1962"	"RRKKCRWFTFINC"	"13"	"Sequence 72 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088429A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1963"	"RRKKCSWFTFINC"	"13"	"Sequence 73 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088430A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1964"	"RRKKCTWFTFINC"	"13"	"Sequence 74 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088431A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1965"	"RRKKCVWFTFINC"	"13"	"Sequence 75 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088432A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1966"	"RRKKCWWFTFINC"	"13"	"Sequence 76 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088433A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1967"	"RRKKCYWFTFINC"	"13"	"Sequence 77 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088434A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1968"	"RRKKCWWFTFIAC"	"13"	"Sequence 78 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088435A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1969"	"RRKKCWWFTFICC"	"13"	"Sequence 79 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088436A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1970"	"RRKKCWWFTFIDC"	"13"	"Sequence 80 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088437A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1971"	"RRKKCWWFTFIEC"	"13"	"Sequence 81 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088438A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1972"	"RRKKCWWFTFIFC"	"13"	"Sequence 82 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088439A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1973"	"RRKKCWWFTFIGC"	"13"	"Sequence 83 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088440A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1974"	"RRKKCWWFTFIHC"	"13"	"Sequence 84 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088441A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1975"	"RRKKCWWFTFIIC"	"13"	"Sequence 85 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088442A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1976"	"RRKKCWWFTFIKC"	"13"	"Sequence 86 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088443A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1977"	"RRKKCWWFTFILC"	"13"	"Sequence 87 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088444A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1978"	"RRKKCWWFTFIMC"	"13"	"Sequence 88 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088445A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1979"	"RRKKCWWFTFIPC"	"13"	"Sequence 89 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088446A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1980"	"RRKKCWWFTFIQC"	"13"	"Sequence 90 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088447A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1981"	"RRKKCWWFTFIRC"	"13"	"Sequence 91 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088448A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1982"	"RRKKCWWFTFISC"	"13"	"Sequence 92 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088449A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1983"	"RRKKCWWFTFITC"	"13"	"Sequence 93 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088450A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1984"	"RRKKCWWFTFIVC"	"13"	"Sequence 94 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088451A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1985"	"RRKKCWWFTFIWC"	"13"	"Sequence 95 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088452A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1986"	"RRKKCWWFTFIYC"	"13"	"Sequence 96 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088453A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1987"	"CTKSRFANC"	"9"	"Sequence 97 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088454A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1988"	"CTKSRFCNC"	"9"	"Sequence 98 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088455A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1989"	"CTKSRFENC"	"9"	"Sequence 99 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088456A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1990"	"CTKSRFFNC"	"9"	"Sequence 100 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088457A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1991"	"CTKSRFGNC"	"9"	"Sequence 101 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088458A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1992"	"CTKSRFHNC"	"9"	"Sequence 102 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088459A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1993"	"CTKSRFINC"	"9"	"Sequence 103 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088460A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1994"	"CTKSRFKNC"	"9"	"Sequence 104 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088461A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1995"	"CTKSRFLNC"	"9"	"Sequence 105 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088462A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1996"	"CTKSRFMNC"	"9"	"Sequence 106 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088463A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1997"	"CTKSRFNNC"	"9"	"Sequence 107 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088464A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1998"	"CTKSRFPNC"	"9"	"Sequence 108 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088465A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa1999"	"CTKSRFQNC"	"9"	"Sequence 109 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088466A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2000"	"CTKSRFRNC"	"9"	"Sequence 110 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088467A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2001"	"CTKSRFTNC"	"9"	"Sequence 111 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088468A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2002"	"CTKSRFTNC"	"9"	"Sequence 112 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088469A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2003"	"CTKSRFVNC"	"9"	"Sequence 113 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088470A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2004"	"CTKSRFWNC"	"9"	"Sequence 114 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088471A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2005"	"CTKSRFYNC"	"9"	"Sequence 115 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088472A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2006"	"RRKKCTASRFINC"	"13"	"Sequence 116 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088473A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2007"	"RRKKCTCSRFINC"	"13"	"Sequence 117 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088474A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2008"	"RRKKCTDSRFINC"	"13"	"Sequence 118 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088475A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2009"	"RRKKCTESRFINC"	"13"	"Sequence 119 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088476A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2010"	"RRKKCTFSRFINC"	"13"	"Sequence 120 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088477A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2011"	"RRKKCTGSRFINC"	"13"	"Sequence 121 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088478A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2012"	"RRKKCTHSRFINC"	"13"	"Sequence 122 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088479A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2013"	"RRKKCTISRFINC"	"13"	"Sequence 123 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088480A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2014"	"RRKKCTKSRFINC"	"13"	"Sequence 124 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088481A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2015"	"RRKKCTLSRFINC"	"13"	"Sequence 125 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088482A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2016"	"RRKKCTMSRFINC"	"13"	"Sequence 126 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088483A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2017"	"RRKKCTNSRFINC"	"13"	"Sequence 127 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088484A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2018"	"RRKKCTPSRFINC"	"13"	"Sequence 128 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088485A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2019"	"RRKKCTQSRFINC"	"13"	"Sequence 129 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088486A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2020"	"RRKKCTRSRFINC"	"13"	"Sequence 130 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088487A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2021"	"RRKKCTSSRFINC"	"13"	"Sequence 131 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088488A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2022"	"RRKKCTTSRFINC"	"13"	"Sequence 132 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088489A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2023"	"RRKKCTVSRFINC"	"13"	"Sequence 133 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088490A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2024"	"RRKKCTWSRFINC"	"13"	"Sequence 134 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088491A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2025"	"RRKKCTWSRFINC"	"13"	"Sequence 136 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088492A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2026"	"RRKKCWWFTAIAC"	"13"	"Sequence 137 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088493A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2027"	"RRKKCWWFTCIAC"	"13"	"Sequence 138 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088494A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2028"	"RRKKCWWFTDIAC"	"13"	"Sequence 139 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088495A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2029"	"RRKKCWWFTEIAC"	"13"	"Sequence 140 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088496A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2030"	"RRKKCWWFTGIAC"	"13"	"Sequence 141 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088497A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2031"	"RRKKCWWFTHIAC"	"13"	"Sequence 142 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088498A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2032"	"RRKKCWWFTIIAC"	"13"	"Sequence 143 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088499A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2033"	"RRKKCWWFTKIAC"	"13"	"Sequence 144 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088500A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2034"	"RRKKCWWFTLIAC"	"13"	"Sequence 145 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088501A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2035"	"RRKKCWWFTMIAC"	"13"	"Sequence 146 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088502A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2036"	"RRKKCWWFTNIAC"	"13"	"Sequence 147 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088503A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2037"	"RRKKCWWFTPIAC"	"13"	"Sequence 148 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088504A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2038"	"RRKKCWWFTQIAC"	"13"	"Sequence 149 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088505A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2039"	"RRKKCWWFTRIAC"	"13"	"Sequence 150 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088506A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2040"	"RRKKCWWFTSIAC"	"13"	"Sequence 151 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088507A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2041"	"RRKKCWWFTTIAC"	"13"	"Sequence 152 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088508A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2042"	"RRKKCWWFTVIAC"	"13"	"Sequence 153 from Patent US10538554B2"	"Synthetic construct"	"Influenza viruses"	"Granted Patent"	"US10538554B2"	"2020-01-21"	"WO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A，JP2022088509A"	"Peptides and uses therefor as antiviral agents"		"Peptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections."		"Anti-influenza virus"
"DRAVPa2043"	"MLSYLIFALAVSPILG"	"16"	"Sequence 1 from Patent US10745448B2"	"Vesicular stomatitis virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2044"	"MKTIIALSYIFCLALG"	"16"	"Sequence 2 from Patent US10745448B2"	"Influenza A virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (3) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2045"	"MKAIIVLLMVVTSNA"	"15"	"Sequence 3 from Patent US10745448B2"	"Influenza B virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (4) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2046"	"MKCLLYLAFLFIGVNC"	"16"	"Sequence 4 from Patent US10745448B2"	"Vesicular stomatitis virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (5) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2047"	"MKTIIALSYIFCQVLA"	"16"	"Sequence 5 from Patent US10745448B2"	"Influenza A virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (6) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2048"	"MKTIIALSYIFCLVFA"	"16"	"Sequence 6 from Patent US10745448B2"	"Influenza A virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (7) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2049"	"MKTIIALSYIFCLVLG"	"16"	"Sequence 7 from Patent US10745448B2"	"Influenza A virus"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (8) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2050"	"RSRKYTSWYVALKR"	"14"	"Sequence 8 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (9) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2051"	"MAKSIRSKHRRQMRMM"	"19"	"Sequence 9 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (10) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2052"	"MARRRRHRGPRRPRPP"	"16"	"Sequence 10 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (11) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2053"	"GRCRRLANFGPRKRRRRRR"	"19"	"Sequence 11 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (12) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2054"	"RRRKRNRDARRRRRKQ"	"16"	"Sequence 12 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (13) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2055"	"MQRKPTIRRKNLRLRRK"	"17"	"Sequence 13 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (14) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2056"	"IMRRRGL"	"7"	"Sequence 14 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (15) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2057"	"KKLKKRNK"	"8"	"Sequence 15 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (16) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2058"	"RRRANNRRR"	"9"	"Sequence 16 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (17) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2059"	"RKKRKKK"	"7"	"Sequence 17 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (18) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2060"	"KRKGKLKNKGSKRKK"	"15"	"Sequence 18 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (19) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2061"	"SKRLSSRARKRAAKRRLG"	"18"	"Sequence 19 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (20) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2062"	"KRPRRRPSRPFRKP"	"14"	"Sequence 20 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (21) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2063"	"KKRTLRKNDRKKR"	"13"	"Sequence 21 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (22) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2064"	"WRRQARFK"	"8"	"Sequence 22 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (23) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2065"	"RKKRRQRRR"	"9"	"Sequence 23 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (24) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2066"	"YARAAARQARA"	"11"	"Sequence 24 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (25) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2067"	"KGRQVKVWFQNRRMKWKK"	"18"	"Sequence 25 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (26) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2068"	"MLSYLIFALAVSPILGKKRTLRKNDRKKR"	"29"	"Sequence 26 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (27) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2069"	"MKTIIALSYIFCLALGKKRTLRKNDRKKR"	"29"	"Sequence 27 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (28) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2070"	"MKAIIVLLMVVTSNAKKRTLRKNDRKKR"	"28"	"Sequence 28 from Patent US10745448B2"	"Synthetic peptide"	" VSV"	"Granted Patent"	"US10745448B2"	"2020-08-18"	"JP6994714B2"	"Antiviral peptide and use therefor"		"An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (29) an amino acid sequence that functions as a cell penetrating peptide (CPP)."		" Anti-VSV"
"DRAVPa2071"	"SGSWLRDVWTWLQSKL"	"16"	"Sequence 1 from Patent US10351604B2"	"Synthetic peptide"	"DENV,CHIKV,YFV,JEV"	"Granted Patent"	"US10351604B2"	"2019-07-16"	"WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2"	"Broad-spectrum anti-infective peptides"		"Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides."		"Anti-DENV,Anti-CHIKV,Anti-YFV,Anti-JEV"
"DRAVPa2072"	"GSSWLRDVWTWLQSKL"	"16"	"Sequence 2 from Patent US10351604B2"	"Synthetic peptide"	"DENV,YFV,JEV"	"Granted Patent"	"US10351604B2"	"2019-07-16"	"WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2"	"Broad-spectrum anti-infective peptides"		"Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides."		"Anti-DENV,Anti-YFV,Anti-JEV"
"DRAVPa2073"	"GSSWLRDVWTWLQSAL"	"16"	"Sequence 3 from Patent US10351604B2"	"Synthetic peptide"	"DENV,CHIKV,YFV,"	"Granted Patent"	"US10351604B2"	"2019-07-16"	"WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2"	"Broad-spectrum anti-infective peptides"		"Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides."		"Anti-DENV,Anti-CHIKV,Anti-YFV"
"DRAVPa2074"	"GSSWLRDVWTKLQSWL"	"16"	"Sequence 4 from Patent US10351604B2"	"Synthetic peptide"	"DENV,CHIKV,YFV,JEV"	"Granted Patent"	"US10351604B2"	"2019-07-16"	"WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2"	"Broad-spectrum anti-infective peptides"		"Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides."		"Anti-DENV,Anti-CHIKV,Anti-YFV,Anti-JEV"
"DRAVPa2075"	"GSSWLRDIWTALQSWI"	"16"	"Sequence 6 from Patent US10351604B2"	"Synthetic peptide"	"DENV,,YFV,JEV"	"Granted Patent"	"US10351604B2"	"2019-07-16"	"WO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2"	"Broad-spectrum anti-infective peptides"		"Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides."		"Anti-DENV,Anti-YFV,Anti-JEV"
"DRAVPa2076"	"RRKKAAWALLPAWLLALLAP"	"20"	"Sequence 1 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2077"	"RRKKAAVALIPAWLLALLA"	"19"	"Sequence 2 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2078"	"RRKKAAWALLPAWLLALL"	"18"	"Sequence 3 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2079"	"RRKKAAWALLPAWLLAL"	"17"	"Sequence 4 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2080"	"RRKKAAWALLPAWLLA"	"16"	"Sequence 5 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2081"	"RRKKAWALLPAWLLALLAP"	"19"	"Sequence 18 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2082"	"RRKKWALLPAWLLALLAP"	"18"	"Sequence 19 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2083"	"RRKKALLPAWLLALLAP"	"17"	"Sequence 20 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2084"	"RRKKLLPAWLLALLAP"	"16"	"Sequence 21 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2085"	"RRKKLPAWLLALLAP"	"15"	"Sequence 22 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2086"	"RRKKWLLALLAP"	"12"	"Sequence 23 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2087"	"RRKKWALLAWLLALLA"	"16"	"Sequence 32 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2088"	"RRKKAAWALLAWLLALLA"	"18"	"Sequence 43 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2089"	"RRKKLLAWLLALLA"	"14"	"Sequence 44 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2090"	"RRKKLAVILLALLA"	"13"	"Sequence 45 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2091"	"RKKLAWLLALLA"	"12"	"Sequence 50 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2092"	"RKAWLLALLA"	"10"	"Sequence 51 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2093"	"KLAVILALLA"	"10"	"Sequence 52 from Patent US9221874B2"	"Synthetic peptide"	"influenza virus"	"Granted Patent"	"US9221874B2"	"2015-12-29"	"WO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4"	"Antiviral peptides against influenza virus"		"The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections."		"Anti-influenza virus"
"DRAVPa2094"	"CNDFRSKTC"	"9"	"Sequence 1 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N2"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2095"	"NDFRSKT"	"7"	"Sequence 2 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N3"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2096"	"QHSTKWF"	"7"	"Sequence 4 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N4"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2097"	"LPYAAKH"	"7"	"Sequence 5 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N5"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2098"	"ILGDKVG"	"7"	"Sequence 6 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N6"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2099"	"ILGYKVG"	"7"	"Sequence 7 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N7"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2100"	"HPOFLSL"	"7"	"Sequence 8 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N8"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2101"	"GLYNHPQ"	"7"	"Sequence 9 from Patent US8883480B2"	"Synthetic peptide"	"H9N2"	"Granted Patent"	"US8883480B2"	"2014-11-11"	"WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1"	"Antiviral peptide against avian influenza virus H9N9"		"The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus."		"Anti-H9N2"
"DRAVPa2102"	"EVKLLEQSGAELVKPGASVRLSCTAS"	"26"	"Sequence 3 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2103"	"YMSWVKQRPEQGLEWIGRI"	"19"	"Sequence 4 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2104"	"TKYDPKFOGKATITADTSSNTAYLHLSSLTSGDTAVYYCSR"	"41"	"Sequence 5 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2105"	"WGQGTLVTVSA"	"11"	"Sequence 6 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2106"	"GFNIKDT"	"7"	"Sequence 7 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2107"	"DPANGD "	"6"	"Sequence 8 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2108"	"GWEGFAY "	"7"	"Sequence 9 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2109"	"ELVMTQTPASLAVSLGQRATISC"	"23"	"Sequence 10 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2110"	"WYQQKAGQPPKLLIY"	"15"	"Sequence 11 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2111"	"GIPARFSGSGSRTDFTLTINPVEADDVATYFC"	"32"	"Sequence 12 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2112"	"FGGGTKLEIKR"	"11"	"Sequence 13 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2113"	"RASENVDRYGNSFMH"	"15"	"Sequence 14 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2114"	"RASNLES"	"7"	"Sequence 15 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2115"	"QRSNEVPWT"	"9"	"Sequence 16 from Patent US9880167B2"	"Synthetic peptide"	"Dengue Virus"	"Granted Patent"	"US9880167B2"	"2018-01-30"	"US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##"	"Anti-dengue virus antibodies and uses thereof"		"The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV."		"Anti-dengue virus"
"DRAVPa2116"	"LRTRKRGRKLRTRKRGRK"	"18"	"Sequence 48 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2117"	"RTRKRGRKRTRKRGRK"	"16"	"Sequence 3 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2118"	"RTRKRGRRTRKRGR"	"14"	"Sequence 4 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2119"	"LRKRKRLLRKRKRL"	"14"	"Sequence 5 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2120"	"LRKRKRLRKLRKRKRLRK"	"18"	"Sequence 6 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2121"	"WRWRKRWRKWRWRKRWRK"	"18"	"Sequence 7 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2122"	"RRWRKRWRKWRWRKRWRK"	"18"	"Sequence 34 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2123"	"KRWRKRWRKWRWRKRWRK"	"18"	"Sequence 35 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2124"	"LRWRKRWRKWRWRKRWRK"	"18"	"Sequence 36 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2125"	"HRWRKRWRKWRWRKRWRK"	"18"	"Sequence 37 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2126"	"RWRKRWRKWRWRKRWRK"	"17"	"Sequence 38 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2127"	"RRWRKRWRKRRWRKRWRK"	"18"	"Sequence 39 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2128"	"KRWRKRWRKKRWRKRWRK"	"18"	"Sequence 40 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2129"	"LRWRKRWRKLRWRKRWRK"	"18"	"Sequence 41 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2130"	"HRWRKRWRKHRWRKRWRK"	"18"	"Sequence 42 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2131"	"RWRKRWRKRWRKRWRK"	"16"	"Sequence 43 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2132"	"RWRKRGRKRWRKRGRK"	"16"	"Sequence 44 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2133"	"RTRKRWRKRTRKRGRK"	"16"	"Sequence 45 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2134"	"RWRKRWRKRWRKRWRK"	"16"	"Sequence 46 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2135"	"RWRKRWRWRKRWRWRKRW"	"18"	"Sequence 47 from Patent US8017579B2"	"Homo sapiens"	"HIV,HSV"	"Granted Patent"	"US8017579B2"	"2011-09-13"	"JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1"	"Treatment of viral infections"		"The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections."		"Anti-HIV,Anti-HSV"
"DRAVPa2136"	"NFRHTHR"	"7"	"Sequence 1 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-19 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-19, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2137"	"FNRHTHR"	"7"	"Sequence 2 from Patent CN111499692B "	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-20 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-20, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2138"	"IGVRGGW"	"7"	"Sequence 3 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-21 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-21, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2139"	"KWPYKKS"	"7"	"Sequence 4 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-22 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-22, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2140"	"KTYHTHR"	"7"	"Sequence 5 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-23 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-23, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2141"	"IRQFFKK"	"7"	"Sequence 6 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-24 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-24, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2142"	"FYIKINH"	"7"	"Sequence 7 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-25 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-25, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2143"	"KSPPYHK"	"7"	"Sequence 8 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-26 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-26, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2144"	"WVHFYHF"	"7"	"Sequence 9 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-27 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-27, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2145"	"KPYIWKS"	"7"	"Sequence 10 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-28 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-28, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2146"	"KWPFKKS"	"7"	"Sequence 11 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-29 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-29, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2147"	"IGHVPGT "	"7"	"Sequence 12 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-30 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-30, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2148"	"WIGVRNW "	"7"	"Sequence 13 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-31 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-31, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2149"	"QGTHTAH"	"7"	"Sequence 14 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-32 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-32, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2150"	"NSGGSVH"	"7"	"Sequence 15 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-33 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-33, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2151"	"AAARFST"	"7"	"Sequence 16 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-34 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-34, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2152"	"PIGVPHT "	"7"	"Sequence 17 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-35 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-35, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2153"	"QVAVLYQ"	"7"	"Sequence 18 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-36 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-36, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2154"	"FLGVYYH"	"7"	"Sequence 19 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-37 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-37, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2155"	"ALTGIAV"	"7"	"Sequence 20 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-38 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-38, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2156"	"FVFLVLL"	"7"	"Sequence 21 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-39 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-39, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2157"	"VVIGIVN"	"7"	"Sequence 22 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-40 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-40, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2158"	"NFTISVTT"	"8"	"Sequence 23 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-41 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-41, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2159"	"RVVVLSFE"	"8"	"Sequence 24 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-42 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-42, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2160"	"AAYYVGYL"	"8"	"Sequence 25 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-43 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-43, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2161"	"SIIAYTMSLG"	"10"	"Sequence 26 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-44 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-44, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2162"	"GVVFLHVTYV"	"10"	"Sequence 27 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-45 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-45, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2163"	"FTGCVIAWNR"	"10"	"Sequence 28 from Patent CN111499692B"	"Synthetic peptide"	"SARS-CoV-2"	"Granted Patent"	"CN111499692B"	"2020-12-04"		"Polypeptide of targeting novel coronavirus COVID-46 and application thereof"		"The invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-46, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs."		"Anti-SARS-CoV-2"
"DRAVPa2164"	"SWETWEREIENYTROIYRILEESOEOODRNERDLLE."	"36"	"Sequence 1 from Patent US8603965B2"	"homo sapiens"	"HIV"	"Granted Patent"	"US8603965B2"	"2013-12-10"	"WO2007143934A1##CN101088557A"	"Pharmaceutical composition for the prophylaxis and treatment of HIV infection and its use"		"Pharmaceutical compositions for the prophylaxis and treatment of HIV infection and its use are provided. Particularly, the present invention provides a pharmaceutical composition comprising anti-virus peptides, use of said composition for manufacturing a medicament for the prophylaxis and treatment of HIV infection, and method for preventing and treating HIV infection by using said composition."		"Anti-HIV"
"DRAVPa2165"	"NGAICWGPCPTAFRQIGNCGHFKVRCCNIR"	"30"	"Sequence 13 from Patent US9822155B2"	"Synthetic peptide"	"Influenza A  virus"	"Granted Patent"	"US9822155B2"	"2017-11-21"	"WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B"	"Method of preventively treating a subject at the risk of developing infections of a respiratory virus"		"A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a peptide synthesized through a chemical route or by a genetic engineering process, characterized in that the peptide has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the peptide has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the peptide; and wherein the peptide consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 15. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities."		"Anti-Influenza A  virus"
"DRAVPa2166"	"NGAICWGPCPTAFRQIGNCGHFKVRCCNID"	"30"	"Sequence 14 from Patent US9822155B2"	"Synthetic peptide"	"Influenza A  virus"	"Granted Patent"	"US9822155B2"	"2017-11-21"	"WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B"	"Method of preventively treating a subject at the risk of developing infections of a respiratory virus"		"A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a peptide synthesized through a chemical route or by a genetic engineering process, characterized in that the peptide has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the peptide has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the peptide; and wherein the peptide consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 16. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities."		"Anti-Influenza A  virus"
"DRAVPa2167"	"NGAICWGPCPTAFRQIGNCGHFKVTCCNID"	"30"	"Sequence 15 from Patent US9822155B2"	"Synthetic peptide"	"Influenza A  virus"	"Granted Patent"	"US9822155B2"	"2017-11-21"	"WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B"	"Method of preventively treating a subject at the risk of developing infections of a respiratory virus"		"A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a peptide synthesized through a chemical route or by a genetic engineering process, characterized in that the peptide has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the peptide has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the peptide; and wherein the peptide consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 17. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities."		"Anti-Influenza A  virus"
"DRAVPa2168"	"DEDNGAICWGPCPTAFRQIGNCGHFKVRCCKIR"	"33"	"Sequence 16 from Patent US9822155B2"	"Synthetic peptide"	"Influenza A  virus"	"Granted Patent"	"US9822155B2"	"2017-11-21"	"WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B"	"Method of preventively treating a subject at the risk of developing infections of a respiratory virus"		"A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a peptide synthesized through a chemical route or by a genetic engineering process, characterized in that the peptide has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the peptide has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the peptide; and wherein the peptide consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 18. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities."		"Anti-Influenza A  virus"
"DRAVPa2169"	"KHRNGAICWGPCPTAFRQIGNCGHFKVRCCKIR"	"33"	"Sequence 17 from Patent US9822155B2"	"Synthetic peptide"	"Influenza A  virus"	"Granted Patent"	"US9822155B2"	"2017-11-21"	"WO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244B"	"Method of preventively treating a subject at the risk of developing infections of a respiratory virus"		"A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of a peptide synthesized through a chemical route or by a genetic engineering process, characterized in that the peptide has a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein the peptide has 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of the peptide; and wherein the peptide consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 19. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities."		"Anti-Influenza A  virus"
"DRAVPa2170"	"SWLRDIWDWICEVLSDFK"	"18"	"Sequence 1 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2171"	"SWLRDIWDWICEVLSDFK"	"18"	"Sequence 2 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2172"	"GSWLRDIWDWICEVLSDFK"	"19"	"Sequence 3 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2173"	"SWLRDIWDWICEVLSDFKTW"	"20"	"Sequence 4 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2174"	"KFDSLVECIWDWIDRLWS"	"18"	"Sequence 5 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2175"	"KWLCRIWSWISDVLDDFE"	"18"	"Sequence 6 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2176"	"SIWRDWVDLICEFLSDWK"	"18"	"Sequence 7 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2177"	"DWLRIIWDWVCSVVSDFK"	"18"	"Sequence 8 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2178"	"PLKPTKRSFIKDLLFNKV"	"18"	"Sequence 9 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2179"	"SWLRDIWDWISEVLSDFK"	"18"	"Sequence 10 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2180"	"SWLRDIWDWISEVLSDFK"	"18"	"Sequence 11 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2181"	"SWLRDIWDWICEVLSDFR"	"18"	"Sequence 12 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2182"	"SYLRDIWDYICEVLSDFK"	"18"	"Sequence 13 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2183"	"SYLRDIWDYISEVLSDFK"	"18"	"Sequence 14 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2184"	"SYLREIWDYISEVLSDFR"	"18"	"Sequence 15 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2185"	"SWLREIWDWICEVLSDFK"	"18"	"Sequence 16 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2186"	"SWLRDIWDWISEVLSDFR"	"18"	"Sequence 32 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2187"	"SWLRDIWDYISEVLSDFR"	"18"	"Sequence 33 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2188"	"SWLRDIWDYISEVLSDFR"	"18"	"Sequence 34 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2189"	"SWLRDIWDYICEVLSDFR"	"18"	"Sequence 35 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2190"	"AWLRDIWDWICEVLSDFK"	"18"	"Sequence 40 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2191"	"SALRDIWDWICEVLSDFK"	"18"	"Sequence 41 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2192"	"SWARDIWDWICEVLSDFK"	"18"	"Sequence 42 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2193"	"SWLADIWDWICEVLSDFK"	"18"	"Sequence 43 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2194"	"SWLRAIWDWICEVLSDFK"	"18"	"Sequence 44 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2195"	"SWLRDAWDWICEVLSDFK"	"18"	"Sequence 45 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2196"	"SWLRDIADWICEVLSDFK"	"18"	"Sequence 46 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2197"	"SWLRDIWAWICEVLSDFK"	"18"	"Sequence 47 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2198"	"SWLRDIWDAICEVLSDFK"	"18"	"Sequence 48 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2199"	"SWLRDIWDWACEVLSDFK"	"18"	"Sequence 49 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2200"	"SWLRDIWDWIAEVLSDFK"	"18"	"Sequence 50 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2201"	"SWLRDIWDWICAVLSDFK"	"18"	"Sequence 51 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2202"	"SWLRDIWDWICEALSDFK"	"18"	"Sequence 52 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2203"	"SWLRDIWDWICEVASDFK"	"18"	"Sequence 53 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2204"	"SWLRDIWDWICEVLADFK"	"18"	"Sequence 54 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2205"	"SWLRDIWDWICEVLSAFK"	"18"	"Sequence 55 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2206"	"SWLRDIWDWICEVLSDAK"	"18"	"Sequence 56 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2207"	"SWLRDIWDWICEVLSDFA"	"18"	"Sequence 57 from Patent US20230256049A1"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"US20230256049A1"	"2023-08-17"	"WO2022020766A1##EP4171746A4##CA3186948A1"	"Materials and methods for the prevention and treatment of viral respiratory diseases"		"This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s) to the respiratory system."		"Anti-SARS-CoV-2"
"DRAVPa2208"	"WRCKVR"	"6"	"AP19"	"Synthetic peptide"	"GAstV"	"Patent Application"	"CN115894614A"	"2023-04-04"		"Antiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptide"		"The invention relates to an antiviral affinity peptide of a targeted goose astrovirus Spike protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-2Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinity peptide for specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research on antiviral polypeptide drugs"		"Anti-GAstV"
"DRAVPa2209"	"WKHKRR"	"6"	"AP21"	"Synthetic peptide"	"GAstV"	"Patent Application"	"CN115894614A"	"2023-04-04"		"Antiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptide"		"The invention relates to an antiviral affinity peptide of a targeted goose astrovirus Spike protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-3Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinity peptide for specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research on antiviral polypeptide drugs"		"Anti-GAstV"
"DRAVPa2210"	"WKHWYK"	"6"	"AP30"	"Synthetic peptide"	"GAstV"	"Patent Application"	"CN115894614A"	"2023-04-04"		"Antiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptide"		"The invention relates to an antiviral affinity peptide of a targeted goose astrovirus Spike protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-4Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinity peptide for specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research on antiviral polypeptide drugs"		"Anti-GAstV"
"DRAVPa2211"	"KYWQRE"	"6"	"Sequence 8 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-4 infection in the future."		"Anti-FAdV-4"
"DRAVPa2212"	"KYWGRN"	"6"	"Sequence 11 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber2 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-5 infection in the future."		"Anti-FAdV-4"
"DRAVPa2213"	"YMKKYA"	"6"	"Sequence 14 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber3 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-6 infection in the future."		"Anti-FAdV-4"
"DRAVPa2214"	"YMKHSD"	"6"	"Sequence 16 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber4 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-7 infection in the future."		"Anti-FAdV-4"
"DRAVPa2215"	"YMKHSR"	"6"	"Sequence 20 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber5 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-8 infection in the future."		"Anti-FAdV-4"
"DRAVPa2216"	"YMKHRH"	"6"	"Sequence 21 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber6 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-9 infection in the future."		"Anti-FAdV-4"
"DRAVPa2217"	"YMKHRV"	"6"	"Sequence 22 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber7 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-10 infection in the future."		"Anti-FAdV-4"
"DRAVPa2218"	"KQWKEH"	"6"	"Sequence 24 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber8 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-11 infection in the future."		"Anti-FAdV-4"
"DRAVPa2219"	"KQWYRT"	"6"	"Sequence 25 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber9 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-12 infection in the future."		"Anti-FAdV-4"
"DRAVPa2220"	"KQWGHR"	"6"	"Sequence 27 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber10 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-13 infection in the future."		"Anti-FAdV-4"
"DRAVPa2221"	"KQWCQW"	"6"	"Sequence 32 from Patent CN116874560A"	"Synthetic peptide"	"FAdV-4"	"Patent Application"	"CN116874560A"	"2023-10-13"		"Antiviral affinity peptide targeting fowl adenovirus 4 type Fiber11 protein and application thereof"		"The invention provides an antiviral affinity peptide targeting fowl adenovirus 4 type Fiber1 protein and application of the antiviral affinity peptide. The sequence of the affinity peptide is YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinity peptide targeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimal peptide having the antiviral activity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and the antiviral drug design, and the new thought is provided for the prevention and the control of the FAdV-14 infection in the future."		"Anti-FAdV-4"
"DRAVPa2222"	"VTFLVGLNQYLV"	"12"	"Sequence 47 from Patent US20140294942A1"	"Synthetic peptide"	"vsv"	"Patent Application"	"US20140294942A1"	"2014-10-02"	"WO/2013/036622"	" ANTIVIRAL PEPTIDES EFFECTIVE AGAINST HEPATITIS C VIRUS"		"In certain embodiments this invention provides novel antiviral peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like."		"Anti-vsv"
"DRAVPa2223"	"VSFRVGLHEYPV"	"12"	"Sequence 48 from Patent US20140294942A1"	"Synthetic peptide"	"vsv"	"Patent Application"	"US20140294942A1"	"2014-10-02"	"WO/2013/036622"	" ANTIVIRAL PEPTIDES EFFECTIVE AGAINST HEPATITIS C VIRUS"		"In certain embodiments this invention provides novel antiviral peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like."		"Anti-vsv"
"DRAVPa2224"	"SDWGVLTNLG ILLLLSIAVL IALSCICGSGKKRTLRKNDRKKR"	"43"	"Sequence 29 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2225"	"RQWIPAGIGVTGVIIAVIALFCICKFVGSGKKRTLRKNDRKKR"	"43"	"Sequence 30 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 101 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2226"	"RQWIPAGIGITGIIIAIIALLCVCKLLGSGKKRTLRKNDRKKR"	"43"	"Sequence 31 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 102 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2227"	"MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSGSGKKRTLRKNDRKKR"	"48"	"Sequence 32 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 103 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2228"	"MEGLSLLQLPRDKFRKSSFFVWVIILFQKAFSGSGKKRTLRKNDRKKR"	"48"	"Sequence 33 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 104 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2229"	"MKTTCFLISLILQGTKNGSGKKRTLRKNDRKKR"	"34"	"Sequence 34 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 105 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2230"	"MKTTCLLISLIQGCKTGSGKKRTLRKNDRKKR"	"34"	"Sequence 35 from Patent US20210380642B2"	"Synthetic peptide"	"Ebola virus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 106 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2231"	"NAIVGIVLLIVVTFLAIKTKKRTLRKNDRKKR"	"32"	"Sequence 36 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 107 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2232"	"FFFIIGLIIGLFLVLRVGIHLKKRTLRKNDRKKR"	"34"	"Sequence 37 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 108 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2233"	"VLAVIIGFVILMFLIKLIGVLKKRTLRKNDRKKR"	"34"	"Sequence 38 from Patent US20210380642B2"	"Synthetic peptide"	"Ebolavirus，Marburg virus "	"Granted Patent"	"US20210380642B2"	"2023-09-26"	"JP2021187810"	"Antiviral peptide and use thereof"		"The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 109 amino acid residues."		"Anti-Ebola virus，Anti-Marburg virus "
"DRAVPa2234"	"SWLRDIWDWICEVLSDFK"	"18"	"Sequence 43 from Patent US20070073039A1"	"Hepatitis C Virus"	"HCV，Dengue viral"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2235"	"SWLRDIWDWICEVL"	"14"	"Sequence 92 from Patent US20070073039A1"	"Hepatitis C Virus"	"Dengue viral"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"		"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2236"	"LRDIWDWICEVLSDFK"	"16"	"Sequence 107 from Patent US20070073039A1"	"Hepatitis C Virus"	"Dengue viral"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"		"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2237"	"LYGNEGCGWAGWLLSPRG"	"18"	"Sequence 6 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2238"	"IFLLALLSCLTVPASAYQ"	"18"	"Sequence 8 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2239"	"GSATLCSALYVGDLCGSV"	"18"	"Sequence 12 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2240"	"ALYVGDLCGSVFLVGQLF"	"18"	"Sequence 13 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2241"	"IMDMIAGAHWGVLAGIAY"	"18"	"Sequence 14 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2242"	"YLYGVGSSIASWAIKWEY"	"18"	"Sequence 24 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2243"	"WMMLLISQAEAALENLVI"	"18"	"Sequence 27 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2244"	"TLVFDITKLLLAIFGPLW"	"18"	"Sequence 30 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2245"	"ATQTFLATCINGVCWTVY"	"18"	"Sequence 32 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2246"	"DWICEVLSDFKTWLKAKL"	"18"	"Sequence 44 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2247"	"DTEDVVCCSMSYSW"	"14"	"Sequence 47 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2248"	"SSGADTEDVVCCSMSYSW"	"18"	"Sequence 48 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2249"	"CTMLVCGDDLVVICESAG"	"18"	"Sequence 53 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by more than ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2250"	"WMNSTGFTKVCGAPPCVI"	"18"	"Sequence 21 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by five-fold to ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2251"	"MYVGGVEHRLEAACNWTR"	"18"	"Sequence 23 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by five-fold to ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2252"	"GAVYAFYGMWPLLLLLLA"	"18"	"Sequence 28 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by five-fold to ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2253"	"TSTWVLVGGVLAAT"	"18"	"Sequence 37 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by five-fold to ten-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2254"	"QIVGGVYLLPRRGPRLGW"	"18"	"Sequence 4 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2255"	"QPGYPWPLYGNEGCGWAG"	"18"	"Sequence 5 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2256"	"GWAGWLLSPRGSRPSWGP"	"18"	"Sequence 7 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2257"	"DAILHTPGCVPCVREGNA"	"18"	"Sequence 9 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2258"	"LPTTQLRRHIDLLVGSAT"	"18"	"Sequence 10 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2259"	"RHIDLLVGSATLCSALYV"	"18"	"Sequence 11 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2260"	"HINSTALINCNESLNTGWL"	"18"	"Sequence 15 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2261"	"NCNESLNTGWLAGLFYQH"	"18"	"Sequence 16 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2262"	"LASCRRLTDFAQGWGPIS"	"18"	"Sequence 17 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2263"	"TDFAQGWGPISYANGSGL"	"18"	"Sequence 18 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2264"	"GPISYANGSGLDERPYCW"	"18"	"Sequence 19 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2265"	"GSGLDERPYCWHYPPRPC"	"18"	"Sequence 20 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2266"	"PCVIGGVGNNTLLCPTDC"	"18"	"Sequence 22 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2267"	"ASWAIKWEYVVLLFLL"	"18"	"Sequence 25 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2268"	"KWEYVVLLFLLLADARVC"	"18"	"Sequence 26 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2269"	"GMWPLLLLLLALPQRAYA"	"18"	"Sequence 29 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2270"	"VSTATQTFLATCIN"	"14"	"Sequence 31 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2271"	"DSSVLCECYDAGCAWYEL"	"18"	"Sequence 33 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2272"	"AYMNTPGLPVCQDHLEFW"	"18"	"Sequence 34 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2273"	"LEFWEGVFTGLTHIDAHF"	"18"	"Sequence 35 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2274"	"HPITKYIMTCMSADLEVV"	"18"	"Sequence 36 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2275"	"WVLVGGVLAALAAYCLST"	"18"	"Sequence 38 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2276"	"LAALAAYCLSTGCVV"	"15"	"Sequence 39 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2277"	"EVFWAKHMWNFISGIQYL"	"18"	"Sequence 40 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2278"	"MWNFISGIQYLAGLSTLP"	"18"	"Sequence 41 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2279"	"PAILSPGALVVGVVCAAI"	"18"	"Sequence 42 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2280"	"YVSGMTTDNLKCPCQIPS"	"18"	"Sequence 45 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2281"	"SSGADTEDVVCCSMS"	"15"	"Sequence 46 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2282"	"DVVCCSMSYSWTGAL"	"15"	"Sequence 49 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2283"	"TVTESDIRTEEAIYQCCD"	"18"	"Sequence 50 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2284"	"GNTILTCYIKARAACRAAG"	"18"	"Sequence 51 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2285"	"RAAGLQDCTMLVCGDDLV"	"18"	"Sequence 52 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2286"	"DDLVVICESAGVQEDAAS"	"18"	"Sequence 54 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2287"	"LELITSCSSNVSVAHDGA"	"18"	"Sequence 55 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2288"	"HTPVNSWLGNIIMFAPTL"	"18"	"Sequence 56 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2289"	"APTLWARMILMTHFFSVL"	"18"	"Sequence 57 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2290"	"DQLEQALNCEIYGACYSI"	"18"	"Sequence 58 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2291"	"GVPPLRAWRHRARSVRAR"	"18"	"Sequence 59 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2292"	"WRHRARSVRARLLSRGGR"	"18"	"Sequence 60 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2293"	"GWFTAGYSGGDIYHSVSH"	"18"	"Sequence 61 from Patent US20070073039A1"	"Hepatitis C Virus"	" HCV"	"Patent Application"	"US20070073039A1"	"2007-03-29"	"EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122"	"Peptides that inhibit viral infections"	"Inhibit HCV infection by two-fold to five-fold."	"The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides."		
"DRAVPa2294"	"ELSTTDDAGTICANIGVC"	"18"	"Sequence 1 from Patent CN113754750B"	"Synthetic peptide"	"SVCV"	"Granted Patent"	"CN113754750B"	"2023-08-25"		"Antibacterial peptide and application thereof in aquaculture"		"The invention discloses an antibacterial peptide and application thereof in aquaculture. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. A section of micromolecule polypeptide caNKL2102-119 with the length of 18aa is selected and artificially synthesized through bioinformatics analysis and fitting of a three-dimensional space structure of a crucian carp NK-lysin protein, and research finds that the micromolecule polypeptide has excellent antibacterial and antiviral activity, does not easily generate drug resistance, is short in synthesis sequence, small in molecular weight, small in chemical synthesis difficulty, and high in bioactivity, can greatly save the cost of large-scale production on the basis of killing pathogenic bacteria in organisms, is expected to become an effective substitute of antibiotics in aquaculture, has high economic value and production and application value, and can inhibit replication of spring viremia virus (SVCV) of carp, a new thought is provided for preparation of aquatic antiviral drugs, and prevention and control of related aquatic viral diseases are facilitated."		
"DRAVPa2295"	"REYNNRSAIGNTIEALFQ"	"18"	"Sequence 1 from Patent CN113999286B"	"Synthetic peptide"	"Enterovirus"	"Granted Patent"	"CN113999286B"	"2024-08-02"	"WO/2022/021902##JP2023535570"	"Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 2C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor"		"The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 2C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs."		
"DRAVPa2296"	"YGRKKRRQRRRGSGREYNNRSAIGNTIEALFQ"	"32"	"Sequence 2 from Patent CN113999286B"	"Synthetic peptide"	"Enterovirus"	"Granted Patent"	"CN113999286B"	"2024-08-02"	"WO/2022/021902##JP2023535570"	"Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 3C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor"		"The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 3C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs."		
"DRAVPa2297"	"YGRKKRRQRRRGSGLIREYNNRSAIGNTIEALFQ"	"34"	"Sequence 3 from Patent CN113999286B"	"Synthetic peptide"	"Enterovirus"	"Granted Patent"	"CN113999286B"	"2024-08-02"	"WO/2022/021902##JP2023535570"	"Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 4C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor"		"The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 4C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs."		
"DRAVPa2298"	"YGRKKRRQRRRGSGSELIREYNNRSAIGNTIEALFQ"	"36"	"Sequence 4 from Patent CN113999286B"	"Synthetic peptide"	"Enterovirus"	"Granted Patent"	"CN113999286B"	"2024-08-02"	"WO/2022/021902##JP2023535570"	"Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 5C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitor"		"The invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 5C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs."		
"DRAVPa2299"	"YPFDDKMSFLFA"	"12"	"Sequence 1 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL8 (or homologues thereof) is also described."		
"DRAVPa2300"	"AGVWGEGGKFVYPFDDKMSFLFA"	"23"	"Sequence 2 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL9 (or homologues thereof) is also described."		
"DRAVPa2301"	"VLAGVWGEGGKFVYPFDDKMSFLFA"	"25"	"Sequence 3 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL10 (or homologues thereof) is also described."		
"DRAVPa2302"	"TGVLAGVWGEGGKFVYPFDDKMSFLFA"	"27"	"Sequence 4 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL11 (or homologues thereof) is also described."		
"DRAVPa2303"	"VFTGVLAGVWGEGGKFVYPFDDKMSFLFA"	"29"	"Sequence 5 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL12 (or homologues thereof) is also described."		
"DRAVPa2304"	"TGVLAGVWGEGGKFV"	"15"	"Sequence 6 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL13 (or homologues thereof) is also described."		
"DRAVPa2305"	"IELVFTGVLAGVWGEGGKFV"	"20"	"Sequence 7 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL14 (or homologues thereof) is also described."		
"DRAVPa2306"	"EILREIELVFTGVLA"	"15"	"Sequence 8 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL15 (or homologues thereof) is also described."		
"DRAVPa2307"	"IVEFLKVGFGTEGGVWLVAG"	"20"	"Sequence 9 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL16 (or homologues thereof) is also described."		
"DRAVPa2308"	"VKLWYQLEKEPIVGA"	"15"	"Sequence 10 from Patent US6337074B1"	"Synthetic peptide"	"Herpesviruses"	"Granted Patent"	"US6337074B1"	"2002-01-08"	"EP0918866##AU1997037013##WO/1998/004707##US20050164163"	"Anti-herpesviral agent"		"An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL17 (or homologues thereof) is also described."		
"DRAVPa2309"	"KHGHHRH"	"7"	"Sequence 1 from Patent US20210040153A1"	"Synthetic peptide"	"DENV"	"Patent Application"	"US20210040153A1"	"2021-02-11"	"CN108395470##WO/2019/137247"	"OLIGOPEPTIDE HAVING DENGUE VIRUS REPLICATION INHIBITION FUNCTION AND APPLICATION THEREOF"		"The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in the present invention is KHGHHRH, i.e. Lys-His-Gly-His-His-Arg-His (SEQ ID NO. 1). The short peptide has a high specificity affinity with NS5 and has the function of efficiently inhibiting dengue virus replication, the anti-viral effect thereof not been limited to DENV-2, but also having a significant inhibitory effect on the replication of type 1, type 3, and type 4 dengue virus. One cysteine is added to the two ends of the short peptide sequence, the short peptide being cyclised by means of the cysteines at the two ends to form a cyclic peptide. The obtained cyclic peptide strengthens the dengue virus replication inhibition function, and can be used for specific treatment of dengue virus infection."		
"DRAVPa2310"	"CKHGHHRHC"	"9"	"Sequence 2 from Patent US20210040153A1"	"Synthetic peptide"	"DENV"	"Patent Application"	"US20210040153A1"	"2021-02-11"	"CN108395470##WO/2019/137247"	"OLIGOPEPTIDE HAVING DENGUE VIRUS REPLICATION INHIBITION FUNCTION AND APPLICATION THEREOF"		"The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in the present invention is KHGHHRH, i.e. Lys-His-Gly-His-His-Arg-His (SEQ ID NO. 1). The short peptide has a high specificity affinity with NS5 and has the function of efficiently inhibiting dengue virus replication, the anti-viral effect thereof not been limited to DENV-2, but also having a significant inhibitory effect on the replication of type 1, type 3, and type 5 dengue virus. One cysteine is added to the two ends of the short peptide sequence, the short peptide being cyclised by means of the cysteines at the two ends to form a cyclic peptide. The obtained cyclic peptide strengthens the dengue virus replication inhibition function, and can be used for specific treatment of dengue virus infection."		
"DRAVPa2311"	"CHPVFCPRRYKQIGTCGLPGTKC"	"23"	"Sequence 2 from Patent CN118451094A"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"CN118451094A"	"2024-08-06"	"WO/2023/125432##EP4457237"	"Antiviral peptides and methods of use thereof"		"Antiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 2 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury."		
"DRAVPa2312"	"CHPVFCPRRYKQIGTCGLPGTKCCKK"	"26"	"Sequence 3 from Patent CN118451094A"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"CN118451094A"	"2024-08-06"	"WO/2023/125432##EP4457237"	"Antiviral peptides and methods of use thereof"		"Antiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 3 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury."		
"DRAVPa2313"	"GAICHPVFCPRRYKQIGTCGLPGTKCCKKP"	"30"	"Sequence 4 from Patent CN118451094A"	"Synthetic peptide"	"SARS-CoV-2"	"Patent Application"	"CN118451094A"	"2024-08-06"	"WO/2023/125432##EP4457237"	"Antiviral peptides and methods of use thereof"		"Antiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 4 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury."		
"DRAVPa2314"	"QPSVQIQVYQGEREIAAHAAAKLPDLCTEL"	"30"	"Sequence 1 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E7, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2315"	"QPSVQIQVYQGEREIAAHAAATLHEYMLDL"	"30"	"Sequence 2 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E8, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2316"	"QPSVQIQVYQGEREIAAHAAAYMLDLQPET"	"30"	"Sequence 3 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E9, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2317"	"QPSVQIQVYQGEREIAAHAAARAHYNIVTF"	"30"	"Sequence 4 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E10, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2318"	"QPSVQIQVYQGEREIAAHAAACDSTLRLCV"	"30"	"Sequence 5 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E11, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2319"	"QPSVQIQVYQGEREIAAHAAARLCVQSTHV"	"30"	"Sequence 6 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E12, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2320"	"QPSVQIQVYQGEREIAAHAAALIMGTLGIV"	"30"	"Sequence 7 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E13, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2321"	"QPSVQIQVYQGEREIAAHAAATLGIVCPI"	"29"	"Sequence 8 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E14, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2322"	"QPSVQIQVYQGEREIAAHAAAYKLPDLCTELNTSLQDIEITCVYCKTVLEL"	"51"	"Sequence 9 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E15, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2323"	"QPSVQIQVYQGEREIAAHAAASVYGDTLEKLTNTGLYNLLIRCLRCQK"	"48"	"Sequence 10 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E16, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		"3"
"DRAVPa2324"	"QPSVQIQVYQGEREIAAHAAAATLQDIVLHLEPQNEIPVDLL"	"42"	"Sequence 11 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E17, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2325"	"QPSVQIQVYQGEREIAAHAAAGVNHQHLPARRAEPQRHTMLCMCCKCEARI"	"51"	"Sequence 12 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E18, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2326"	"QPSVQIQVYQGEREIAAHAAAVVESSADDLRAFQQLFLSTLSFVCPWCA"	"49"	"Sequence 13 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E19, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2327"	"QPSVQIQVYQGEREIAAHAAAFQQLFLNTL"	"30"	"Sequence 14 from Patent CN108409866A"	"Synthetic peptide"	"HPV"	"Patent Application"	"CN108409866A"	"2018-08-17"	"WO/2019/144607"	"Multi-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases"		"The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E20, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients."		
"DRAVPa2328"	"FLKHIKSFWRGAKAIFRGARQGWREHR"	"27"	"Sequence 1 from CN119326871A"	"Synthetic construct"	"MSRV"	"Patent Application"	"CN119326871A"	"2025-01-21"	"CN 119326871 A"	"Ms-Piscidin抗菌肽在制备大口黑鲈弹状病毒抑制剂或治疗药物中的应用"		"本发明公开了Ms‑Piscidin抗菌肽在制备大口黑鲈弹状病毒抑制剂或治疗药物中的应用，特点是提供Ms‑Piscidin抗菌肽在制备大口黑鲈弹状病毒抑制剂中的应用以及Ms‑Piscidin抗菌肽在制备大口黑鲈弹状病毒感染治疗药物中的应用，Ms‑Piscidin抗菌肽的氨基酸序列为SEQ ID NO.1所示:FLKHIKSFWRGAKAIFRGARQGWREHR，优点是Ms‑Piscidin抗菌肽能够抑制MSRV增殖、提高MSRV感染的大口黑鲈的存活率，可作为防治MSRV感染疾病的潜在药物。"		"Anti-MSRV"
"DRAVPa2329"	"KYGPTPVRDGFK"	"12"	"Sequence 1 from CN 118767104 A"	"Synthetic construct"	"PEDV"	"Patent Application"	"CN 118767104 A"	"2024-10-15"	"CN 118767104 A"	"Application of pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis"		"The invention discloses an application of pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis, and relates to the technical field of antiviral biologica.According to the application, synthesized pea active peptide is utilized, toxicity of peptides with different concentrations to Vero cells is determined by adopting a CCK-8 test, and the application of the pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis is achieved. The inhibition effect of the pea active peptide KYGPTPVRDGFK on the porcine epidemic diarrhea virus in Vero cells is determined through indirect immunofluorescence, virus copy number, immunoblotting and half tissue infection amount, and the inhibition effect of the KYGPTPVRDGFK on Vero cell apoptosis induced by the porcine epidemic diarrhea virus is verified through immunoblotting. Results show that the pea bioactive peptide can significantly inhibit the replication of the porcine epidemic diarrhea virus and significantly reduce the Vero cell apoptosis level induced by the porcine epidemic diarrhea virus, thereby providing a new idea and method for the prevention and treatment of the PEDV."		"Anti-PEDV"
"DRAVPa2330"	"VSIPWTHKV"	"9"	"Sequence 124 from CN118620040A"	"human"	"HBV"	"Patent Application"	"CN118620040A"	"2024-09-10"	"CN 114478711 A## CN 118580321 A3## CN 118580322 A##CN 118620040 A##CN 114478711 B##CN 119039403 A"	"Antigen peptide aiming at hepatitis B virus"		"The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-124. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis."		"Anti-HBV"
"DRAVPa2331"	"FLLAQFTSAI"	"10"	"Sequence 3 from CN118620041A"	"human"	"HBV"	"Patent Application"	"CN118620040A"	"2024-09-10"	"CN 114478711 A## CN 118580321 A,##CN 118580322 A,##CN 118620040 A##CN 114478711 B##CN 119039403 A"	"Antigen peptide aiming at hepatitis B virus"		"The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-125. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis."		"Anti-HBV"
"DRAVPa2332"	"FLPDFFPSI"	"9"	"Sequence 6 from CN118620042A"	"human"	"HBV"	"Patent Application"	"CN118620040A"	"2024-09-10"	"CN 114478711 A##CN 118580321 A## CN 118580322 A## CN 118620040 A## CN 114478711 B##CN 119039403 A"	"Antigen peptide aiming at hepatitis B virus"		"The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-126. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis."		"Anti-HBV"
"DRAVPa2333"	"RVRALYFPA"	"9"	"Sequence 84 from CN118620043A"	"human"	"HBV"	"Patent Application"	"CN118620040A"	"2024-09-10"	"CN 114478711 A##CN 118580321 A##CN 118580322 A## CN 118620040 A##CN 114478711 B##CN 119039403 A"	"Antigen peptide aiming at hepatitis B virus"		"The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-127. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis."		"Anti-HBV"
"DRAVPa2334"	"GWKDFKKTIKKLLRGASRLLKF"	"22"	"Sequence 1 from CN117024530B"	"Synthetic construct"	"Hantaan virus, Chikungunya virus"	"Granted Patent"	"CN117024530B"	"2024-03-19"	"CN 117024530 A## CN 117024530 B"	"抗微生物肽Perceptide-TJ-2及其在制备广谱抗病毒药物中的用途"		"本发明涉及药物制备技术领域，具体公开了新型抗微生物肽Perceptide‑TJ‑2及其在制备广谱抗病毒药物中的用途。本发明提供的新型抗微生物肽Perceptide‑TJ‑2是基于人工智能方法全新设计、构建并合成，具有广谱抗病毒感染活性，高效抑制汉滩病毒、基孔肯雅病毒、1型单纯疱疹病毒和2型登革病毒传染性病原体，有效降低病毒载量，为开发新一代广谱抗病毒药物提供依据和基础，为保障人类健康提供全新的技术手段。"		"Anti-Hantaan virus, Anti-Chikungunya virus"
"DRAVPa2335"	"MGVKVLFALICIAVAEA"	"17"	"Sequence 1 from CN119390792A"	"Synthetic construct"	"Monkeypox virus M1R"	"Granted Patent"	"CN116024265B"	"2025-02-07"	"CN 116024265 A##CN 116024265 B"	"制备猴痘病毒M1r抗原分泌蛋白的方法及其所用核酸分子"		"本发明公开了一种制备猴痘病毒M1R抗原分泌蛋白的方法及其所用核酸分子。本发明涉及生物技术领域，具体涉及一种制备猴痘病毒M1R抗原分泌蛋白的方法及其所用核酸分子。本发明提供的方法包括如下步骤：(A1)将核酸分子导入宿主细胞，得到重组细胞；核酸分子编码融合蛋白，融合蛋白为将多肽(氨基酸序列是SEQ ID No.1)融合于猴痘病毒M1R抗原的N端得到的蛋白质；(A2)培养重组细胞，从培养上清中获得猴痘病毒M1R抗原分泌蛋白。采用荧光素酶信号肽Ga引导猴痘病毒M1R真核细胞分泌表达水平显著优于白蛋白信号肽Al和抗体轻链信号肽Lc，更适用于大规模工业化生产，降低生产成本。"		"Anti-Monkeypox virus M1R"
"DRAVPa2336"	"APAICHDGKAHFPRE"	"15"	"Sequence 1 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2337"	"EGVFVSNGTHWFVTQ"	"15"	"Sequence 2 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2338"	"AGLIAIVMVTIMLCCM"	"16"	"Sequence 3 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2339"	"KFNGLTVLPPLLTDE"	"15"	"Sequence 4 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2340"	"GTHWFVTQRNFYEPQI"	"16"	"Sequence 5 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2341"	"EDLLFNKVTLADAG"	"14"	"Sequence 6 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2342"	"TFEYVSQPFLMDLEG"	"15"	"Sequence 7 from CN119320428A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN119320428A"	"2025-01-17"	"CN 119320428 A"	"新型冠状病毒广谱免疫优势Cd4+t细胞表位肽及其应用"		"本发明涉及生物医学技术领域，公开了新型冠状病毒广谱免疫优势CD4+T细胞表位肽，包括针对新型冠状病毒原始株及其变异株共有的Th表位肽，还包括针对奥秘克戎变异株特有的免疫优势突变Th表位肽；还公开了Th表位肽‑MHC四聚体及应用。本发明获得的表位肽比较符合天然状态下HLA‑II类分子结合肽被提呈的规律，对Th表位的检出率较高，且能够降低四分之一的经济成本；利用本发明的表位肽制备的Th表位肽‑MHC四聚体具有强烈的刺激CD4+T细胞活化的效应；本发明的表位肽和Th表位肽‑MHC四聚体可制作成试剂盒。"		"Anti-COVID-19"
"DRAVPa2343"	"NDDTPVDEALGRVLTPTAVDEALVDLAPDADP"	"32"	"Sequence 1 from CN119285713A"	"Synthetic construct"	"Seneca virus type A"	"Patent Application"	"CN119285713A"	"2025-01-10"	"CN 119285713 A"	"A型塞内卡病毒3a蛋白抗原表位肽、单克隆抗体及其应用"		"本发明属于生物医药技术领域，具体公开了一种A型塞内卡病毒3A蛋白抗原表位肽或其编码核酸，与A型塞内卡病毒3A蛋白抗原表位特异性结合的单克隆抗体，分泌该单克隆抗体的杂交瘤细胞株及其在制备预防和/或治疗A型塞内卡病毒感染的药物、或者检测和/或诊断A型塞内卡病毒感染的试剂中的应用。本发明提供的单克隆抗体由保藏编号为CCTCC NO：C202466的杂交瘤细胞株SVA‑3A‑5A7分泌产生，该单抗能够特异性结合A型塞内卡病毒3A蛋白（抗原表位位于3A蛋白胞外结构域第5‑36位氨基酸），可用于制备预防和/或治疗A型塞内卡病毒感染的药物，或者检测和/或诊断A型塞内卡病毒感染的试剂。"		"Anti-Seneca virus type A"
"DRAVPa2344"	"SPTVWLSVI"	"9"	"Sequence 1 from CN119241665A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN 119241665 A"	"2025-01-03"	"CN 119241665 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SPTVWLSVI；LPLLPIFFCL；CPTVQASKL；LPSDFFPSI；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2345"	"LPLLPIFFCL"	"10"	"Sequence 2 from CN119241665A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN 119241665 A"	"2025-01-03"	"CN 119241665 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SPTVWLSVI；LPLLPIFFCL；CPTVQASKL；LPSDFFPSI；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2346"	"CPTVQASKL"	"9"	"Sequence 3 from CN119241665A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN 119241665 A"	"2025-01-03"	"CN 119241665 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SPTVWLSVI；LPLLPIFFCL；CPTVQASKL；LPSDFFPSI；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2347"	"LPSDFFPSI"	"9"	"Sequence 4 from CN119241665A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN 119241665 A"	"2025-01-03"	"CN 119241665 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SPTVWLSVI；LPLLPIFFCL；CPTVQASKL；LPSDFFPSI；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2348"	"GYSITSDFA"	"9"	"Sequence 31 from CN119119255A"	"Synthetic construct"	"PEDV"	"Patent Application"	"CN119119255A"	"2024-12-13"	"CN 119119255 A"	"Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof"		"The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment."		"Anti-PEDV"
"DRAVPa2349"	"ISYSGTT"	"7"	"Sequence 32 from CN119119255A"	"Synthetic construct"	"PEDV"	"Patent Application"	"CN119119255A"	"2024-12-13"	"CN 119119255 A"	"Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof"		"The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment."		"Anti-PEDV"
"DRAVPa2350"	"QSLLHSDGKTY"	"11"	"Sequence 37 from CN119119255A"	"Synthetic construct"	"PEDV"	"Patent Application"	"CN119119255A"	"2024-12-13"	"CN 119119255 A"	"Pig acute diarrhea syndrome coronavirus spike protein antigen epitope peptide and monoclonal antibody and application thereof"		"The invention belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus as well as a monoclonal antibody and application of the spike protein antigen epitope peptide. The invention provides an antibody or an antigen binding fragment thereof. A nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is as shown in SEQ ID NO. 2; the nucleotide sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. The amino acid sequence of the minimum binding epitope is as shown in SEQ ID NO.22. The antigen epitope is highly conserved in a plurality of different subtypes of SADS-CoV. The antibody can be applied to fundamental research on an SADS-CoV invasive molecular mechanism and provides a good scientific research material for application research on SADS-CoV detection and treatment."		"Anti-PEDV"
"DRAVPa2351"	"APFARLLNL"	"9"	"Sequence 1 from CN119080879A"	"Synthetic construct"	"EBOV"	"Patent Application"	"CN119080879A"	"2024-12-06"	"CN 119080879 A"	"Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof"		"The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future."		"Anti-EBOV"
"DRAVPa2352"	"SAPDDLVLF"	"9"	"Sequence 2 from CN119080879A"	"Synthetic construct"	"EBOV"	"Patent Application"	"CN119080879A"	"2024-12-06"	"CN 119080879 A"	"Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof"		"The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future."		"Anti-EBOV"
"DRAVPa2353"	"FEEMYRHIL"	"9"	"Sequence 3 from CN119080879A"	"Synthetic construct"	"EBOV"	"Patent Application"	"CN119080879A"	"2024-12-06"	"CN 119080879 A"	"Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof"		"The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future."		"Anti-EBOV"
"DRAVPa2354"	"TEANAGQFL"	"9"	"Sequence 4 from CN119080879A"	"Synthetic construct"	"EBOV"	"Patent Application"	"CN119080879A"	"2024-12-06"	"CN 119080879 A"	"Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof"		"The invention belongs to the technical field of pathogenic microorganism immunology, and particularly relates to a generic MHC I dominant epitope peptide of ebola virus nucleoprotein, and a coding gene and application thereof. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO. 1-4. According to the invention, the prediction, screening and identification of generic MHC class I antigen specific dominant epitopes are carried out on Ebola virus nucleoprotein (EBOV NP), 12 candidate epitopes are obtained and verified, and 4 representatives are selected for experimental verification. In a word, the generic MHC-I immunoreactivity of the EBOV NP is comprehensively evaluated, the immunology characteristics of the EBOV NP are beneficially understood, and guidance is provided for development of EBOV epitope vaccines in the future."		"Anti-EBOV"
"DRAVPa2355"	"ESLVNEYDDN"	"10"	"Sequence 1 from CN119020340A"	"human"	"RV"	"Patent Application"	"CN119020340A"	"2024-11-26"	"CN 119020340 A"	"Polypeptide and application thereof in preparation of anti-rabies virus medicine"		"The invention discloses a polypeptide and application thereof in preparation of anti-rabies virus drugs, and belongs to the technical field of biological medicines. The amino acid sequence of the polypeptide is as shown in SEQ ID NO.1, the polypeptide is derived from 190-199 amino acids of human PDIA3 protein, the polypeptide can be fused with a cell penetrating peptide to form a polypeptide with an amino acid sequence as shown in SEQ ID NO.2, and the problems that the polypeptide is easy to degrade and difficult to enter cells are solved. The polypeptide can be combined with surface glycoprotein of the rabies virus to resist infection of the rabies virus, and can be used for preparing anti-rabies virus drugs. The polypeptide disclosed by the invention has the advantages of simple and feasible preparation method, good biocompatibility, small side effect, safety, high efficiency and the like, and can be produced on a large scale in a short time. The invention lays a foundation for designing safe and effective polypeptide for treating rabies, and has good development and application prospects."		"Anti-RV"
"DRAVPa2356"	"YGRKKRRQRRRESLVNEYDDN"	"21"	"Sequence 2 from CN119020340A"	"human"	"RV"	"Patent Application"	"CN119020340A"	"2024-11-26"	"CN 119020340 A"	"Polypeptide and application thereof in preparation of anti-rabies virus medicine"		"The invention discloses a polypeptide and application thereof in preparation of anti-rabies virus drugs, and belongs to the technical field of biological medicines. The amino acid sequence of the polypeptide is as shown in SEQ ID NO.1, the polypeptide is derived from 190-199 amino acids of human PDIA3 protein, the polypeptide can be fused with a cell penetrating peptide to form a polypeptide with an amino acid sequence as shown in SEQ ID NO.2, and the problems that the polypeptide is easy to degrade and difficult to enter cells are solved. The polypeptide can be combined with surface glycoprotein of the rabies virus to resist infection of the rabies virus, and can be used for preparing anti-rabies virus drugs. The polypeptide disclosed by the invention has the advantages of simple and feasible preparation method, good biocompatibility, small side effect, safety, high efficiency and the like, and can be produced on a large scale in a short time. The invention lays a foundation for designing safe and effective polypeptide for treating rabies, and has good development and application prospects."		"Anti-RV"
"DRAVPa2357"	"LVIARQKVR"	"9"	"Sequence 2 from CN118994306A"	"Synthetic construct"	"Hantaan virus, Chikungunya virus"	"Patent Application"	"CN118994306A"	"2024-11-22"	"CN 118994306 A"	"Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine"		"The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptide of hantavirus nucleocapsid protein and application of the dominant epitope peptide in preparation of an anti-hantavirus vaccine. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO.1-9, the common amino acid fragment of the dominant epitope peptide is an MHC-II type antigenic nonapeptide, and the nonapeptide sequence is shown as SEQ ID NO.10-12. The invention further discloses a preparation method of the MHC-II type antigenic nonapeptide. According to the present invention, the binding capacity and the immune response effect of the dominant epitope peptides and MHC II molecules are verified through the ELISpot test, and the immunological characteristics of the dominant epitope peptides are determined by the nonapeptide core, such that the immunobiology of the HTNV NP can be easily understood, and the epitope vaccine design for the HTNV NP can be perfected in the future."		"Anti-Hantaan virus"
"DRAVPa2358"	"YVSLPNAQS"	"9"	"Sequence 2 from CN118994306A"	"Synthetic construct"	"Hantaan virus, Chikungunya virus"	"Patent Application"	"CN118994306A"	"2024-11-22"	"CN 118994306 A"	"Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine"		"The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptide of hantavirus nucleocapsid protein and application of the dominant epitope peptide in preparation of an anti-hantavirus vaccine. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO.1-9, the common amino acid fragment of the dominant epitope peptide is an MHC-II type antigenic nonapeptide, and the nonapeptide sequence is shown as SEQ ID NO.10-12. The invention further discloses a preparation method of the MHC-II type antigenic nonapeptide. According to the present invention, the binding capacity and the immune response effect of the dominant epitope peptides and MHC II molecules are verified through the ELISpot test, and the immunological characteristics of the dominant epitope peptides are determined by the nonapeptide core, such that the immunobiology of the HTNV NP can be easily understood, and the epitope vaccine design for the HTNV NP can be perfected in the future."		"Anti-Hantaan virus"
"DRAVPa2359"	"ILQDMRNTI"	"9"	"Sequence 2 from CN118994306A"	"Synthetic construct"	"Hantaan virus, Chikungunya virus"	"Patent Application"	"CN118994306A"	"2024-11-22"	"CN 118994306 A"	"Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine"		"The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptide of hantavirus nucleocapsid protein and application of the dominant epitope peptide in preparation of an anti-hantavirus vaccine. The amino acid sequence of the dominant epitope peptide is one of SEQ ID NO.1-9, the common amino acid fragment of the dominant epitope peptide is an MHC-II type antigenic nonapeptide, and the nonapeptide sequence is shown as SEQ ID NO.10-12. The invention further discloses a preparation method of the MHC-II type antigenic nonapeptide. According to the present invention, the binding capacity and the immune response effect of the dominant epitope peptides and MHC II molecules are verified through the ELISpot test, and the immunological characteristics of the dominant epitope peptides are determined by the nonapeptide core, such that the immunobiology of the HTNV NP can be easily understood, and the epitope vaccine design for the HTNV NP can be perfected in the future."		"Anti-Hantaan virus"
"DRAVPa2360"	"ADSFVIRGDEVRQIAPGQ"	"18"	"Sequence 14 from CN118852366A"	"SARS-CoV-2"	"SARS-CoV-2"	"Patent Application"	"CN118852366A"	"2024-10-29"	"CN 118852366 A"	"Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof"		"The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines."		"Anti-SARS-CoV-2"
"DRAVPa2361"	"YNYKLPDDFTGCVIAWNS"	"18"	"Sequence 18 from CN118852366A"	"SARS-CoV-2"	"SARS-CoV-2"	"Patent Application"	"CN118852366A"	"2024-10-29"	"CN 118852366 A"	"Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof"		"The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines."		"Anti-SARS-CoV-2"
"DRAVPa2362"	"NCYFPLQSYGFQPTNGVG"	"18"	"Sequence 29 from CN118852366A"	"SARS-CoV-2"	"SARS-CoV-2"	"Patent Application"	"CN118852366A"	"2024-10-29"	"CN 118852366 A"	"Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof"		"The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines."		"Anti-SARS-CoV-2"
"DRAVPa2363"	"YQPYRVVVLSFELLHAPA"	"18"	"Sequence 32 from CN118852366A"	"SARS-CoV-2"	"SARS-CoV-2"	"Patent Application"	"CN118852366A"	"2024-10-29"	"CN 118852366 A"	"Novel antigen epitope peptide of coronavirus specific CD4 + T cell and application thereof"		"The invention provides an antigen epitope peptide of a novel coronavirus specific CD4 + T cell and application of the antigen epitope peptide. The antigen epitope peptide comprises antigen epitope peptides of which the amino acid sequences are SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 29 and/or SEQ ID NO: 32. According to the antigen epitope peptide provided by the invention, in an AddaS03 adjuvant or T cell immunodominance epitope under the assistance of AddaS03, the amino acid sequences of RBD103-120, RBD187-204, RBD79-96 and RBD169-186 are highly consistent when different virus strains are selected, so that the antigen epitope peptide has relatively strong conservative property. The epitope peptide provided by the invention can be used for vaccine effect evaluation and novel coronavirus infection diagnostic reagent development, and has vaccine application value and potential for preparing epitope vaccines."		"Anti-SARS-CoV-2"
"DRAVPa2364"	"IRLQAEA"	"7"	"Sequence 1 from CN118725023A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN118725023A"	"2024-10-01"	"CN 118725023 A"	"Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus"		"The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN"		"Anti-COVID-19"
"DRAVPa2365"	"LMLQAEP"	"7"	"Sequence 2 from CN118725023A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN118725023A"	"2024-10-01"	"CN 118725023 A"	"Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus"		"The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN"		"Anti-COVID-19"
"DRAVPa2366"	"GRLQSLQ"	"7"	"Sequence 3 from CN118725023A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN118725023A"	"2024-10-01"	"CN 118725023 A"	"Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus"		"The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN"		"Anti-COVID-19"
"DRAVPa2367"	"VQRQAFN"	"7"	"Sequence 4 from CN118725023A"	"Synthetic construct"	"COVID-19"	"Patent Application"	"CN118725023A"	"2024-10-01"	"CN 118725023 A"	"Design of antiviral peptide and application of antiviral peptide in inhibition of activity of main protease of new coronavirus"		"The four antiviral peptides with the activity of inhibiting the main protease of the new coronavirus have the following amino acid sequences. Experiments prove that the S202301, the S202303, the S202305 and the S202307 have very good inhibitory activity on the main protease of the new coronavirus. The invention discloses amino acid sequences of four antiviral peptides and main protease inhibition activity. And S202301: IRLQAEAS202301: LMLQAEPS 202305: GRLQSLQS202307: VQRQAFN, and S202301: LMLQAEPS 202305: GRLQSLQS202307: GQRQAFN"		"Anti-COVID-19"
"DRAVPa2368"	"KKWRKVIKKVVARYK"	"15"	"Sequence 2 from Patent CN118615425A"	"Synthetic construct"	"IAV"	"Patent Application"	"CN118615425A"	"2024-09-10"	"CN 118615425 A"	"Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus"		"The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A."		"Anti-IAV"
"DRAVPa2369"	"FWKKVIKRVRKAVKK"	"15"	"Sequence 3 from Patent CN118615425A"	"Synthetic construct"	"IAV"	"Patent Application"	"CN118615425A"	"2024-09-10"	"CN 118615425 A"	"Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus"		"The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A."		"Anti-IAV"
"DRAVPa2370"	"VVKKVRKLYKKIYKR"	"15"	"Sequence 4 from Patent CN118615425A"	"Synthetic construct"	"IAV"	"Patent Application"	"CN118615425A"	"2024-09-10"	"CN 118615425 A"	"Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus"		"The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A."		"Anti-IAV"
"DRAVPa2371"	"VCVKKVRKLYKKIYKCR"	"17"	"Sequence 5 from Patent CN118615425A"	"Synthetic construct"	"IAV"	"Patent Application"	"CN118615425A"	"2024-09-10"	"CN 118615425 A"	"Application of antiviral polypeptide and/or original peptide thereof in preparation of product for preventing and treating virus"		"The invention relates to the technical field of biological medicine, in particular to application of antiviral polypeptide and/or original peptide thereof in preparation of products for preventing and treating viruses. The invention provides an antiviral polypeptide. The amino acid sequence of the antiviral polypeptide is one or more of SEQ ID NO.2-5. The antiviral polypeptide provided by the invention is obtained by replacing or increasing specific amino acids and simultaneously retaining an alpha-spiral functional region for playing a role of the Cathelicidin polypeptide (SEQ ID NO.1) through modification, can enhance the expression of host I-type interferon, plays a relatively strong antiviral function at in-vivo and in-vitro levels, and has a half inhibition concentration to H1N1 virus of 2.47-8.14 mu M. The invention also provides a preparation method of the antiviral polypeptide. The antiviral polypeptide provided by the invention has low toxicity to cells, and can be applied to preparation of drugs or reagents for preventing and treating influenza A."		"Anti-IAV"
"DRAVPa2372"	"AKVGDEAYYRGSYYYTRPYYYGMKY"	"25"	"Sequence 1 from Patent CN118530344A"	"Synthetic construct"	"AAV"	"Patent Application"	"CN118530344A"	"2024-08-23"	"CN 118530344 A##CN 118530344 B"	"Small peptide sequence for combining various serotype adenoviruses and application of small peptide sequence"		"The invention discloses a small peptide sequence for binding various serotype adenoviruses and application of the small peptide sequence, and belongs to the technical field of biological medicines. The small peptide sequence can be used for manufacturing AAV affinity chromatography medium ligands; an adenovirus for binding a plurality of different serotypes; the alkali resistance is relatively high; the affinity is high; the method can be used for purifying AAV virus particles or AAV virus vectors."		"Anti-AAV"
"DRAVPa2373"	"AAGPTLMSGSYNSARDYDY"	"19"	"Sequence 1 from Patent CN118530345A"	"Synthetic construct"	"AAV"	"Patent Application"	"CN118530345A"	"2024-08-23"	"CN 118530345 A##CN 118530345 B"	"Two small peptide sequences for binding multiple serotype adenoviruses and application thereof"		"The invention discloses two small peptide sequences for combining various serotype adenoviruses and application of the two small peptide sequences, and belongs to the technical field of biological medicines. The two small peptide sequences can be used for manufacturing AAV affinity chromatography medium ligands; an adenovirus for binding a plurality of different serotypes; the alkali resistance is relatively high; the affinity is high; the method can be used for purifying AAV virus particles or AAV virus vectors."		"Anti-AAV"
"DRAVPa2374"	"ADAAGISDYGGSYYVCPHPYGMEY"	"24"	"Sequence 2 from Patent CN118530345A"	"Synthetic construct"	"AAV"	"Patent Application"	"CN118530345A"	"2024-08-23"	"CN 118530345 A##CN 118530345 B"	"Two small peptide sequences for binding multiple serotype adenoviruses and application thereof"		"The invention discloses two small peptide sequences for combining various serotype adenoviruses and application of the two small peptide sequences, and belongs to the technical field of biological medicines. The two small peptide sequences can be used for manufacturing AAV affinity chromatography medium ligands; an adenovirus for binding a plurality of different serotypes; the alkali resistance is relatively high; the affinity is high; the method can be used for purifying AAV virus particles or AAV virus vectors."		"Anti-AAV"
"DRAVPa2375"	"SYVNVNMGL"	"9"	"Sequence 1 from Patent CN119613505A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN119613505A"	"2025-03-14"	"CN 119613505 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SYVNVNMGL；LATWVGSNL；RRMETTVNA；MAARVCCQL；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2376"	"LATWVGSNL"	"9"	"Sequence 2 from Patent CN119613505A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN119613505A"	"2025-03-14"	"CN 119613505 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SYVNVNMGL；LATWVGSNL；RRMETTVNA；MAARVCCQL；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2377"	"RRMETTVNA"	"9"	"Sequence 3 from Patent CN119613505A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN119613505A"	"2025-03-14"	"CN 119613505 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SYVNVNMGL；LATWVGSNL；RRMETTVNA；MAARVCCQL；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2378"	"MAARVCCQL"	"9"	"Sequence 4 from Patent CN119613505A"	"Synthetic construct"	"HBV"	"Patent Application"	"CN119613505A"	"2025-03-14"	"CN 119613505 A"	"乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用"		"本发明公开了乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及应用，属于医学免疫学和感染病学领域。乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽，所述表位肽的氨基酸序列包括以下任意一种或多种：SYVNVNMGL；LATWVGSNL；RRMETTVNA；MAARVCCQL；上述氨基酸序列单个氨基酸的去除或者更换后的氨基酸序列。本申请的表位肽可以特异性地与细胞毒性胸腺依赖性淋巴细胞结合，刺激后者活化、增殖和分化，从而发挥抗乙型肝炎病毒的免疫效应作用；这些抗原肽可以用来制备乙型肝炎病毒感染的治疗性和预防性疫苗，也可以用来制备检测乙型肝炎病毒特异性细胞毒型胸腺依赖性淋巴细胞的检测试剂，在乙型肝炎的预防、治疗和诊断中有着潜在的应用价值。"		"Anti-HBV"
"DRAVPa2379"	"RRPREQIIIGSLWVF"	"15"	"Sequence 1 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2380"	"IVWHDSLYSTHVQYV"	"15"	"Sequence 2 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2381"	"NARILQRWFPELAHL"	"15"	"Sequence 3 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2382"	"SIENYLKKLGYVLLW"	"15"	"Sequence 4 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2383"	"VIWHPDRWTSVVLQI"	"15"	"Sequence 5 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2384"	"SVVFSADGRHYYWDS"	"15"	"Sequence 6 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2385"	"LVFHDNVYTVTVVHV"	"15"	"Sequence 7 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2386"	"IVLHDGLRSATVLWI"	"15"	"Sequence 8 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2387"	"RVPRKLVIIGSVWNF"	"15"	"Sequence 9 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2388"	"LIWYQSYYQTEVVWF"	"15"	"Sequence 10 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2389"	"IILYRTYFQPFRWEF"	"15"	"Sequence 11 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2390"	"CFFWYENYYTAITVT"	"15"	"Sequence 12 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2391"	"TSQICQELDALGDWI"	"15"	"Sequence 13 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2392"	"RAPREQIIIGSLWVF"	"15"	"Sequence 17 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2393"	"RRAREQIIIGSLWVF"	"15"	"Sequence 18 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2394"	"RRPAEQIIIGSLWVF"	"15"	"Sequence 19 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2395"	"RRPRAQIIIGSLWVF"	"15"	"Sequence 20 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2396"	"RRPREAIIIGSLWVF"	"15"	"Sequence 21 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2397"	"RRPREQIAIGSLWVF"	"15"	"Sequence 23 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2398"	"RRPREQIIAGSLWVF"	"15"	"Sequence 24 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2399"	"RRPREQIIIASLWVF"	"15"	"Sequence 25 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2400"	"RRPREQIIIGALWVF"	"15"	"Sequence 26 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2401"	"RRPREQIIIGSLAVF"	"15"	"Sequence 28 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2402"	"RRPREQIIIGSLWAF"	"15"	"Sequence 29 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2403"	"RRPREQIIIGSLWVA"	"15"	"Sequence 30 from Patent CN119630683A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN119630683A"	"2025-03-14"	"WO 2024/013390 A1##CN 119630683 A"	"抗病毒环状化合物"		"本发明涉及新型环状肽。这些肽结合病毒蛋白，特别是SARS‑CoV‑2刺突蛋白上的保守位点，并且因此这些肽可以用于中和SARS‑CoV‑2变体。因此，本发明还涉及这些肽的医学用途。"		"Anti-SARS-CoV-2"
"DRAVPa2404"	"GFSLTSYV"	"8"	"Sequence 1 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2405"	"IWAGGST"	"7"	"Sequence 2 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2406"	"ASPYYYGSSAWFAY"	"14"	"Sequence 3 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2407"	"ASVSY"	"5"	"Sequence 4 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2408"	"QQWSSNPPIT"	"10"	"Sequence 5 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2409"	"QVQLKESGPGLVAPSQSLSITCTVS"	"25"	"Sequence 6 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2410"	"VHWVRQPPGKGLEWLGE"	"17"	"Sequence 7 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2411"	"NYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYC"	"38"	"Sequence 8 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2412"	"WGQGTLVTVSA"	"11"	"Sequence 9 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2413"	"QIVLTQSPAIMSASPGEKVTMTCSPS"	"26"	"Sequence 10 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2414"	"MHWYQQKSGTSPKRWIF"	"17"	"Sequence 11 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2415"	"KLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYC"	"36"	"Sequence 12 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2416"	"FGAGTKLELK"	"10"	"Sequence 13 from Patent CN118725094B"	"Synthetic construct"	"FCV"	"Granted Patent"	"CN118725094B"	"2025-03-11"	"CN 118725094 A##CN 118725094 B"	"猫杯状病毒Vp1蛋白的单克隆抗体及其抗原表位肽和应用"		"本发明公开了一种猫杯状病毒VP1蛋白的单克隆抗体，通过使用SH14株FCV全病毒作为免疫原，腹腔注射法免疫BALB/c小鼠，制备了针对VP1蛋白的mAb。通过ELISA筛选，成功获得特异性单克隆抗体3A3C1株，能特异性地识别并结合FCV SH14株、F9株和GZ22株。本发明还公开了3A3C1株mAb的线性抗原表位，通过截短表达VP1蛋白并进行详细的Western blot分析，最终确定3A3C1株mAb的线性抗原表位位于VP1蛋白的426PSRLTPAGDYAITSG440区域。除此之外，本发明还公开了编码所述3A3C1株可变区mAb的核酸，以及该单克隆抗体在制备FCV检测试剂盒中的应用。本发明制备的3A3C1株mAb不仅是理解FCV免疫学特性的重要工具，也对发展FCV诊断方法和疫苗策略具有潜在应用价值。"		"Anti-FCV"
"DRAVPa2417"	"MALQEACEAYLVGLFEDTNLCAIHAKRVTIMPKDIQ"	"36"	"Sequence 1 from Patent CN119564829A"	"Synthetic construct"	"TiLV"	"Patent Application"	"CN119564829A"	"2025-03-07"	"CN 119564829 A"	"抗菌肽在制备预防或治疗罗非鱼湖病毒病的药物中的应用"		"本申请公开了一种抗菌肽在制备预防或治疗罗非鱼湖病毒病的药物中的应用，本申请的抗菌肽为Seq ID No.1所示序列的多肽。本申请研究发现，Seq IDNo.1所示序列的多肽能够有效的抑制罗非鱼湖病毒的在罗非鱼体内的生长，从而起到预防和治疗罗非鱼湖病毒病的作用，为罗非鱼湖病毒病的预防和治疗提供了一种新的方案和途径。"		"Anti-TiLV"
"DRAVPa2418"	"AHIVMVDAYKPTK"	"13"	"Sequence 19 from Patent CN119552227A"	"Synthetic construct"	"RABV"	"Patent Application"	"CN119552227A"	"2025-03-04"	"CN 119552227 A"	"狂犬病病毒G蛋白突变体及其制备方法和应用"		"本发明涉及生物医药技术领域，特别涉及狂犬病病毒G蛋白突变体及其制备方法和应用。本发明的狂犬病病毒G蛋白突变体为对G蛋白的胞外域进行点突变获得，所述的突变体实现了G蛋白胞外域的可溶性表达，且能诱导产生高滴度的中和抗体，与商品化人用狂犬疫苗、犬用狂犬疫苗相比，具有更优异的细胞免疫和抗体免疫反应，有望减少接种的次数，缩短免疫程序和减少免疫剂量。"		"Anti-RABV"
"DRAVPa2419"	"DSATHIKFSKRDEDGKELAGATMELRDSSGKTISTWISDGQVKDFYLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHI"	"92"	"Sequence 20 from Patent CN119552227A"	"Synthetic construct"	"RABV"	"Patent Application"	"CN119552227A"	"2025-03-04"	"CN 119552227 A"	"狂犬病病毒G蛋白突变体及其制备方法和应用"		"本发明涉及生物医药技术领域，特别涉及狂犬病病毒G蛋白突变体及其制备方法和应用。本发明的狂犬病病毒G蛋白突变体为对G蛋白的胞外域进行点突变获得，所述的突变体实现了G蛋白胞外域的可溶性表达，且能诱导产生高滴度的中和抗体，与商品化人用狂犬疫苗、犬用狂犬疫苗相比，具有更优异的细胞免疫和抗体免疫反应，有望减少接种的次数，缩短免疫程序和减少免疫剂量。"		"Anti-RABV"
"DRAVPa2420"	"AAIEEEDIQFINP"	"13"	"Sequence 1 from Patent CN118240031A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN118240031A"	"2024-06-25"	"CN 118240031 A"	"African swine fever virus p54 protein antigen epitope peptide and monoclonal antibody and application thereof"		"The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein. The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein."		"Anti-ASFV"
"DRAVPa2421"	"MATGGPAAAPAAASAPAHPAE"	"21"	"Sequence 2 from Patent CN118240031A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN118240031A"	"2024-06-25"	"CN 118240031 A"	"African swine fever virus p54 protein antigen epitope peptide and monoclonal antibody and application thereof"		"The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein. The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein."		"Anti-ASFV"
"DRAVPa2422"	"MSAIENLRQRNTY"	"13"	"Sequence 3 from Patent CN118240031A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN118240031A"	"2024-06-25"	"CN 118240031 A"	"African swine fever virus p54 protein antigen epitope peptide and monoclonal antibody and application thereof"		"The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein. The invention discloses an antigen epitope peptide of an African swine fever virus p54 protein, the antigen epitope peptide is a peptide fragment 60-72, a peptide fragment 128-148 or/and a peptide fragment 163-175 of the African swine fever virus p54 protein, and the amino acid sequence of the antigen epitope peptide is as follows: 60 AAIEEEDIQFINP72, 128 MATGGPAAAPAAASAPAHPAE148 or/and 163 MSAIENLRQRNTY175. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p54 protein."		"Anti-ASFV"
"DRAVPa2423"	"KTFPPTEPK"	"9"	"Sequence 1 from Patent CN116375822B"	"SARS-CoV-2"	"SARS-CoV-2"	"Granted Patent"	"CN116375822B"	"2024-06-25"	"CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B"	"新冠病毒特异性Cd8+t细胞表位肽及其应用"		"本发明属于免疫学技术领域，具体公开了新冠病毒特异性CD8+T细胞表位肽，氨基酸序列为SEQ ID NO:18。本发明还公开了上述新冠病毒特异性CD8+T细胞表位肽的应用。本发明所提供的新冠病毒特异性CD8+T细胞表位肽能够产生强烈的细胞免疫应答，分泌高水平IFN‑γ，对于新型冠状病毒感染的预防、临床治疗和疫苗的研发均具有重要的科学意义和应用前景。"		"Anti-SARS-CoV-2"
"DRAVPa2424"	"NYNYLYRLF"	"9"	"Sequence 9 from Patent CN116375822B"	"SARS-CoV-2"	"SARS-CoV-2"	"Granted Patent"	"CN116375822B"	"2024-06-25"	"CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B"	"新冠病毒特异性Cd8+t细胞表位肽及其应用"		"本发明属于免疫学技术领域，具体公开了新冠病毒特异性CD8+T细胞表位肽，氨基酸序列为SEQ ID NO:18。本发明还公开了上述新冠病毒特异性CD8+T细胞表位肽的应用。本发明所提供的新冠病毒特异性CD8+T细胞表位肽能够产生强烈的细胞免疫应答，分泌高水平IFN‑γ，对于新型冠状病毒感染的预防、临床治疗和疫苗的研发均具有重要的科学意义和应用前景。"		"Anti-SARS-CoV-2"
"DRAVPa2425"	"NATRFASVYAWNRKR"	"15"	"Sequence 16 from Patent CN116375822B"	"SARS-CoV-2"	"SARS-CoV-2"	"Granted Patent"	"CN116375822B"	"2024-06-25"	"CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B"	"新冠病毒特异性Cd8+t细胞表位肽及其应用"		"本发明属于免疫学技术领域，具体公开了新冠病毒特异性CD8+T细胞表位肽，氨基酸序列为SEQ ID NO:18。本发明还公开了上述新冠病毒特异性CD8+T细胞表位肽的应用。本发明所提供的新冠病毒特异性CD8+T细胞表位肽能够产生强烈的细胞免疫应答，分泌高水平IFN‑γ，对于新型冠状病毒感染的预防、临床治疗和疫苗的研发均具有重要的科学意义和应用前景。"		"Anti-SARS-CoV-2"
"DRAVPa2426"	"FASVYAWNRKRISNC"	"15"	"Sequence 17 from Patent CN116375822B"	"SARS-CoV-2"	"SARS-CoV-2"	"Granted Patent"	"CN116375822B"	"2024-06-25"	"CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B"	"新冠病毒特异性Cd8+t细胞表位肽及其应用"		"本发明属于免疫学技术领域，具体公开了新冠病毒特异性CD8+T细胞表位肽，氨基酸序列为SEQ ID NO:18。本发明还公开了上述新冠病毒特异性CD8+T细胞表位肽的应用。本发明所提供的新冠病毒特异性CD8+T细胞表位肽能够产生强烈的细胞免疫应答，分泌高水平IFN‑γ，对于新型冠状病毒感染的预防、临床治疗和疫苗的研发均具有重要的科学意义和应用前景。"		"Anti-SARS-CoV-2"
"DRAVPa2427"	"RKRISNCVADYSVLY"	"15"	"Sequence 18 from Patent CN116375822B"	"SARS-CoV-2"	"SARS-CoV-2"	"Granted Patent"	"CN116375822B"	"2024-06-25"	"CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B"	"新冠病毒特异性Cd8+t细胞表位肽及其应用"		"本发明属于免疫学技术领域，具体公开了新冠病毒特异性CD8+T细胞表位肽，氨基酸序列为SEQ ID NO:18。本发明还公开了上述新冠病毒特异性CD8+T细胞表位肽的应用。本发明所提供的新冠病毒特异性CD8+T细胞表位肽能够产生强烈的细胞免疫应答，分泌高水平IFN‑γ，对于新型冠状病毒感染的预防、临床治疗和疫苗的研发均具有重要的科学意义和应用前景。"		"Anti-SARS-CoV-2"
"DRAVPa2428"	"SNCVADYSVLYNSAS"	"15"	"Sequence 19 from Patent CN116375822B"	"SARS-CoV-2"	"SARS-CoV-2"	"Granted Patent"	"CN116375822B"	"2024-06-25"	"CN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 B"	"新冠病毒特异性Cd8+t细胞表位肽及其应用"		"本发明属于免疫学技术领域，具体公开了新冠病毒特异性CD8+T细胞表位肽，氨基酸序列为SEQ ID NO:18。本发明还公开了上述新冠病毒特异性CD8+T细胞表位肽的应用。本发明所提供的新冠病毒特异性CD8+T细胞表位肽能够产生强烈的细胞免疫应答，分泌高水平IFN‑γ，对于新型冠状病毒感染的预防、临床治疗和疫苗的研发均具有重要的科学意义和应用前景。"		"Anti-SARS-CoV-2"
"DRAVPa2429"	"FHDMVGHHILGACH"	"14"	"Sequence 1 from Patent CN118221784A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN118221784A"	"2024-06-21"	"CN 118221784 A"	"African swine fever virus p72 protein antigen epitope peptide as well as monoclonal antibody and application thereof"		"The invention discloses an antigen epitope peptide of an African swine fever virus p72 protein, which is a peptide fragment 102 to 114 or/and a peptide fragment 239 to 248 of the African swine fever virus p72 protein, and the amino acid sequence of the antigen epitope peptide is 102FHDMVGHHILGACH114 or/and 239GPLLCNIHDL248. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p72 protein."		"Anti-ASFV"
"DRAVPa2430"	"GPLLCNIHDL"	"10"	"Sequence 2 from Patent CN118221784A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN118221784A"	"2024-06-21"	"CN 118221784 A"	"African swine fever virus p72 protein antigen epitope peptide as well as monoclonal antibody and application thereof"		"The invention discloses an antigen epitope peptide of an African swine fever virus p72 protein, which is a peptide fragment 102 to 114 or/and a peptide fragment 239 to 248 of the African swine fever virus p72 protein, and the amino acid sequence of the antigen epitope peptide is 102FHDMVGHHILGACH114 or/and 239GPLLCNIHDL248. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p72 protein."		"Anti-ASFV"
"DRAVPa2431"	"MSILEKITSSPSECAEHLTNKDSCL"	"25"	"Sequence 1 from Patent CN118184749A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN118184749A"	"2024-06-14"	"CN 118184749 A"	"African swine fever virus pS273R protein antigen epitope peptide as well as monoclonal antibody and application thereof"		"The invention discloses an antigen epitope peptide of an African swine fever virus pS273R protein and a monoclonal antibody aiming at the antigen epitope, the antigen epitope peptide is 1-25 peptide fragments of the African swine fever virus pS273R protein, and the amino acid sequence of the antigen epitope peptide is 1MSILEKITSSPSECAEHLTNKDSCL25. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for researching the biological function of the African swine fever virus pS273R protein."		"Anti-ASFV"
"DRAVPa2432"	"DAEFRHDSGYEVHHQK"	"16"	"Sequence 1 from Patent CN118161592A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN118161592A"	"2024-06-11"	"CN 118161592 A"	"Glycopeptide compound for inhibiting SARS-CoV-2 virus infection and application thereof"		"The invention relates to the field of biological medicine, in particular to a glycopeptide compound for inhibiting SARS-CoV-2 virus infection. The glycopeptide compound disclosed by the invention comprises polypeptide and polysaccharide, wherein the polypeptide comprises a polypeptide P1 or a polypeptide P2, and the amino acid sequence of the polypeptide P1 is as shown in SEQ ID NO.1; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.1 through amino acid substitution, deletion or increase; the amino acid sequence of the polypeptide P2 is as shown in SEQ ID NO. 2; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.2 through amino acid substitution, deletion or increase; the structural fragment of the polysaccharide comprises any one or more than two of xFuc-N1Gal-N1 (xFuc-N1) GlcNAc structural units, x is equal to 0 or 1, and N1 is equal to 1, 2, 3, 4 or 6. The glycopeptide compound can be combined with S protein of the novel coronavirus and heparin molecules on the surface of human cells, and host cells are protected from invasion of the novel coronavirus through competitive inhibition."		"Anti-SARS-CoV-2"
"DRAVPa2433"	"DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA"	"42"	"Sequence 2 from Patent CN118161592A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN118161592A"	"2024-06-11"	"CN 118161592 A"	"Glycopeptide compound for inhibiting SARS-CoV-2 virus infection and application thereof"		"The invention relates to the field of biological medicine, in particular to a glycopeptide compound for inhibiting SARS-CoV-2 virus infection. The glycopeptide compound disclosed by the invention comprises polypeptide and polysaccharide, wherein the polypeptide comprises a polypeptide P1 or a polypeptide P2, and the amino acid sequence of the polypeptide P1 is as shown in SEQ ID NO.1; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.1 through amino acid substitution, deletion or increase; the amino acid sequence of the polypeptide P2 is as shown in SEQ ID NO. 2; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.2 through amino acid substitution, deletion or increase; the structural fragment of the polysaccharide comprises any one or more than two of xFuc-N1Gal-N1 (xFuc-N1) GlcNAc structural units, x is equal to 0 or 1, and N1 is equal to 1, 2, 3, 4 or 6. The glycopeptide compound can be combined with S protein of the novel coronavirus and heparin molecules on the surface of human cells, and host cells are protected from invasion of the novel coronavirus through competitive inhibition."		"Anti-SARS-CoV-2"
"DRAVPa2434"	"NMLSTVLGV"	"9"	"Sequence 1 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2435"	"FMYSDFHFI"	"9"	"Sequence 2 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2436"	"STICFFMQI"	"9"	"Sequence 3 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2437"	"CLPACVYGL"	"9"	"Sequence 4 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2438"	"AMDSNTLEL"	"9"	"Sequence 5 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2439"	"MQIAILITT"	"9"	"Sequence 6 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2440"	"FQGRGVFEL"	"9"	"Sequence 7 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2441"	"AIMDKNIIL"	"9"	"Sequence 8 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2442"	"CVNGSCFTV"	"9"	"Sequence 9 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2443"	"KADTKILFI"	"9"	"Sequence 10 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2444"	"IVLEANFSV"	"9"	"Sequence 11 from Patent CN117430665B"	"Synthetic construct"	"IAV"	"Granted Patent"	"CN117430665B"	"2024-06-04"	"CN 117430665 A##CN 117430665 B"	"甲型流感病毒T细胞抗原表位肽及其应用"		"本发明属于免疫治疗技术领域，具体涉及甲型流感病毒T细胞抗原表位肽及其应用。本发明要解决的技术问题是目前在甲型流感病毒领域尚没有开发一种用于甲型流感病毒通用疫苗的T细胞抗原表位肽。本发明的技术方案甲型流感病毒T细胞抗原表位肽，其氨基酸序列如SEQ ID No.10所示。本发明提供了的抗原表位肽具有很强的免疫原性，能诱导抗原特异性的CD8+T细胞；其可以和HLA‑A2重链和HLA‑A2轻链β2m蛋白组装成pMHC复合物；或直接负荷到抗原递呈细胞，能活化T细胞，有效诱导T细胞免疫，可用于甲型流感病毒通用疫苗研发、制备和药物研发、临床治疗。"		"Anti-IAV"
"DRAVPa2445"	"AEQRASPLTSIVSAVVGILLVVVLGVVFGILIKRRQQKIRKYT"	"43"	"Sequence 1 from Patent CN116574685B"	"Synthetic construct"	"ZIKV"	"Granted Patent"	"CN116574685B"	"2024-05-31"	"CN 116574685 A##CN 116574685 B"	"一种装载抗菌肽Ll-37的外泌体及其在抗寨卡病毒中的应用"		"本发明公开了一种装载抗菌肽LL‑37的外泌体及其在抗寨卡病毒中的应用，其中，抗菌肽LL‑37通过修饰在其N端或C端的跨膜蛋白装载于外泌体膜上，制备得到的产品安全性好，血清稳定性也大大提高，无论在体内还是体外都有显著的抗病毒作用，尤其是LL‑37‑TM‑exo，在对ZIKV感染的预防和治疗上均有极为优异的效果，可以作为防治寨卡病毒感染药物的有力备选。"		"Anti-ZIKV"
"DRAVPa2446"	"KFLNPDREYDFRDLR"	"15"	"Sequence 1 from Patent CN107033225B"	"Synthetic construct"	"PPRV"	"Granted Patent"	"CN107033225B"	"2024-05-14"	"CN 107033225 A##CN 107033225 B"	"一种小反刍兽疫病毒Hn蛋白抗原表位肽及其确定、制备方法和应用"		"本发明涉及一种小反刍兽疫病毒HN蛋白抗原表位肽，抗原表位肽的氨基酸序列为：H123：123KFLNPDREYDFRDLR137,或/和H185：185GTGCLGRTVTRA196,或/和H487：487IRGPRGRCH495,或/和H569：569ECFPWYHKVWCYHDCLI585；本发明使用多种免疫信息学软件对目标蛋白进行B细胞表位进行预测，然后对预测的不同表位分别进行人工合成，应用间接ELISA方法进行验证其反应原性，不同的多肽包被氨基化酶标板，检测与HN蛋白的抗体的反应原性，从而鉴定出PPRV HN蛋白的B细胞表位。"		"Anti-PPRV"
"DRAVPa2447"	"GTGCLGRTVTRA"	"12"	"Sequence 2 from Patent CN107033225B"	"Synthetic construct"	"PPRV"	"Granted Patent"	"CN107033225B"	"2024-05-14"	"CN 107033225 A##CN 107033225 B"	"一种小反刍兽疫病毒Hn蛋白抗原表位肽及其确定、制备方法和应用"		"本发明涉及一种小反刍兽疫病毒HN蛋白抗原表位肽，抗原表位肽的氨基酸序列为：H123：123KFLNPDREYDFRDLR137,或/和H185：185GTGCLGRTVTRA196,或/和H487：487IRGPRGRCH495,或/和H569：569ECFPWYHKVWCYHDCLI585；本发明使用多种免疫信息学软件对目标蛋白进行B细胞表位进行预测，然后对预测的不同表位分别进行人工合成，应用间接ELISA方法进行验证其反应原性，不同的多肽包被氨基化酶标板，检测与HN蛋白的抗体的反应原性，从而鉴定出PPRV HN蛋白的B细胞表位。"		"Anti-PPRV"
"DRAVPa2448"	"IRGPRGRCH"	"9"	"Sequence 3 from Patent CN107033225B"	"Synthetic construct"	"PPRV"	"Granted Patent"	"CN107033225B"	"2024-05-14"	"CN 107033225 A##CN 107033225 B"	"一种小反刍兽疫病毒Hn蛋白抗原表位肽及其确定、制备方法和应用"		"本发明涉及一种小反刍兽疫病毒HN蛋白抗原表位肽，抗原表位肽的氨基酸序列为：H123：123KFLNPDREYDFRDLR137,或/和H185：185GTGCLGRTVTRA196,或/和H487：487IRGPRGRCH495,或/和H569：569ECFPWYHKVWCYHDCLI585；本发明使用多种免疫信息学软件对目标蛋白进行B细胞表位进行预测，然后对预测的不同表位分别进行人工合成，应用间接ELISA方法进行验证其反应原性，不同的多肽包被氨基化酶标板，检测与HN蛋白的抗体的反应原性，从而鉴定出PPRV HN蛋白的B细胞表位。"		"Anti-PPRV"
"DRAVPa2449"	"ECFPWYHKVWCYHDCLI"	"17"	"Sequence 4 from Patent CN107033225B"	"Synthetic construct"	"PPRV"	"Granted Patent"	"CN107033225B"	"2024-05-14"	"CN 107033225 A##CN 107033225 B"	"一种小反刍兽疫病毒Hn蛋白抗原表位肽及其确定、制备方法和应用"		"本发明涉及一种小反刍兽疫病毒HN蛋白抗原表位肽，抗原表位肽的氨基酸序列为：H123：123KFLNPDREYDFRDLR137,或/和H185：185GTGCLGRTVTRA196,或/和H487：487IRGPRGRCH495,或/和H569：569ECFPWYHKVWCYHDCLI585；本发明使用多种免疫信息学软件对目标蛋白进行B细胞表位进行预测，然后对预测的不同表位分别进行人工合成，应用间接ELISA方法进行验证其反应原性，不同的多肽包被氨基化酶标板，检测与HN蛋白的抗体的反应原性，从而鉴定出PPRV HN蛋白的B细胞表位。"		"Anti-PPRV"
"DRAVPa2450"	"GLYILEPHEGLYALAILEALAGLYPHEILEGLUASNGLYTRPGLUGLYMETVALASPGLYTRPTYRGLY"	"69"	"Sequence 1 from Patent CN116947982B"	"Influenza virus"	"Influenza virus"	"Granted Patent"	"CN116947982B"	"2024-05-14"	"CN 116947982 A##CN 116947982 B"	"三条优势表位肽序列及其在流感病毒疫苗的应用"		"本发明涉及免疫学技术领域，涉及包含用于预防和治疗流感病毒介导的疾病的肽免疫原的组合物，公开了三条流感病毒HA2的优势表位肽序列及其在流感病毒疫苗研发的应用。本发明的三条优势表位肽的氨基酸序列如SEQ ID NO:1‑3所示。本发明通过对流感病毒HA2进行免疫信息学预测和动物实验验证相结合筛选出三条具有免疫原性的优势表位肽，这三条优势表位肽具有T/B细胞表位，能够诱导细胞免疫和体液免疫；作为鼻内疫苗的免疫原能够诱导强效的黏膜免疫，可诱导针对流感病毒的高滴度的sIgA。相比同样针对该抗原区的其他多肽，本发明的优势表位肽具有高效价和高保守性，可作为流感疫苗的候选免疫原。"		"Anti-Influenza virus"
"DRAVPa2451"	"ARGLEUILEGLYLYSTHRASNGLULYSPHEHISGLNILEGLULYSGLUPHESERGLUVAL"	"60"	"Sequence 2 from Patent CN116947982B"	"Influenza virus"	"Influenza virus"	"Granted Patent"	"CN116947982B"	"2024-05-14"	"CN 116947982 A##CN 116947982 B"	"三条优势表位肽序列及其在流感病毒疫苗的应用"		"本发明涉及免疫学技术领域，涉及包含用于预防和治疗流感病毒介导的疾病的肽免疫原的组合物，公开了三条流感病毒HA2的优势表位肽序列及其在流感病毒疫苗研发的应用。本发明的三条优势表位肽的氨基酸序列如SEQ ID NO:1‑3所示。本发明通过对流感病毒HA2进行免疫信息学预测和动物实验验证相结合筛选出三条具有免疫原性的优势表位肽，这三条优势表位肽具有T/B细胞表位，能够诱导细胞免疫和体液免疫；作为鼻内疫苗的免疫原能够诱导强效的黏膜免疫，可诱导针对流感病毒的高滴度的sIgA。相比同样针对该抗原区的其他多肽，本发明的优势表位肽具有高效价和高保守性，可作为流感疫苗的候选免疫原。"		"Anti-Influenza virus"
"DRAVPa2452"	"GLYSERILEARGASNGLYTHRTYRASPHISASPVALTYRARGASPGLUALALEUASNASN"	"60"	"Sequence 3 from Patent CN116947982B"	"Influenza virus"	"Influenza virus"	"Granted Patent"	"CN116947982B"	"2024-05-14"	"CN 116947982 A##CN 116947982 B"	"三条优势表位肽序列及其在流感病毒疫苗的应用"		"本发明涉及免疫学技术领域，涉及包含用于预防和治疗流感病毒介导的疾病的肽免疫原的组合物，公开了三条流感病毒HA2的优势表位肽序列及其在流感病毒疫苗研发的应用。本发明的三条优势表位肽的氨基酸序列如SEQ ID NO:1‑3所示。本发明通过对流感病毒HA2进行免疫信息学预测和动物实验验证相结合筛选出三条具有免疫原性的优势表位肽，这三条优势表位肽具有T/B细胞表位，能够诱导细胞免疫和体液免疫；作为鼻内疫苗的免疫原能够诱导强效的黏膜免疫，可诱导针对流感病毒的高滴度的sIgA。相比同样针对该抗原区的其他多肽，本发明的优势表位肽具有高效价和高保守性，可作为流感疫苗的候选免疫原。"		"Anti-Influenza virus"
"DRAVPa2453"	"ENNVPVTHAKELLHTEHNGM"	"20"	"Sequence 3 from Patent CN118027159A"	"Synthetic construct"	"AIV"	"Patent Application"	"CN118027159A"	"2024-05-14"	"CN 118027159 A"	"Broad-spectrum B cell epitope peptide of HA1 protein of H9 subtype avian influenza virus and application of broad-spectrum B cell epitope peptide"		"The invention belongs to the technical field of biology, and particularly relates to an H9 subtype avian influenza virus HA1 protein broad-spectrum B cell epitope peptide and application thereof, two sections of H9 subtype AIV HA1-derived B cell epitopes of an aa 39-59 polypeptide (ENNVPVTHAKELLHTEHNGM) and an aa 309-329 polypeptide (YAFGNCPKYIGVKSLKLAVG) are screened and identified, the B cell epitopes have high conservative property, besides the 320 < th > amino acid of the aa 309-329 polypeptide, the B cell epitopes of the aa 39-59 polypeptide and the YAFGNCPKYIGVKSLKLAVG are added into the B cell epitopes of the aa 309-329 polypeptide, and The conservative rates of other sites of the two polypeptides in the H9 AIV subtype are both greater than 96%. Serological experiments find that the two polypeptides can be specifically combined with different branch strains in the H9 AIV subtype and do not react with other subtype avian influenza viruses; meanwhile, the aa 309-329 polypeptide immune serum can also be specifically combined with different branched strains."		"Anti-AIV"
"DRAVPa2454"	"YAFGNCPKYIGVKSLKLAVG"	"20"	"Sequence 30 from Patent CN118027159A"	"Synthetic construct"	"AIV"	"Patent Application"	"CN118027159A"	"2024-05-14"	"CN 118027159 A"	"Broad-spectrum B cell epitope peptide of HA1 protein of H9 subtype avian influenza virus and application of broad-spectrum B cell epitope peptide"		"The invention belongs to the technical field of biology, and particularly relates to an H9 subtype avian influenza virus HA1 protein broad-spectrum B cell epitope peptide and application thereof, two sections of H9 subtype AIV HA1-derived B cell epitopes of an aa 39-59 polypeptide (ENNVPVTHAKELLHTEHNGM) and an aa 309-329 polypeptide (YAFGNCPKYIGVKSLKLAVG) are screened and identified, the B cell epitopes have high conservative property, besides the 320 < th > amino acid of the aa 309-329 polypeptide, the B cell epitopes of the aa 39-59 polypeptide and the YAFGNCPKYIGVKSLKLAVG are added into the B cell epitopes of the aa 309-329 polypeptide, and The conservative rates of other sites of the two polypeptides in the H9 AIV subtype are both greater than 96%. Serological experiments find that the two polypeptides can be specifically combined with different branch strains in the H9 AIV subtype and do not react with other subtype avian influenza viruses; meanwhile, the aa 309-329 polypeptide immune serum can also be specifically combined with different branched strains."		"Anti-AIV"
"DRAVPa2455"	"QVQLQQPGAELVKPGASVKLSCKSSGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTKYNEKFKTKATLTADKSSSTAYMQLSSLTSEDSAVYYCARAF"	"116"	"Sequence 1 from Patent CN116903709B"	"Synthetic construct"	"ASFV"	"Granted Patent"	"CN116903709B"	"2024-05-07"	"CN 116903709 A##CN 116903709 B"	"一种非洲猪瘟病毒pK205R蛋白抗原表位肽及其单克隆抗体与应用"		"本发明公开了一种非洲猪瘟病毒(African swine fever virus,ASFV)pK205R蛋白抗原表位肽，所述抗原表位肽的氨基酸序列如SEQ ID NO：3所示，本发明还公开了一种抗所述抗原表位肽的单克隆抗体及其制备方法和应用，属于分子生物学领域。本发明提供的抗原表位肽和单克隆抗体能用于非洲猪瘟病毒的检测，具有特异性好准确度高等优点，为研究非洲猪瘟病毒pK205R蛋白的生物学功能及开发检测方法提供了有价值的新工具。"		"Anti-ASFV"
"DRAVPa2456"	"DVQITQSPSYLAASPGETITINCRASKSINKYLAWYQEKPGKTNKLLIQSGSSLQSGIPSRFSGSGSGTDFALTISSLEPEDFAMYYCQQNLEYPWTFGG"	"107"	"Sequence 2 from Patent CN116903709B"	"Synthetic construct"	"ASFV"	"Granted Patent"	"CN116903709B"	"2024-05-07"	"CN 116903709 A##CN 116903709 B"	"一种非洲猪瘟病毒pK205R蛋白抗原表位肽及其单克隆抗体与应用"		"本发明公开了一种非洲猪瘟病毒(African swine fever virus,ASFV)pK205R蛋白抗原表位肽，所述抗原表位肽的氨基酸序列如SEQ ID NO：3所示，本发明还公开了一种抗所述抗原表位肽的单克隆抗体及其制备方法和应用，属于分子生物学领域。本发明提供的抗原表位肽和单克隆抗体能用于非洲猪瘟病毒的检测，具有特异性好准确度高等优点，为研究非洲猪瘟病毒pK205R蛋白的生物学功能及开发检测方法提供了有价值的新工具。"		"Anti-ASFV"
"DRAVPa2457"	"GAIIAQLEILMINGTPLPA"	"19"	"Sequence 3 from Patent CN116903709B"	"ASFV"	"ASFV"	"Granted Patent"	"CN116903709B"	"2024-05-07"	"CN 116903709 A##CN 116903709 B"	"一种非洲猪瘟病毒pK205R蛋白抗原表位肽及其单克隆抗体与应用"		"本发明公开了一种非洲猪瘟病毒(African swine fever virus,ASFV)pK205R蛋白抗原表位肽，所述抗原表位肽的氨基酸序列如SEQ ID NO：3所示，本发明还公开了一种抗所述抗原表位肽的单克隆抗体及其制备方法和应用，属于分子生物学领域。本发明提供的抗原表位肽和单克隆抗体能用于非洲猪瘟病毒的检测，具有特异性好准确度高等优点，为研究非洲猪瘟病毒pK205R蛋白的生物学功能及开发检测方法提供了有价值的新工具。"		"Anti-ASFV"
"DRAVPa2458"	"KINKQKIKNGAKKALGVASKVAPVVAAFAR"	"30"	"Sib3"	"Simulium bannaense"	"ZIKV"	"Patent Application"	"CN117919378A"	"2024-04-26"	"CN 117919378 A"	"Application of Simulium bannaense host defense peptide Siba3"		"The invention discloses an application of a Simulium bannaense host defense peptide Siba3. The invention also discloses an application of the Simulium bannaense host defense peptide Siba3 in preparation of a medicine for resisting Zika virus infection diseases. The amino acid sequence of the Simulium bannaense host defense peptide Siba3 is as follows: KINKQKIKNGAKKALGVASKVAPVVAAFAR-NH2, and the amino acid sequence of the Simulium bannaense host defense peptide Siba3 is as follows. According to the invention, a host defense peptide Siba3 derived from Simulium bannaense is taken as a research object, and the effect of Siba3 in ZIKV infection is planned to be clarified. Research finds that Siba3 can significantly inhibit ZIKV infection in vitro and also can significantly inhibit ZIKV infection in vivo, and has both prevention and treatment effects. Results show that Siba3 can directly act on ZIKV, destroy virus envelopes and induce virus genomes to leak, so that virus particles are inactivated; the Siba3 can also reduce the susceptibility of the host cell to the Zika virus. The molecular weight is small, the structure is simple, and therefore the wide development and application prospects are achieved."		"Anti-ZIKV"
"DRAVPa2459"	"PKCPEPCPP"	"9"	"Sequence 5 from Patent CN117919373A"	"Synthetic construct"	"TLR9"	"Patent Application"	"CN117919373A"	"2024-04-26"	"CN 117919373 A"	"Application of polypeptide and polypeptide combination in improvement of antiviral immunity"		"The invention belongs to the field of biological medicines, and particularly relates to a polypeptide and an effect of a polypeptide combination in improvement of antiviral immunity. The invention proves that the polypeptide or polypeptide combination containing 9 amino acids (PKCPEPCPP), for example, SPRR2 family polypeptide (such as antibacterial peptide SPRR2A from a host) can effectively activate a natural immune signal channel, can be used as an endogenous agonist of TLR9, is crucial to activation of the SPRR2 family mediated TLR9 signal channel, and has a remarkable effect in the aspect of virus resistance for the first time."		"Activate-TLR9"
"DRAVPa2460"	"IFLWLLWPV"	"9"	"Sequence 2 from Patent CN117903264A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117903264A"	"2024-04-19"	"CN 117903264 A"	"Novel coronavirus SARS-CoV-2 HLA-A2 restrictive epitope peptide and application thereof"		"The invention provides a novel coronavirus SARS-CoV-2HLA-A2 restrictive epitope peptide and an application thereof. Specifically, the invention provides a separated polypeptide, the amino acid sequence of the separated polypeptide is IFLWLLWPV (SEQ ID NO: 2), and the separated polypeptide is a novel coronavirus SARS-CoV-2HLA-A2 restrictive epitope polypeptide. Also provided herein are complexes comprising the polypeptides, articles of manufacture, and uses thereof. The related active substances and products can be used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related diseases."		"Anti-SARS-CoV-2"
"DRAVPa2461"	"RESGGIDKEPMGFTYNGIRTNGVTS"	"25"	"Sequence 1 from Patent CN117886901A"	"Synthetic construct"	"AIV"	"Patent Application"	"CN117886901A"	"2024-04-16"	"CN 117886901 A"	"Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide"		"The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses."		"Anti-AIV"
"DRAVPa2462"	"FNGAFIAPDRASFLRGKSMGIQSGV"	"25"	"Sequence 2 from Patent CN117886901A"	"Synthetic construct"	"AIV"	"Patent Application"	"CN117886901A"	"2024-04-16"	"CN 117886901 A"	"Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide"		"The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses."		"Anti-AIV"
"DRAVPa2463"	"LPFQNIDSRAVGKCPRYVKQRSLLL"	"25"	"Sequence 3 from Patent CN117886901A"	"Synthetic construct"	"AIV"	"Patent Application"	"CN117886901A"	"2024-04-16"	"CN 117886901 A"	"Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide"		"The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses."		"Anti-AIV"
"DRAVPa2464"	"RNNTYDHRKYREEAMQNRIQIDPVK"	"25"	"Sequence 4 from Patent CN117886901A"	"Synthetic construct"	"AIV"	"Patent Application"	"CN117886901A"	"2024-04-16"	"CN 117886901 A"	"Chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus HA protein and application of chicken T cell antigen epitope peptide"		"The invention belongs to the technical field of biology, and relates to a chicken T cell antigen epitope peptide of H7N9 subtype avian influenza virus (AIV) HA protein and application of the chicken T cell antigen epitope peptide, and the amino acid sequence of the chicken T cell antigen epitope peptide is shown as SEQ ID NO.1-4. Immunoinformatics is combined with an overlapping peptide library method to systematically screen potential T cell epitopes in H7N9 subtype AIV HA protein, candidate polypeptides are synthesized and stimulate lymphocytes, and peptide fragments with remarkable immunodominance response are identified by detecting the level and proliferation level of IFN-gamma secreted by specific T cells of the H7N9 subtype AIV HA protein stimulated by the polypeptides. And the types of the antigen epitopes of the chicken T cells are identified by further utilizing cell sorting and ELISpot test. The T cell antigen epitope peptide has strong immunogenicity, can be applied to H7N9 virus immunodetection and vaccine research and development, and has potential application value in prevention and control of H7N9 viruses."		"Anti-AIV"
"DRAVPa2465"	"PAYTNSFTRGVYYPD"	"15"	"Sequence 1 from Patent CN117843735A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117843735A"	"2024-04-09"	"CN 117843735 A"	"Novel specific CD4T cell epitope peptide for screening coronavirus S1 holoproteome and application of specific CD4T cell epitope peptide"		"The invention discloses a specific CD4T cell epitope peptide for screening a novel coronavirus S1 holoproteome and application of the specific CD4T cell epitope peptide, relates to the technical field of biological medicines, and is technically characterized in that the scheme of the invention provides a novel coronavirus CD4T cell epitope peptide. The invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The specific CD4T cell epitope peptide screened by the novel coronavirus S1 holoproteome can safely and effectively induce CD4T cell immune response aiming at novel coronavirus protein, and has important significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2466"	"GSH"	"3"	"Glutathione"	"Synthetic construct"	"BmNPV"	"Granted Patent"	"CN117257914B"	"2024-03-22"	"CN 117257914 A##CN 117257914 B"	"谷胱甘肽在制备预防或治疗家蚕核型多角体病毒病药物中的应用"		"本发明公开了谷胱甘肽用于治疗或预防家蚕核型多角体病毒药物中的应用，本发明研究表明家蚕小肽谷胱甘肽可以有效抑制家蚕核型多角体病毒(BmNPV)在家蚕细胞内的复制，因此，通过合适的浓度和药物添加时间可利用谷胱甘肽抑制该病毒在家蚕细胞和家蚕体内的复制，为家蚕的BmNPV感染的预防提供了新的思路。"		"Anti-BmNPV"
"DRAVPa2467"	"SDPPVVWLGGRPGDF"	"15"	"Sequence 1 from Patent CN117659134A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN117659134A"	"2024-03-12"	"CN 117659134 A"	"Antigen epitope peptide of African swine fever virus pD205R protein, monoclonal antibody and application of antigen epitope peptide and monoclonal antibody"		"The invention belongs to the field of biotechnology and biomedicine, and particularly discloses an antigen epitope peptide of African swine fever virus pD205R protein, a monoclonal antibody and application of the antigen epitope peptide and the monoclonal antibody. The antigenic epitope of the African swine fever virus pD205R protein provided by the invention is a linear epitope and is located at the 167th to 181th amino acids (namely 167-SDPPVVWLGGRPGDF-181) of the African swine fever virus pD205R protein, and the key amino acids are S167, W173, L174, G175, P178 and D180. Meanwhile, the monoclonal antibody for resisting the African swine fever virus pD205R protein provided by the invention can specifically recognize and combine with the epitope, and can be used for preparing medicines for preventing and/or treating African swine fever virus infection and reagents for detecting and/or diagnosing African swine fever virus infection. And a new thought is provided for vaccine development and serological diagnosis method establishment."		"Anti-ASFV"
"DRAVPa2468"	"DPLASQRDIYY"	"11"	"Sequence 1 from Patent CN117659135A"	"Synthetic construct"	"ASFV"	"Patent Application"	"CN117659135A"	"2024-03-08"	"CN 117659135 A"	"Antigen epitope peptide of African swine fever virus pB125R protein, monoclonal antibody and application of antigen epitope peptide and monoclonal antibody"		"The invention belongs to the field of biotechnology and biomedicine, and particularly discloses an antigen epitope peptide of African swine fever virus pB125R protein, a monoclonal antibody and application of the antigen epitope peptide and the monoclonal antibody. The antigenic epitope of the African swine fever virus pB125R protein provided by the invention is a B cell linear epitope, and the minimum antigenic epitope is located at the 52nd-62nd amino acids of the African swine fever virus pB125R protein. A mouse model experiment verifies that the antigen epitope has immunocompetence and is highly conserved in different African swine fever virus strains. Meanwhile, the monoclonal antibody for resisting the African swine fever virus pB125R protein and the hybridoma cell strain provided by the invention can specifically recognize and combine the African swine fever virus pB125R protein, and have stronger reaction activity compared with a screened 15A9 antibody; the compound can be used for preparing a reagent for detecting and/or diagnosing African swine fever virus infection and a medicine for preventing and/or treating African swine fever virus infection."		"Anti-ASFV"
"DRAVPa2469"	"FLWLLWPVT"	"9"	"Sequence 5 from Patent CN117659140A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659140A"	"2024-03-08"	"CN 117659140 A"	"New coronavirus HLA-A2 restrictive epitope peptide and application thereof"		"The invention provides a novel coronavirus HLA-A2 restrictive epitope peptide and application thereof. Specifically, the invention provides a separated polypeptide, the amino acid sequence of the separated polypeptide is FLWLLWPVT (SEQ ID NO: 5), and the separated polypeptide is a novel coronavirus SARS-CoV-2HLA-A2 restrictive epitope polypeptide. Also provided herein are complexes comprising the polypeptides, articles of manufacture, and uses thereof. The related active substances and products can be used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related diseases."		"Anti-SARS-CoV-2"
"DRAVPa2470"	"VVIKVCEFQFCNDPF"	"15"	"Sequence 1 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2471"	"SVLHSTQDLFLPFFS"	"15"	"Sequence 2 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2472"	"HKNNKSWMESEFRVY"	"15"	"Sequence 3 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2473"	"LYIIKLIFLWLLWPV"	"15"	"Sequence 4 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2474"	"FIASFRLFARTRSMW"	"15"	"Sequence 5 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2475"	"RPLLESELVIGAVIL"	"15"	"Sequence 6 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2476"	"SELVIGAVILRGHLR"	"15"	"Sequence 7 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2477"	"LNTDHSSSSDNIALL"	"15"	"Sequence 8 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2478"	"LPYGANKDGIIWVAT"	"15"	"Sequence 9 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2479"	"IWVATEGALNTPKDH"	"15"	"Sequence 10 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2480"	"KAYNVTQAFGRRGPE"	"15"	"Sequence 11 from Patent CN117659141A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117659141A"	"2024-03-08"	"CN 117659141 A"	"Novel specific T cell epitope peptide for screening coronavirus S1, N and M protein holoproteome and application thereof"		"The invention discloses a specific T cell epitope peptide for screening a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicines, and has the technical key points that the scheme of the invention provides a plurality of novel coronavirus CD4 + T and CD8 + T cell epitope polypeptides, the invention also relates to a gene for coding the epitope polypeptide, a recombinant protein or a compound containing the epitope polypeptide, a sensitization antigen presenting cell and a specific immune effector cell aiming at the epitope polypeptide in research and development of novel coronavirus vaccines and disease treatment. The polypeptide is screened on the basis of a peripheral blood sample of a convalescent patient infected with Omicro BA.5 after enhanced inoculation of an inactivated vaccine, CD4 + T and CD8 + T cellular immune response aiming at novel coronavirus protein can be safely and effectively induced, and the polypeptide has important guiding significance on research and development of novel vaccines of novel coronavirus."		"Anti-SARS-CoV-2"
"DRAVPa2481"	"ITVATSRT"	"8"	"Sequence 27 from Patent CN117535323A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117535323A"	"2024-02-09"	"CN 117535323 A"	"Recombinant lactic acid bacteria vector for expressing coronavirus M protein epitope peptide, recombinant lactobacillus plantarum and application"		"The invention provides a fusion gene for expressing coronavirus M protein epitope peptide, a recombinant lactic acid bacteria vector, recombinant lactobacillus plantarum and application, and belongs to the technical field of molecular biology. The fusion gene for expressing the coronavirus M protein epitope peptide comprises a gene sequence for coding a signal peptide, a target gene and an SCWA signal peptide. The invention also provides a recombinant lactic acid bacteria vector containing the fusion gene and recombinant lactobacillus plantarum constructed by the recombinant lactic acid bacteria vector, and results show that the recombinant lactobacillus plantarum has high exogenous gene expression efficiency and good immunogenicity, and has high application value in mucosal immunity. And a foundation is laid for developing a novel crown M protein peptide epitope novel nasal drop vaccine."		"Anti-SARS-CoV-2"
"DRAVPa2482"	"GQPSGRRRGRRSGG"	"14"	"Sequence 4 from Patent CN112384530B"	"Synthetic construct"	"HEV"	"Granted Patent"	"CN112384530B"	"2024-02-06"	"WO 2020/011752 A1##CN 112384530 A##EP 3820892 A1##US 2021/0269510 A1##JP 2021524483 A##EP 3820892 B1"	"戊型肝炎病毒Orf2i蛋白的表位肽"		"本发明提供一种表位肽，其来自戊型肝炎病毒的ORF2i蛋白，其中所述表位肽包含如SEQ ID NO：4所示的氨基酸序列。"		"Anti-HEV"
"DRAVPa2483"	"NSASQS"	"6"	"Sequence 1 from Patent CN116751280B"	"Synthetic construct"	"SARS-CoV-2"	"Granted Patent"	"CN116751280B"	"2024-01-26"	"CN 116751280 A##CN 116751280 B"	"一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用"		"一种特异性识别SARS‑CoV‑2新冠病毒S蛋白抗原肽的T细胞受体，包括α链可变区和β链可变区；α链可变区包含如SEQ ID NO.1所示的氨基酸序列组成的互补决定区ACDR1，如SEQ ID NO.2所示的氨基酸序列组成的α链互补决定区ACDR2，以及如SEQ ID NO.3所示的氨基酸序列组成的α链互补决定区ACDR3；β链可变区包含如SEQ ID NO.4所示的氨基酸序列组成的β链互补决定区BCDR1、如SEQ ID NO.5所示的氨基酸序列组成的β链互补决定区BCDR2以及如SEQ ID NO.6所示的氨基酸序列组成的β链互补决定区BCDR3。还提供了上述T细胞受体的制备方法。还提供了上述的T细胞受体在制备用于检测或诊断新冠病毒SARS‑CoV‑2的产品中的应用、用于治疗或预防新冠病毒SARS‑CoV‑2所引起疾病的药物中的应用。"		"Anti-SARS-CoV-2"
"DRAVPa2484"	"VYSSGN"	"6"	"Sequence 2 from Patent CN116751280B"	"Synthetic construct"	"SARS-CoV-2"	"Granted Patent"	"CN116751280B"	"2024-01-26"	"CN 116751280 A##CN 116751280 B"	"一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用"		"一种特异性识别SARS‑CoV‑2新冠病毒S蛋白抗原肽的T细胞受体，包括α链可变区和β链可变区；α链可变区包含如SEQ ID NO.1所示的氨基酸序列组成的互补决定区ACDR1，如SEQ ID NO.2所示的氨基酸序列组成的α链互补决定区ACDR2，以及如SEQ ID NO.3所示的氨基酸序列组成的α链互补决定区ACDR3；β链可变区包含如SEQ ID NO.4所示的氨基酸序列组成的β链互补决定区BCDR1、如SEQ ID NO.5所示的氨基酸序列组成的β链互补决定区BCDR2以及如SEQ ID NO.6所示的氨基酸序列组成的β链互补决定区BCDR3。还提供了上述T细胞受体的制备方法。还提供了上述的T细胞受体在制备用于检测或诊断新冠病毒SARS‑CoV‑2的产品中的应用、用于治疗或预防新冠病毒SARS‑CoV‑2所引起疾病的药物中的应用。"		"Anti-SARS-CoV-2"
"DRAVPa2485"	"VVTKTSYDKVI"	"11"	"Sequence 3 from Patent CN116751280B"	"Synthetic construct"	"SARS-CoV-2"	"Granted Patent"	"CN116751280B"	"2024-01-26"	"CN 116751280 A##CN 116751280 B"	"一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用"		"一种特异性识别SARS‑CoV‑2新冠病毒S蛋白抗原肽的T细胞受体，包括α链可变区和β链可变区；α链可变区包含如SEQ ID NO.1所示的氨基酸序列组成的互补决定区ACDR1，如SEQ ID NO.2所示的氨基酸序列组成的α链互补决定区ACDR2，以及如SEQ ID NO.3所示的氨基酸序列组成的α链互补决定区ACDR3；β链可变区包含如SEQ ID NO.4所示的氨基酸序列组成的β链互补决定区BCDR1、如SEQ ID NO.5所示的氨基酸序列组成的β链互补决定区BCDR2以及如SEQ ID NO.6所示的氨基酸序列组成的β链互补决定区BCDR3。还提供了上述T细胞受体的制备方法。还提供了上述的T细胞受体在制备用于检测或诊断新冠病毒SARS‑CoV‑2的产品中的应用、用于治疗或预防新冠病毒SARS‑CoV‑2所引起疾病的药物中的应用。"		"Anti-SARS-CoV-2"
"DRAVPa2486"	"SGHAT"	"5"	"Sequence 4 from Patent CN116751280B"	"Synthetic construct"	"SARS-CoV-2"	"Granted Patent"	"CN116751280B"	"2024-01-26"	"CN 116751280 A##CN 116751280 B"	"一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用"		"一种特异性识别SARS‑CoV‑2新冠病毒S蛋白抗原肽的T细胞受体，包括α链可变区和β链可变区；α链可变区包含如SEQ ID NO.1所示的氨基酸序列组成的互补决定区ACDR1，如SEQ ID NO.2所示的氨基酸序列组成的α链互补决定区ACDR2，以及如SEQ ID NO.3所示的氨基酸序列组成的α链互补决定区ACDR3；β链可变区包含如SEQ ID NO.4所示的氨基酸序列组成的β链互补决定区BCDR1、如SEQ ID NO.5所示的氨基酸序列组成的β链互补决定区BCDR2以及如SEQ ID NO.6所示的氨基酸序列组成的β链互补决定区BCDR3。还提供了上述T细胞受体的制备方法。还提供了上述的T细胞受体在制备用于检测或诊断新冠病毒SARS‑CoV‑2的产品中的应用、用于治疗或预防新冠病毒SARS‑CoV‑2所引起疾病的药物中的应用。"		"Anti-SARS-CoV-2"
"DRAVPa2487"	"FQNNGV"	"6"	"Sequence 5 from Patent CN116751280B"	"Synthetic construct"	"SARS-CoV-2"	"Granted Patent"	"CN116751280B"	"2024-01-26"	"CN 116751280 A##CN 116751280 B"	"一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用"		"一种特异性识别SARS‑CoV‑2新冠病毒S蛋白抗原肽的T细胞受体，包括α链可变区和β链可变区；α链可变区包含如SEQ ID NO.1所示的氨基酸序列组成的互补决定区ACDR1，如SEQ ID NO.2所示的氨基酸序列组成的α链互补决定区ACDR2，以及如SEQ ID NO.3所示的氨基酸序列组成的α链互补决定区ACDR3；β链可变区包含如SEQ ID NO.4所示的氨基酸序列组成的β链互补决定区BCDR1、如SEQ ID NO.5所示的氨基酸序列组成的β链互补决定区BCDR2以及如SEQ ID NO.6所示的氨基酸序列组成的β链互补决定区BCDR3。还提供了上述T细胞受体的制备方法。还提供了上述的T细胞受体在制备用于检测或诊断新冠病毒SARS‑CoV‑2的产品中的应用、用于治疗或预防新冠病毒SARS‑CoV‑2所引起疾病的药物中的应用。"		"Anti-SARS-CoV-2"
"DRAVPa2488"	"ASRGLAGSETQY"	"12"	"Sequence 6 from Patent CN116751280B"	"Synthetic construct"	"SARS-CoV-2"	"Granted Patent"	"CN116751280B"	"2024-01-26"	"CN 116751280 A##CN 116751280 B"	"一种特异性识别SARS-CoV-2新冠病毒S蛋白抗原肽的T细胞受体及制备和应用"		"一种特异性识别SARS‑CoV‑2新冠病毒S蛋白抗原肽的T细胞受体，包括α链可变区和β链可变区；α链可变区包含如SEQ ID NO.1所示的氨基酸序列组成的互补决定区ACDR1，如SEQ ID NO.2所示的氨基酸序列组成的α链互补决定区ACDR2，以及如SEQ ID NO.3所示的氨基酸序列组成的α链互补决定区ACDR3；β链可变区包含如SEQ ID NO.4所示的氨基酸序列组成的β链互补决定区BCDR1、如SEQ ID NO.5所示的氨基酸序列组成的β链互补决定区BCDR2以及如SEQ ID NO.6所示的氨基酸序列组成的β链互补决定区BCDR3。还提供了上述T细胞受体的制备方法。还提供了上述的T细胞受体在制备用于检测或诊断新冠病毒SARS‑CoV‑2的产品中的应用、用于治疗或预防新冠病毒SARS‑CoV‑2所引起疾病的药物中的应用。"		"Anti-SARS-CoV-2"
"DRAVPa2489"	"MGRFKRFRKKFKKLFKKLS"	"19"	"Sequence 1 from Patent CN117427145A"	"Synthetic construct"	"EV"	"Patent Application"	"CN117427145A"	"2024-01-23"	"CN 117427145 A"	"一种预防或抑制肠道病毒的肽类组合物及其用途"		"本发明涉及生物医药领域,具体涉及一种预防或抑制肠道病毒的肽类组合物及其用途,所述肽类组合物包含多肽和蒙脱石散,也可以包括其他药物有效成分、辅料、载体或辅助性成分。本发明还公开了该肽类组合物在预防或抑制肠道病毒方面的用途,所述肽类组合物在降低多肽、蒙脱石散使用浓度的同时,可有效提高抗病毒作用,两者的组合对预防或抑制肠道病毒具有协同作用。与现有技术相比,该肽类组合物对肠道病毒的预防或抑制具有协同作用,尤其对柯萨奇病毒及肠道病毒71型,并且安全性高,无激素,高效,安全,因此具有很好的商业应用前景。"		"Anti-EV"
"DRAVPa2490"	"KLNSGDSKV"	"9"	"Sequence 1 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2491"	"KMNSGDSKV"	"9"	"Sequence 2 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2492"	"KINSGDSKV"	"9"	"Sequence 3 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2493"	"KQNSGDSKV"	"9"	"Sequence 4 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2494"	"KVNSGDSKV"	"9"	"Sequence 5 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2495"	"KLNSGDSFV"	"9"	"Sequence 6 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2496"	"KLNSGDSKL"	"9"	"Sequence 7 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2497"	"KLNSGDSKI"	"9"	"Sequence 8 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2498"	"KLNSGDSKA"	"9"	"Sequence 9 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2499"	"KLNSGDSPV"	"9"	"Sequence 10 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2500"	"KLNSGISKV"	"9"	"Sequence 11 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2501"	"KLNSGLSKV"	"9"	"Sequence 12 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2502"	"KLNSGVSKV"	"9"	"Sequence 13 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2503"	"KLMSGDSKV"	"9"	"Sequence 14 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2504"	"KLWSGDSKV"	"9"	"Sequence 15 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2505"	"KLFSGDSKV"	"9"	"Sequence 16 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2506"	"KLYSGDSKV"	"9"	"Sequence 17 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2507"	"FLNSGDSKV"	"9"	"Sequence 18 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2508"	"YLNSGDSKV"	"9"	"Sequence 19 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2509"	"KLNSGDWKV"	"9"	"Sequence 20 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2510"	"KLNSGDFKV"	"9"	"Sequence 21 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2511"	"KLNSGDYKV"	"9"	"Sequence 22 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2512"	"KLNSGDSYV"	"9"	"Sequence 23 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2513"	"KLNSGDSKVV"	"9"	"Sequence 24 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2514"	"KLNSGDSKVL"	"9"	"Sequence 25 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2515"	"FKLNSGDSKV"	"9"	"Sequence 26 from Patent CN117377679A"	"Synthetic construct"	"SARS-CoV-2"	"Patent Application"	"CN117377679A"	"2024-01-09"	"WO 2022/242432 A1##US 2022/0370604 A1## TW 202300513 A##CN 117377679 A##EP 4341274 A1##JP 2024517927 A"	"Peptide vaccines against viral infection"		"The present invention relates to an immunogenic composition for resisting viral infection, and in particular, to an immunogenic composition having a peptide capable of binding to a molecule of the major histocompatibility complex (MHC) and inducing a broad-acting immunity against coronavirus, and more particularly, to an immunogenic composition having a peptide capable of binding to the molecule of the major histocompatibility complex (MHC)."		"Anti-SARS-CoV-2"
"DRAVPa2516"	"DQPAKDPRMSPRESD"	"15"	"Sequence 1 from Patent CN117343149A"	"Synthetic construct"	"PRRSV"	"Patent Application"	"CN117343149A"	"2024-01-05"	"CN 117343149 A"	"Preparation and application of PRRSV non-structural protein Nsp2 synthetic peptide polyclonal antibody"		"The invention relates to the technical field of biology, and particularly discloses an antigen peptide of a porcine reproductive and respiratory syndrome virus non-structural protein 2, a polyclonal antibody prepared by using the antigen peptide and application of the polyclonal antibody. The amino acid sequence of the antigen peptide disclosed by the invention is as shown in SEQ ID NO. 1. Meanwhile, the invention also discloses a preparation method of the antigen peptide and a polyclonal antibody prepared by using the antigen peptide. The polyclonal antibody prepared by the invention is relatively high in sensitivity and specificity, can specifically recognize the Nsp2 protein, can be used for detection of the Nsp2 protein, protein function identification, cell localization and the like, provides an important experimental material for researching biological functions of the Nsp2 protein, and lays a biological foundation for detection of porcine reproductive and respiratory syndrome virus."		"Anti-PRRSV"
"DRAVPa2517"	"LKKLKWLAHRLKGMLKKYLKPTAASS"	"26"	"Sequence 1 from Patent CN117343148A"	"Synthetic construct"	"CHIKV,HTNV,DENV,HSV"	"Patent Application"	"CN117343148A"	"2024-01-05"	"CN 117343148 A"	"Antibacterial peptide and application thereof in preparation of antibacterial drugs or antiviral drugs"		"The invention discloses an antibacterial peptide and application thereof in preparation of an antibacterial drug or an antiviral drug. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.2. The MIC of the antibacterial peptide disclosed by the invention on escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and acinetobacter baumannii is less than or equal to 20 mu g/mL; multiple drug-resistant escherichia coli, drug-resistant staphylococcus aureus, drug-resistant pseudomonas aeruginosa and drug-resistant acinetobacter baumannii can be inhibited; the inhibition effect on drug-resistant acinetobacter baumannii which is focused by WHO is outstanding; the antibacterial peptide disclosed by the invention is good in safety and has relatively low cytotoxicity and hemolytic activity, and the animal toxicity is lower than that of the existing clinical antibacterial peptide polymyxin B; the compound also has a broad-spectrum antiviral effect, and has an inhibiting effect on hantavirus, chikungunya virus, herpes simplex virus type 1 or dengue virus type 2."		"Anti-CHIKV##Anti-HTNV##Anti-DENV##Anti-HSV"